*All Sessions will take place in Central Time

Virtual Scientific Sessions Program

Table of Contents

Friday, June 12th ..................................................................................................................Pages 2-19

Saturday, June 13th ..........................................................................................................Pages 20-44

Sunday, June 14th .............................................................................................................Pages 45-69

Monday, June 15th ............................................................................................................Pages 70-95

Tuesday, June 16th ...........................................................................................................Pages 96-99
FRIDAY, JUNE 12, 2020

Scientific Sessions
11:30 a.m.-12:30 p.m.

Mini-Symposium
Theme Area: Acute and Chronic Complications
Debate—Technology Alone Can Solve the Problem of Hypoglycemia in Diabetes
Chair: Belinda P. Childs, APRN, MN, BC-ADM, CDE
11:30 a.m.-12:00 p.m.  For—Technology Alone Can Solve the Problem of Hypoglycemia
   Richard M. Bergenstal, MD
12:00 p.m.-12:30 p.m. Against—Technology Alone Can Solve the Problem of Hypoglycemia
   Emma G. Wilmot, MD

Mini-Symposium
Theme Area: Acute and Chronic Complications
Is a Routine Lipid Panel Sufficient for Determining Cardiovascular Risk?
Chair: Alan Chait, MD
11:30 a.m.-12:00 p.m.  When Should You Order Advanced Lipoprotein Testing?
   Ronald M. Krauss, MD
12:00 p.m.-12:30 p.m.  When Should You Order Coronary Calcium Scans?
   Matthew Budoff, MD

Mini-Symposium
Theme Area: Acute and Chronic Complications
Sex Differences in Renal and Cardiovascular Disease in Diabetes
Chair: Susanne Nicholas, MD, MPH, PhD
11:30 a.m.-12:00 p.m.  Pathophysiology of Sex Differences in Micro- and Macrovascular Complications in Diabetes Mellitus
   Christine Maric-Bilkan, PhD
12:00 p.m.-12:30 p.m.  Is There a Role of Sex in the Progression of Renal and Cardiovascular Disease in Diabetes?
   Joel Neugarten, MD, JD

Mini-Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Improving Type 1 Diabetes Management in Young Adults—Time to (Re)Strategize?
Chair: Jessica Pierce, PhD
11:30 a.m.-11:50 a.m.  Using Lived Experiences as a Mechanism for Engagement in Diabetes Care
   Jennifer Saylor, PhD, APRN, ACNS-BC
11:50 a.m.-12:10 p.m.  “Adulting” with Diabetes—Things to Teach the Hard to Reach
   Persis V. Commissariat, PhD
12:10 p.m.-12:30 p.m.  The Simple Magic of Peer Connections in Type 1 Diabetes—Lessons from the College Diabetes Network
   Anna Floreen Sabino, MSW, CDCES

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

11:30 a.m.-12:30 p.m.
(continued)

Mini-Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
2018 Physical Activity Guidelines for Americans
Chair: Sheri Colberg, PhD, FACSM
11:30 a.m.-12:00 p.m.  What Are the 2018 Physical Activity Guidelines for People of All Ages?
                        Katrina L. Piercy, PhD, RD, ACSM-CEP
12:00 p.m.-12:30 p.m.  How Applicable Are the 2018 Physical Activity Guidelines to Youth and Adults with Diabetes?
                        Ronald J. Sigal, MD, MPH, FRCPC

Mini-Symposium
Theme Area: Clinical Diabetes/Therapeutics
Female Sexual Dysfunction in Diabetes—Therapeutic Interventions
Chair: Diana Sherifali, PhD, RN, CDE
11:30 a.m.-12:00 p.m.  Female Sexual Dysfunction—Pharmacological Interventions
                        Alice Y.Y. Cheng, MD, FRCPC
12:00 p.m.-12:30 p.m.  Female Sexual Dysfunction—Sex Counseling Therapy Evidence
                        Sharon J. Parish, MD

Mini-Symposium
Theme Area: Epidemiology/Genetics
Diabetes and Genetic Predictors in Ethnically Diverse Populations
Chair: James B. Meigs, MD, MPH
11:30 a.m.-12:00 p.m.  Genetic Factors Influencing Complex Metabolic Traits in Ethnically Diverse Africans
                        Sarah A. Tishkoff, PhD
12:00 p.m.-12:30 p.m.  Precision Diabetes Genetic Medicine in Asia—The Taichung Experience
                        Wayne H-H Sheu, MD, PhD

Mini-Symposium
Theme Area: Immunology/Transplantation
Bioengineered Cell Therapy for Diabetes
Chair: Nayara Leite, PhD
11:30 a.m.-11:50 a.m.  Generation and Analysis of Immune Cloaked Beta Cells from Human Stem Cells
                        Audrey Parent, PhD
11:50 a.m.-12:10 p.m.  Islet Microchip Technology
                        Maike Sander, MD
12:10 p.m.-12:30 p.m.  Islet Bioprinting
                        Francesca Spagnoli, MD, PhD

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

11:30 a.m.-12:30 p.m.
(continued)

**Mini-Symposium**
*Theme Area: Insulin Action/Molecular Metabolism*

**The Randle Debate—The Effects of Dietary Carbohydrate, Fat, and Calorie Intake on Metabolic Disease**
Chair: Peter A. Crawford, MD, PhD

11:30 a.m.-11:50 a.m.  *Dietary Fat as a Cause of Metabolic Disease*
Sarah Hallberg, DO, MS, ACSM-CEP, FOMA, FNLA

11:50 a.m.-12:10 p.m.  *Dietary Carbohydrate as a Cause of Metabolic Disease*
Barbara E. Corkey, PhD

12:10 p.m.-12:30 p.m.  *Dietary Quality and Calories as a Cause of Metabolic Disease*
Kevin D. Hall, PhD

**Mini-Symposium**
*Theme Area: Integrated Physiology/Obesity*

**Debate—Metabolic Changes Related to Alteration in Circadian Rhythm**
Chair: Maren Laughlin, PhD

11:30 a.m.-11:50 a.m.  *Point—It’s All about Sleep*
Josiane L. Broussard, PhD

11:50 a.m.-12:10 p.m.  *Counterpoint—It’s All about Food*
Andrew W. McHill, PhD

12:10 p.m.-12:20 p.m.  *Rebuttal*
Josiane L. Broussard, PhD

12:20 p.m.-12:30 p.m.  *Rebuttal*
Andrew W. McHill, PhD

**Mini-Symposium**
*Theme Area: Acute and Chronic Complications*

**Male Sexual Dysfunction in Diabetes**
Chair: Andrew J.M. Boulton, MD, DSc (Hon), FACP, FICP, FRCP

12:45 p.m.-1:15 p.m.  *Erectile Dysfunction in Diabetes—Epidemiology, Pathogenesis, and Psychological Aspects*
Aruna V. Sarma, PhD

1:15 p.m.-1:45 p.m.  *Medical Management of Erectile Dysfunction*
Deepak K. Jumani, MBBS, FCGP
FRIDAY, JUNE 12, 2020

12:45 p.m.-1:45 p.m.
(continued)

Mini-Symposium
Theme Area: Acute and Chronic Complications
The Future Is Now—Designing Smarter Trials for Cardiovascular Protection in Diabetes
Chair: Sanjay Kaul, MD, FACC, FAHA
12:45 p.m.-12:57 p.m. 2008 FDA Guidelines on Antidiabetic Therapies Has Served Its Purpose—Time to Move On
   Milton Packer, MD
12:57 p.m.-1:09 p.m. 2008 FDA Guidelines on Antidiabetic Therapies Is Still Relevant
   Steven Nissen, MD
1:09 p.m.-1:24 p.m. What Are the Gaps in the Evidence, and How to Target Them?
   Ann Marie Navar, MD, PhD
1:24 p.m.-1:45 p.m. Panel Discussion
   Bruce M. Psaty, MD, PhD
   Peter Stein, MD
   Lisa Yanoff, MD

Mini-Symposium
Theme Area: Acute and Chronic Complications
Functional Outcomes in Diabetic Foot following Amputation
Chair: Adam E. Fleischer, DPM, MPH, FACFAS
12:45 p.m.-1:15 p.m. High vs. Low-Level Amputations
   George T. Liu, DPM, FACFAS
1:15 p.m.-1:45 p.m. Advancements in Prosthetic Devices
   Phillip Stevens, MEd, CPO

Mini-Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
The Weight-Neutral Approach in Diabetes Management
Chair: Patti Urbanski, MEd, RD, LD, CDE
12:45 p.m.-1:15 p.m. Definition and Benefits of a Weight-Neutral Approach
   Erin Phillips, MPH, RDN, CDE
1:15 p.m.-1:45 p.m. Implementing Weight-Neutral Care in Diabetes Management
   Holly Paulsen, RD, CEDRD-S, LD

Mini-Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Creative Mealtime Boluses for Pumps and Multiple Daily Injections
Chair: Gary Scheiner, MS, CDE
12:45 p.m.-1:15 p.m. Creative Insulin Pump Bolusing—Practice Makes Perfect
   Margaret Pellizzari, MBA, MS, RN, CDCES, CDT, FDCES
1:15 p.m.-1:45 p.m. Optimizing Mealtime Insulin Dosing for Patients on Multiple Daily Injections—High-Fat Meals and More
   Amy Hess Fischl, MS, RDN, LDN, BC-ADM, CDE

Information is subject to change. Sessions current as of 5/15/20.
**FRIDAY, JUNE 12, 2020**

12:45 p.m.-1:45 p.m. 
(continued)

**Mini-Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
**Strategies and Tools to Improve the Transition from Pediatric to Adult Diabetes Care**  
Chair: Lori M. Laffel, MD, MPH  
12:45 p.m.-1:15 p.m.  
*A U.S. Perspective*  
Robert S. Zimmerman, MD  
1:15 p.m.-1:45 p.m.  
*A Canadian Perspective*  
Sonia Butalia, BSc, MD, FRCPC, MSc (epi)

**Mini-Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
**Diabetes and Pregnancy and the Use of Oral Agents**  
Chair: Camille E. Powe, MD  
12:45 p.m.-1:15 p.m.  
*Type 2 Diabetes in Pregnancy—A Growing Concern—Is Metformin the Answer?*  
Denice Feig, MD, MSc, FRCPC  
1:15 p.m.-1:45 p.m.  
*Oral Agents for Gestational Diabetes Mellitus—Are We Stuck Using Insulin?*  
Linda (Lynn) A. Barbour, MD, MSPH, FACP

**Mini-Symposium**  
*Theme Area: Epidemiology/Genetics*  
**Debate—Can We Rely on Nutrition Science for Diabetes and Cardiovascular Disease?**  
Chair: Nita Forouhi, MD, PhD  
12:45 p.m.-1:15 p.m.  
*No, and Why Not—A Critique of Diet-Centrism*  
Edward Archer, PhD  
1:15 p.m.-1:45 p.m.  
*Yes, and Why So*  
Walter C. Willett, MD

**Mini-Symposium**  
*Theme Area: Immunology/Transplantation*  
**Combination Immunotherapy to Preserve Beta-Cell Function in Type 1 Diabetes**  
Chair: Aaron W. Michels, MD  
12:45 p.m.-1:15 p.m.  
*Combination Immune Therapies in Type 1 Diabetes—What Have We Tried?*  
Peter Gottlieb, MD  
1:15 p.m.-1:45 p.m.  
*Combination Immune Therapies in Type 1 Diabetes—Where Do We Go Next?*  
Linda DiMeglio, MD, MPH

**Mini-Symposium**  
*Theme Area: Integrated Physiology/Obesity*  
**The Banting Exchange—Diabetes Discovery—How the Past Informs the Future**  
Chair: Michael P. Czech, PhD  
12:45 p.m.-1:15 p.m.  
*Is Beta-Cell Failure Reversible?*  
Domenico Accili, MD  
1:15 p.m.-1:45 p.m.  
*Can Lipids Improve Insulin Resistance and Beta-Cell Function?*  
Barbara B. Kahn, MD

*Information is subject to change. Sessions current as of 5/15/20.*
FRIDAY, JUNE 12, 2020

12:45 p.m.-1:45 p.m.
(continued)

Mini-Symposium
Theme Area: Islet Biology/Insulin Secretion
Are There Different Beta-Cell Subpopulations?
Chair: Maike Sander, MD
12:45 p.m.-1:15 p.m.  
Single-Cell Approaches Revealed Disease-Associated Beta-Cell Heterogeneity  
Yan Li, PhD
1:15 p.m.-1:45 p.m.  
The Challenges We Face to Detect Beta-Cell Subpopulations  
Mark Huising, PhD

2:00 p.m.-3:20 p.m.

Symposium
Theme Area: Integrated Physiology/Obesity
The Best Strategy for Diabetes Remission Using Obesity Treatments Is...
Chair: W. Timothy Garvey, MD
2:00 p.m.-2:40 p.m.  
Lifestyle  
Sriram Machineni, MD
2:40 p.m.-3:20 p.m.  
Pharmacotherapy  
Ania M. Jastreboff, MD

2:00 p.m.-3:40 p.m.

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Ethnic and Racial Disparities in Maternal, Perinatal, and Neonatal Mortality
Chair: Rebecca A. Simmons, MD
2:00 p.m.-2:20 p.m.  
Ethnic Disparities in Maternal Pregnancy Complications and Mortality  
Marissa H. Platner, MD
2:20 p.m.-2:40 p.m.  
Ethnic Disparities in Preterm Birth and Neonatal Survival  
Heather H. Burris, MD, MPH
2:40 p.m.-3:00 p.m.  
Prospective Longitudinal Study of the Pregnancy DNA Methylome—The U.S. Pregnancy, Race, Environment, Genes (PREG) Study  
Dana Lapato, PhD
3:00 p.m.-3:20 p.m.  
Risk and Protective Factors among Racially/Ethnically Diverse Women with Gestational Diabetes  
Susan D. Brown, PhD
3:20 p.m.-3:40 p.m.  
Ethnic Differences in Neonatal Health in Premature Infants  
Teresa Janevic, PhD, MPH

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

2:00 p.m.-4:00 p.m.

**Symposium**
*Theme Area: Acute and Chronic Complications*
**Doing Better for Diabetes and Chronic Kidney Disease (CKD)**
Chair: Luiza Caramori, MD, MSc, PhD
2:00 p.m.-2:30 p.m.  *The Worldwide Impact of Diabetes and CKD*
Nilka Rios Burrows, MT, MPH
2:30 p.m.-3:00 p.m.  *Identification of Diabetes and CKD in Clinical Practice*
Susanne Nicholas, MD, MPH, PhD
3:00 p.m.-3:30 p.m.  *Recommendations for Glycemia Monitoring and Targets in CKD*
Peter Rossing, MD, DMSc
3:30 p.m.-4:00 p.m.  *Recommended Therapies for the Treatment of CKD in Diabetes*
Katherine R. Tuttle, MD, FACP, FASN, FNKF

**Symposium**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*
**Using Technologies to Track Physical Activity and Improve Health**
Chair: Boris Kovatchev, PhD
2:00 p.m.-2:30 p.m.  *Physical Activity Tracking—Technology under the Hood*
Kong Y. Chen, PhD, MSCI
2:30 p.m.-3:00 p.m.  *Learning from Smartphone Sensor Data—Activity, Location, and Sociability*
Ashutosh Sabharwal, PhD
3:00 p.m.-3:30 p.m.  *Being Physically Active with Artificial Pancreas Systems and Continuous Glucose Monitoring*
Dessi Zaharieva, PhD
3:30 p.m.-4:00 p.m.  *Activity and the Type 2 Diabetes Digital Ecosystem—Insights from Technology*
David Kerr, MD

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
**Update on Heart Failure for the Diabetologist**
Chair: Lawrence A. Leiter, MD, FRCP, FACP, FACE, FAHA, FACC
2:00 p.m.-2:35 p.m.  *Heart Failure—A Primer on Etiology, Diagnosis, and Treatment*
Kim A. Connelly, MBBS, PhD, FRACP
2:35 p.m.-3:10 p.m.  *What Do We Know about the Effects of Antihyperglycemic Medication on Heart Failure?*
John J.V. McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, FRCP, FESC
3:10 p.m.-3:45 p.m.  *Implications for the Practicing Diabetologist—How Can Endocrinology and Cardiology Work Together?*
Yehuda Handelsman, MD
3:45 p.m.-4:00 p.m.  *Panel Discussion*

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

2:00 p.m.-4:00 p.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Transitions in Diabetes
Chair: Desmond Schatz, MD
2:00 p.m.-2:40 p.m. Diabetes Transitions in the Hospital—Strategies to Consider when the Formulary Does Not Match Your Patient’s Home Insulin
Irl B. Hirsch, MD
2:40 p.m.-3:20 p.m. Diabetes Management in a Long-Term Care Facility—Strategies for Providers
Ruth S. Weinstock, MD, PhD
3:20 p.m.-4:00 p.m. Transitioning Across Time Zones—Diabetes Management Across the Country and Around the World
Subbulaxmi Trikudanathan, MD, MRCP, MMSc

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Which Diet Is Best for Treatment of Diabetes and Obesity?
Chair: Melinda D. Maryniuk, MEd, RDN, CDCES
2:00 p.m.-2:40 p.m. Low-Calorie Diets
John Wilding, DM, FRCP
2:40 p.m.-3:20 p.m. Low-Carbohydrate Diets and Nutritional Ketosis
Jessica Turton, APD, BAppSc (Ex&SpSc), MNutrDiet
3:20 p.m.-4:00 p.m. Mediterranean Diets
Miguel A. Martinez-Gonzalez, MD, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
The Next Generation of Automated Insulin Delivery Systems for Persons with Type 1 Diabetes—Four New Clinical Trials
Chair: Timothy S. Bailey, MD, FACE, CPI
2:00 p.m.-2:30 p.m. U.S. Advanced Hybrid Closed-Loop (AHCL) Pivotal Safety Study
Bruce W. Bode, MD
2:30 p.m.-3:00 p.m. FLAIR—An NIDDK-Sponsored International, Multi-site Randomized Crossover Trial of AHCL vs. 670G
Richard M. Bergenstal, MD
3:00 p.m.-3:30 p.m. New Zealand AHCL Randomized Crossover Trial
Martin de Bock, FRACP, PhD
3:30 p.m.-4:00 p.m. Horizon Automated Glucose Control System Pre-pivotal Trial Data
Bruce A. Buckingham, MD

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

2:00 p.m.-4:00 p.m.  
(continued)

Symposium  
Theme Area: Epidemiology/Genetics  
Biobanks and Electronic Health Records in Diabetes Care and Research  
Chair: Naveed Sattar, MD, PhD
2:00 p.m.-2:40 p.m.  
Biobanks in Diabetes and Obesity Research and Treatment  
Dana C. Crawford, PhD
2:40 p.m.-3:20 p.m.  
Type 2 Diabetes and Cardiovascular Disease Risk Using Biobank Data  
Naveed Sattar, MD, PhD
3:20 p.m.-4:00 p.m.  
Diabetes and Complications in Adults—The Million Veteran Program  
Lawrence S. Phillips, MD

Symposium  
Theme Area: Insulin Action/Molecular Metabolism  
Adipose Innervation  
Chair: Meilian Liu, PhD
2:00 p.m.-2:30 p.m.  
3D Imaging—Visualizing Adipose Tissue Innervation  
Paul Cohen, MD, PhD
2:30 p.m.-3:00 p.m.  
Central Nervous System Regulation of the Sympathetic Outflow to Brown Adipose Tissue  
Shaun Morrison, PhD
3:00 p.m.-3:30 p.m.  
Lipid Signals in the Control of Adipose Tissue Innervation  
Michael P. Czech, PhD
3:30 p.m.-4:00 p.m.  
Regulation of Adipose Sympathetic Plasticity  
Wenwen Zeng, PhD

Symposium  
Theme Area: Islet Biology/Insulin Secretion  
What’s New with Beta-Cell Replacement?  
Chair: M. Cristina Nostro, PhD
2:00 p.m.-2:30 p.m.  
Autologous Islet Transplantation—Proof of Principle for Beta-Cell Replacement  
Melena Bellin, MD
2:30 p.m.-3:00 p.m.  
State of the Field—Beta-Cell Replacement Strategies in Type 1 Diabetes  
Elco J.P. de Koning, MD, PhD
3:00 p.m.-3:30 p.m.  
Expanding the Human Beta-Cell Progenitor Population  
Senta Georgia, PhD
3:30 p.m.-4:00 p.m.  
Stem Cells and Duct Cells as Beta-Cell Precursors  
H. Teresa Ku, PhD

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

4:15 p.m.-5:55 p.m.
(continued)

Symposium
Theme Area: Immunology/Transplantation
Functional Cure of Type 1 Diabetes—Where Shall We Take the Islet Cells From?
Chair: Julie A. Kerr-Conde, PhD
4:15 p.m.-4:35 p.m. The Developmental Biology of Pancreatic Islet Cells
Solomon Afeli, PhD
4:35 p.m.-4:55 p.m. How Do Islet Cells Function, and How Can We Measure It?
Yong Wang, MD
4:55 p.m.-5:15 p.m. Generation of Human Islet Cells from Stem Cells
Matthias Hebrok, PhD
5:15 p.m.-5:35 p.m. Generating New Beta Cells from Adult Human Pancreatic Islets
Adolfo Garcia-Ocaña, PhD
5:35 p.m.-5:55 p.m. Islets from Porcine Origin for Diabetes Cell Therapy
Gregory Korbott, PhD

Symposium
Theme Area: Integrated Physiology/Obesity
Bariatric Surgery—What Is New, and What Lessons Have We Learned?
Chair: Roy Taylor, MD
4:15 p.m.-4:35 p.m. Novel Pathophysiology—Remodeling of Metabolism
Michael Roden, MD
4:35 p.m.-4:55 p.m. Clinical Management of Patients (Adults)
Maria Collazo-Clavell, MD
4:55 p.m.-5:15 p.m. Clinical Management of Patients (Youth)
Megan Moriarty Kelsey, MD, MS
5:15 p.m.-5:35 p.m. Complications of Bariatric Surgery—Hypoglycemia Pathophysiology and Management
Marzieh Salehi, MD, MS
5:35 p.m.-5:55 p.m. Complications of Bariatric Surgery—Effects on Bone
Anne Schafer, MD

Symposium
Theme Area: Acute and Chronic Complications
Diabetic Foot Management—Care Strategies for the Primary Care and Medical Teams
Chair: Ryan T. Crews, MS, CCRP
4:15 p.m.-4:45 p.m. Diabetic Foot Self-Care Management—Are We Using All the Right Tools?
Timethia Bonner, DPM, PhD
4:45 p.m.-5:15 p.m. Diabetic Foot Ulcer Pressure Relief—What You Can Do in the Office Today
Ryan T. Crews, MS, CCRP
5:15 p.m.-5:45 p.m. Antidiabetic Therapy and Amputation Risk
Michael Fralick, MD, PhD, SM, FRCPC
5:45 p.m.-6:15 p.m. Putting It All Together—Are We Meeting the Mark on Diabetic Foot Ulcer Prevention?
Sicco A. Bus, PhD

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m.
(continued)

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Taking the Technology Plunge—Integrating Digital Technology into Practice
Chair: David Kerr, MD

4:15 p.m.-4:45 p.m. Diabetes Apps—To Recommend, or Not to Recommend?
Rachel Stahl, MS, RD, CDN, CDCE

4:45 p.m.-5:15 p.m. Diabetes Care Text Messages—Do They Work?
David V. Wagner, PhD

5:15 p.m.-5:45 p.m. Utilizing Personal Health Data—How Much Do We Need, and What Should We Do with It?
David Ahn, MD

5:45 p.m.-6:15 p.m. Is Peer Support the Answer for the Technologically Challenged?
Michelle L. Litchman, PhD, FNP-BC, APRN

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Expanding the Use of Continuous Glucose Monitoring in Pediatric Settings
Chair: Rose Gubitosi-Klug, MD, PhD

4:15 p.m.-4:45 p.m. Glucose Monitoring in Stage 2 Type 1 Diabetes
Brigitte I. Frohnert, MD, PhD

4:45 p.m.-5:15 p.m. Continuous Glucose Monitor Use in Early Stage 3 Type 1 Diabetes
Jan Fairchild, FRACP

5:15 p.m.-5:45 p.m. Continuous Glucose Monitor Use in Pediatric Type 2 Diabetes
Fida Bacha, MD, FAAP

5:45 p.m.-6:15 p.m. Continuous Glucose Monitor Use in Hospital Settings
Gregory P. Forlenza, MD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Tailoring Treatment Options Based on Diabetes Comorbidities
Chair: Ofri Mosenzon, MD, MSc

4:15 p.m.-4:45 p.m. Patients with Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Kenneth Cusi, MD

4:45 p.m.-5:15 p.m. Patients with Low Estimated Glomerular Filtration Rate
George Bakris, MD

5:15 p.m.-5:45 p.m. Patients Post-Stroke/Transient Ischemic Attack
Jesse Dawson, MD, BSc (Hons), FRCP, FESO

5:45 p.m.-6:15 p.m. Patients with Heart Failure
Silvio E. Inzucchi, MD

Information is subject to change. Sessions current as of 5/15/20.
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m.

Oral Presentations
Theme Area: Acute and Chronic Complications
Cardiovascular Risk Evaluation and Mitigation in Diabetes

4:15 p.m.-4:30 p.m.
1-OR Analyses of First Plus Recurrent Cardiovascular (CV) and Hospitalization Events in the CAROLINA Trial
NIKOLAUS MARX, DARREN K. MCGUIRE, ODD ERIK JOHANSEN, JULIO ROSENSTOCK, EGON PFARR, MICHAELA MATTHEUS, JYOTHIS T. GEORGE, MARK ESPELAND, BERNARD ZINMAN, Aachen, Germany, Askør, Norway, Dallas, TX, Ingelheim, Germany, Winston-Salem, NC, Toronto, ON, Canada

4:30 p.m.-4:45 p.m.
2-OR Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes
MARCUS V.B. MALACHIAS, PARDEEP JHUND, BRIAN CLAGGETT, MAGNUS O. WIJKMAN, RHONDA BENTLEY-LEWIS, PATRICK C. BRUNEL, NISHI CHATURVEDI, AKSHAY S. DESAI, STEVEN M. HAFFNER, HANS-HENRIK D. PARVING, MARGARET F. PRESCOTT, SCOTT SOLOMON, DICK DE ZEEUW, JOHN J. MCMURRAY, MARC A. PFEFFER, Boston, MA, Bonneville-sur-Touques, France, London, United Kingdom, Shavano Park, TX, Copenhagen, Denmark, East Hanover, NJ, Groningen, Netherlands, Glasgow, United Kingdom

4:45 p.m.-5:00 p.m.
3-OR Intensive Glycemic Control Can Reduce Major Adverse Cardiovascular Events (MACE): A Bayesian’s Narrative
HUI SHAO, SHUANG YANG, VIVIAN FONSECA, JIANG BIAN, LIZHENG SHI, Gainesville, FL, New Orleans, LA

5:00 p.m.-5:15 p.m.
4-OR Diabetes Duration and the Relative Importance of Cardiovascular Risk Factors in Type 1 Diabetes
ELKE R. FAHRMANN, HENRY DRISCOLL, Huntington, WV

5:15 p.m.-5:30 p.m.
5-OR Prior Bariatric Surgery and Perioperative Cardiovascular Outcomes following Noncardiac Surgery in Patients with Type 2 Diabetes Mellitus
JIEWEN JIN, HAI LI, PENGYUAN ZHANG, YANBING LI, Guangzhou, China

5:30 p.m.-5:45 p.m.
6-OR Blood Pressure as Predictor of Coronary Artery Disease (CAD)/Cerebrovascular Disease (CVD) According to Glucose Tolerance Status (GTS): Implications for Updated Guidelines
MAYUKO H. YAMADA, KAZUYA FUJIHARA, YUTA YAGUCHI, TAEKO OSAWA, MASARU KITAZAWA, YASUHIRO MATSUBAYASHI, MIDORI IWANAGA, TAKAHO YAMADA, NAUTA YAMANAKA, HIROYASU SEIDA, WATARU OGAWA, HIROHITO SONE, Niigata, Japan, Tokyo, Japan, Kobe, Japan

(continued on next page)
5:45 p.m.-6:00 p.m.

7-OR  Comparison of Two Recent Ceramide-Based Coronary Risk Prediction Scores: CERT and CERT-2
ANDREAS LEIHERER, AXEL MUENDLEIN, CHRISTOPH H. SAELY, REIJO LAAKSONEN, MITJA LAAPERI,
ALEXANDER VONBANK, PETER FRAUNBERGER, HEINZ DREXEL, Triesen, Liechtenstein, Espoo,
Finland, Feldkirch, Austria, Philadelphia, PA

6:00 p.m.-6:15 p.m.

8-OR  Coronary Calcium Scoring to Select Asymptomatic Diabetic Patients with Coronary Artery
Stenoses Suitable for Revascularization
NARIMANE BERKANE, EMMANUEL COSSON, SARA PINTO, TIT-LIVIU CIUNGANU, PAUL VALENSI,
Bobigny, France, Bondy, France
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m.
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Innovative Behavioral and Psychosocial Interventions in Diabetes (With ADA Presidents' Select Abstract Presentation)

4:15 p.m.-4:30 p.m.
9-OR ADA Presidents' Select Abstract: Reductions in Management Distress following a Distress Intervention Are Associated with Improved Management and Glycemic Control over Time
DANIELLE M. HESSLER, LAWRENCE FISHER, UMESH MASHARANI, WILLIAM POLONSKY, San Francisco, CA, San Diego, CA

4:30 p.m.-4:45 p.m.
10-OR Implementing CGM with a Family Behavioral Intervention (FBI) Reduces Psychosocial Distress in Parents of Children 2-8 Y/O: A Pre–Post Comparison
PERSIS V. COMMISSARIAT, LAUREN KANAPKA, KELLEE MILLER, MARISA E. HILLIARD, BARBARA ANDERSON, LINDA DIMEGLIO, LORI M. LAFFEL, Boston, MA, Tampa, FL, Houston, TX, Indianapolis, IN

4:45 p.m.-5:00 p.m.
11-OR Youth Empowerment Skills (YES): A Novel Psychosocial Behavioural Intervention for Adolescents with Type 1 Diabetes
DULMINI KARIYAWASAM, KHULAT A. SAQI, FARANAZ DEHZAD, SIOBHAN PENDER, MARIE JONES, NARDOSE YEMANE, REBECCA H. GRIFFITHS, TAYANA SOUKUP, STEPHANIE M. SINGHAM, ANGUS FORBES, London, United Kingdom

5:00 p.m.-5:15 p.m.
12-OR Participation in a Virtual Diabetes Clinic and Reduced Diabetes-Related Distress in Individuals with Type 2 Diabetes
WILLIAM H. POLONSKY, JENNIFER E. LAYNE, CHRISTOPHER G. PARKIN, COCO KUSIAK, NATHAN A. BARLEEN, DAVID P. MILLER, HOWARD ZISSER, RONALD F. DIXON, San Diego, CA, Henderson, NV, Newton, MA, South San Francisco, CA

5:15 p.m.-5:30 p.m.
13-OR Piloting the Problem Areas in Diabetes Scale in Clinical Practice: The DiaPROM Pilot Trial
INGVILD HERNAR, MARIT GRAUE, DAVID RICHARDS, RAGNHILD B. STRANDBERG, KARIANNE F. LØVAAS, TONE VONHEIM MADESEN, GRETHE S. TELL, ANNE HAUGSTVEIDT, Exeter, United Kingdom, Bergen, Norway

5:30 p.m.-5:45 p.m.
14-OR Piloting a Video-Based Telehealth Intervention to Reduce Distress and Depression in Parents of Schoolagers with Type 1 Diabetes (T1D)
SUSANA R. PATTON, ARWEN M. MARKER, ALEXANDRA MONZON, EVE-LYNN NELSON, MARK A. CLEMENTS, Jacksonville, FL, Lawrence, KS, Kansas City, KS, Kansas City, MO

(continued on next page)

Information is subject to change. Sessions current as of 5/15/20.
5:45 p.m.-6:00 p.m.
15-OR  Self-Efficacy and Mood in Youths with T1D before and after a Curriculum-Based Group Intervention
CYNTHIA E. MUNOZ, OLIVIA HSIN, SARAH H. GAMEZ, JENNIFER RAYMOND, LYNSA K. FISHER, Los Angeles, CA

6:00 p.m.-6:15 p.m.
16-OR  Codesigning an Intervention for Adults with New-Onset Type 1 Diabetes to Improve Psychological and Social Adaptation
METTE DUE-CHRISTENSEN, LENE E. JOENSEN, SOPHIE SARRE, JULIE L. WAD, EWA ROMANZUK, RITA FORDE, INGRID WILLAING, ANGUS FORBES, Gentofte, Denmark, London, United Kingdom, Odense, Denmark
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Addressing Challenges to Diabetes Care Delivery

17-OR WITHDRAWN

4:15 p.m.-4:30 p.m.

OSAMA HAMDY, JOANNA MITRI, ALANA BARRETT, ROBERT A. GABBAY, Boston, MA

4:30 p.m.-4:45 p.m.

19-OR Glycemic Control Differences between Individuals with Accurately and Inaccurately Provider-Perceived Literacy and Numeracy
RASHECA LOGENDRAN, ANGELICA CRISTELLO, JULIEN DUBOIS, BRANDON S. FRIEDMAN, ELIZABETH J. MAYER-DAVIS, Chapel Hill, NC

4:45 p.m.-5:00 p.m.

20-OR Psychological Impact and Need for Psychological Care and Support: What Do People with Diabetes and Caregivers Say? Results of a Scientific Survey of 9,869 People with Diabetes and Caregivers in Denmark
SOREN E. SKOVLUND, KASPER A. NIELSEN, NIELS EJSKJAER, Glostrup, Denmark, Aalborg, Denmark

5:00 p.m.-5:15 p.m.

21-OR Implementation of an Intensive Telehealth Intervention for Rural Patients with Uncontrolled Diabetes
ELIZABETH A. KOBE, ALLISON LEWINSKI, SUSANNE DANUS, ELISABETH L. SIDOLI, BETH GRECK, LEANNE C. HORNE, DAVID SAXON, SUSAN D. SHOOK, LINA E. AGUIRRE, CLARENE EVENSON, CHRISTOPHER S. ELIZAGARAY, GEORGE L. JACKSON, HAYDEN B. BOSWORTH, DAVID EDELMAN, MATTHEW CROWLEY, Asheville, NC, Aurora, CO, Denver, CO, Albuquerque, NM, Fort Harrison, MT, Kalispell, MT, Durham, NC

5:15 p.m.-5:30 p.m.

22-OR Increased Adverse Glycemia and Hospital-Acquired Infection following Withdrawal of the RAPIDS Early Intervention Model for Diabetes Care in Medical and Surgical Inpatients
MERVYN KYI, JOANNA WANG, PAUL R. WRAIGHT, PETER G. COLMAN, SPIROS FOURLANOS, Melbourne, Australia, Parkville, Australia

5:30 p.m.-5:45 p.m.

23-OR EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center
LEIGH B. BAK, THOMAS M. FANDEL, JANIS E. BOZZO, MICHELLE L. DEWITT, PING CHEN, RICHARD A. PANDO, LINDA FERRO, RORY KAPLAN, KARRIE C. HENDRICKSON, STEPHANIE B. AMPORT, L. SCOTT SUSSMAN, SILVIO E. INZUCCHI, Greenwich, CT, New Haven, CT

(continued on next page)
5:45 p.m.-6:00 p.m.

24-OR  Electronic Decision Support for Insulin Therapy Is Safe and Efficient in Inpatients with Type 2 Diabetes
DANIEL A. HOCHFELLNER, HARIS ZIKO, MAXIMILIAN H. SAGMEISTER, HESHAM ELSAYED, MONIKA CIGLER, TINA POETTLER, FELIX ABERER, GERALD SENDLHOFER, PETER BECK, JULIA K. MADER,
Graz, Austria
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
SGLT Inhibitors

4:15 p.m.-4:30 p.m.
25-OR Acid–Base Changes during Diabetic Ketoacidosis (DKA) in T1DM with and without SGLT2 Inhibitor (SGLT2i)
INES MURSIC, EVA SVEHLIKOVA, WERNER REGITTNIG, THOMAS AUGUSTIN, CHRISTOPH MAGNES, ANITA EBERL, TIM HEISE, OLIVER KLEIN, MICHAEL WOLF, MARTINA URSCHITZ, MARTINA BRUNNER, HARALD SOURIJ, THOMAS PIEBER, Graz, Austria, Neuss, Germany

4:30 p.m.-4:45 p.m.
26-OR Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE
MEGUMI OSHIMA, MEG J. JARDINE, RAJIV AGARWAL, GEORGE BAKRIS, CHRISTOPHER CANNON, DAVID M. CHARYTAN, DICK DE ZEEUW, ROBERT EDWARDS, TOM GREENE, ADEERA LEVIN, KENNETH W. MAHAFFEY, BRUCE NEAL, CAROL A. POLLOCK, NORM ROSENTHAL, DAVID C. WHEELER, HONG ZHANG, BERNARD ZINMAN, VLADO PERKOVIC, HIDDO L. HEERSPINK, Newtown, Australia, Sydney, Australia, Indianapolis, IN, Chicago, IL, Boston, MA, New York, NY, Groningen, Netherlands, Raritan, NJ, Salt Lake City, UT, Vancouver, BC, Canada, Stanford, CA, St Leonards, Australia, London, United Kingdom, Beijing, China, Toronto, ON, Canada

4:45 p.m.-5:00 p.m.
27-OR Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease
JINGWEI LI, MEG J. JARDINE, BRUCE NEAL, HIDDO L. HEERSPINK, CHRISTOPHER CANNON, RAJIV AGARWAL, GEORGE BAKRIS, DAVID M. CHARYTAN, DICK DE ZEEUW, ROBERT EDWARDS, TOM GREENE, ADEERA LEVIN, CAROL A. POLLOCK, NORM ROSENTHAL, DAVID C. WHEELER, HONG ZHANG, BERNARD ZINMAN, VLADO PERKOVIC, KENNETH W. MAHAFFEY, CLARE ARNOTT, Sydney, Australia, Sydney, Australia, Boston, MA, Indianapolis, IN, Chicago, IL, New York, NY, Groningen, Netherlands, Raritan, NJ, Salt Lake City, UT, Vancouver, BC, Canada, St Leonards, Australia, London, United Kingdom, Beijing, China, Toronto, ON, Canada, Stanford, CA

5:00 p.m.-5:15 p.m.
28-OR How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
SUBODH VERMA, LAWRENCE A. LEITER, ABHINAV SHARMA, BERNARD ZINMAN, MICHAELA MATTHEUS, DAVID H. FITCHETT, JYOTISH T. GEORGE, ANNE PERNILLE OFSTAD, CHRISTOPH WANNE, SILVIO E. INZUCCHI, Montreal, QC, Canada, Toronto, ON, Canada, Ingelheim, Germany, Asker, Norway, Wuerzburg, Germany, New Haven, CT

(continued on next page)
5:15 p.m.-5:30 p.m.

**29-OR** Comparison of Empagliflozin and Sitagliptin on Ectopic Fat Accumulation and Tissue-Specific Insulin Sensitivity
SHIGENORI HIRUMA, FUMIKA SHIGIYAMA, SHINJI HISATAKE, SUNAO MIZUMURA, NOBUYUKI SHIRAGA, MASAAKI HORI, TAKANORI IKEDA, TAKAHISA HIROSE, NAOKI KUMASHIRO, Tokyo, Japan

5:30 p.m.-5:45 p.m.

**30-OR** Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
MUTHIAH VADUGANATHAN, NAVEED SATTAR, DAVID H. FITCHETT, ANNE PERNILLE OFSTAD, MARTINA BRUECKMANN, JYOTHIS T. GEORGE, SUBODH VERMA, MICHAELA MATTHEUS, CHRISTOPH WANNER, SILVIO E. INZUCCHI, BERNARD ZINMAN, JAVED BUTLER, Boston, MA, Glasgow, United Kingdom, Askar, Norway, Ingelheim, Germany, Wuerzburg, Germany, New Haven, CT, Toronto, ON, Canada, Jackson, MS

5:45 p.m.-6:00 p.m.

**31-OR** Ipragliflozin Ameliorated Overweight and Pathological Liver Fibrosis in Diabetic Patients with Nonalcoholic Fatty Liver Disease in a Multicenter Randomized Controlled Trial
HIROKAZU TAKAHASHI, TAKAOMI KESSOKU, MIWA KAWANAKA, MICHIHIRO NONAKA, HIDEYUKI HYOGO, HIDEKI FUJI, TOMOAKI NAKAJIMA, KENTO IMAO, KENICHI TANAKA, YOSHIHITO KUBOTSU, HIROSHI ISODA, SATOSHI OEDA, OSAMU KURAI, MASATO YONEDA, MASAFUMI ONO, AYAKO TAKAMORI, RYO TAJIRI, ATSUSHI KAWAGUCHI, SHINICHI AISHIMA, MASAYOSHI KAGE, ATSUSHI NAKAJIMA, YUICHIRO EGUCHI, KEIZO ANZAI, Yokohama, Japan, Okayama, Japan, Hatsukaichi, Japan, Sapporo, Japan, Osaka, Japan, Tokyo, Japan, Kurume, Japan, Saga, Japan

6:00 p.m.-6:15 p.m.

**32-OR** The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase III, Clinical Trial
JOHN J.V. McMURRAY, MASON W. FREEMAN, JOE MASSARO, SCOTT SOLOMON, PAUL LOCK, MATTHEW C. RIDDLE, ELDRIN LEWIS, YUAN-DI C. HALVORSEN, Glasgow, United Kingdom, Boston, MA, Worcester, MA, Portland, OR

*Information is subject to change. Sessions current as of 5/15/20.*
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m.
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics
Advances in Type 2 Diabetes Treatment—Are We Making an Impact?

4:15 p.m.-4:30 p.m.

33-OR A Novel Data Mining Approach to Detect Adverse Events of New Diabetes Drugs in Routine Care
MIKE FRALICK, MARTIN KULLDORFF, SHIRLEY WANG, SEBASTIAN SCHNEEWISSL, DONALD
REDELMEIER, ELISABETTA PATORNO, Boston, ON, Toronto, ON, Canada, Boston, MA

4:30 p.m.-4:45 p.m.

34-OR SGLT2 Inhibitors: A Comparison of Cardiovascular, Medical, and Cost Outcomes
PHIL SCHWAB, ANDY BOWE, MICHAEL TINDAL, YUNUS A. MEAH, INSIYA POONAWALLA,
Louisville, KY

4:45 p.m.-5:00 p.m.

35-OR Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors
vs. Sulfonylureas to Baseline GLP-1RA Therapy
CHINTAN DAVE, SEOYOUNG C. KIM, ALLISON GOLDFINE, ROBERT GLYNN, ELISABETTA PATORNO,
Boston, MA

5:00 p.m.-5:15 p.m.

36-OR Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists
INSIYA POONAWALLA, ANDY BOWE, MICHAEL TINDAL, YUNUS A. MEAH, PHIL SCHWAB,
Louisville, KY

5:15 p.m.-5:30 p.m.

37-OR Racial and Socioeconomic Disparities in the Use of Newer Classes of Diabetes Medications
AHMED ELHUSSEIN, MICHAEL BANKS, WILLIAM C. KNOWLER, ANNE L. PETERS, ELIZABETH M.
VAUGHAN, NISA M. MARUTHUR, JEANNE CLARK, SCOTT J. PILLA, Winston-Salem, NC, Phoenix,
AZ, Los Angeles, CA, Houston, TX, Baltimore, MD, Philadelphia, PA

5:30 p.m.-5:45 p.m.

38-OR Differences in Diabetes Medication Use between Commercial and Medicare Advantage
Beneficiaries, 2013-2018
ROZALINA G. MCCOY, HOLLY VAN HOUTEN, JOSEPH ROSS, PINAR KARACA-MANDIC, VICTOR M.
MONTORI, NILAY SHAH, Rochester, MN, New Haven, CT, Minneapolis, MN

5:45 p.m.-6:00 p.m.

39-OR Secular Trends in Glucose-Lowering Drug Utilization, Glycemic Control, and Severe Hypoglycemia
in Adults with Diabetes between 2002 and 2016 in Hong Kong
AIMIN YANG, HONGJIANG WU, ERIC S. LAU, RONALD C. MA, ALICE P. KONG, WING YEE SO,
ANDREA LUK, JULIANA C. CHAN, ELAINE CHOW, Hong Kong, China

(continued on next page)
6:00 p.m.-6:15 p.m.  
40-OR Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER  
ANTONIO NICOLUCCI, HUNGTA CHEN, ANDREW COOPER, MARILIA B. GOMES, LINONG JI, KAMLESH KHUNTI, MIKHAILE N. KOSIBOROD, PAUL LEIGH, LARISA RAMIREZ, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, AFRAH SIDDQUI, FENGMING TANG, JITEN VORA, HIROTAKA WATADA, SUZANNE V. ARNOLD, Pescara, Italy, Gaithersburg, MD, Cambridge, United Kingdom, Rio de Janeiro, Brazil, Beijing, China, Leicester, United Kingdom, Luton, United Kingdom, Moscow, Russian Federation, Suita, Japan, Kansas City, MO, Liverpool, United Kingdom, Tokyo, Japan
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m. (continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Adipose Biology

4:15 p.m.-4:30 p.m.
41-OR Single Cell RNA-Sequencing Reveals the Developmental Heterogeneity of Brown Adipocytes
FARNAZ SHAMSI, MARY PIPER, LI-LUN HO, TIAN LIAN HUANG, YU-HUA TSENG, Boston, MA, Cambridge, MA

4:30 p.m.-4:45 p.m.
42-OR The Impact of GSNOR-Mediated Nitroso-Redox Signaling on Immuno-Metabolic Interaction in the Brown Adipose Tissue
SARA SEBAG, QINGWEN QIAN, ZEYUAN ZHANG, MARK LI, VITOR A. LIRA, MATTHEW J. POTTHOFF, LING YANG, Iowa City, IA

4:45 p.m.-5:00 p.m.
44-OR PAR2-Regulated MIF Secretion from Non-Immune Cells in Adipose Tissue Is a Key Mechanism Involved in the Development of Metabolic Dysfunction
YIHENG HUANG, LIUJUN CHEN, YADAN QJ, DAKE QI, Winnipeg, MB, Canada

5:00 p.m.-5:15 p.m.
46-OR The Transcriptional Coregulator Ldb1 Directly Regulates Brown Adipose Thermogenic Function
JESSICA KEPPLE, YANPING LIU, TEAYOUN KIM, KIRK M. HABEGGER, MARTIN YOUNG, CHAD S. HUNTER, Birmingham, AL
FRIDAY, JUNE 12, 2020

4:15 p.m.-6:15 p.m.
(continued)

Oral Presentations
Theme Area: Islet Biology/Insulin Secretion
It Takes Teamwork—Beta-Cell Organelles

4:15 p.m.-4:30 p.m.
47-OR  A Reference Map of the Human Proinsulin Biosynthetic Interaction Network
DUC T. TRAN, PETER ARVAN, RANDAL J. KAUFMAN, PAMELA ITKIN-ANSARI, La Jolla, CA, Ann Arbor, MI

4:30 p.m.-4:45 p.m.
48-OR  Pancreatic β Cell SERCA2 Deficiency Leads to Impaired Proinsulin Processing and Reduced ER to Golgi Protein Trafficking
TATSUYOSHI KONO, HITOSHI IIDA, TIMOTHY S. JARVELA, CHIH-CHUN LEE, XIN TONG, PETER ARVAN, IRIS LINDBERG, CARMELLA EVANS-MOLINA, Tokyo, Japan, Baltimore, MD, Indianapolis, IN, Nashville, TN, Ann Arbor, MI

4:45 p.m.-5:00 p.m.
49-OR  Synergistic Effect of ERAD and Autophagy in Preventing Proinsulin Aggregation and Promoting Beta-Cell Survival
NEHA SHRESTHA, RACHEL B. REINERT, PETER ARVAN, LING QI, Ann Arbor, MI

5:00 p.m.-5:15 p.m.
50-OR  Beta Cell GDF15 Contributes to Diabetic Stress-Induced Beta-Cell Loss
GUANLAN XU, SEONGHO JO, JUNQIN CHEN, TRUMAN GRAYSON, ANATH SHALEV, Birmingham, AL

5:15 p.m.-5:30 p.m.
51-OR  Loss of Critical ER Chaperone GRP78 Leads to Beta-Cell Death by a JNK Dependent Mechanism
ROHIT B. SHARMA, CHRISTINE O. DARKO, BRIAN GABLASKI, AMY S. LEE, LAURA C. ALONSO, New York, NY, Worcester, MA, Los Angeles, CA

5:30 p.m.-5:45 p.m.
52-OR  Mitophagy Forms a Protective Response to Inflammatory Damage in Pancreatic β-Cells
VAIBHAV SIDARALA, SCOTT SOLEIMANPOUR, Ann Arbor, MI

5:45 p.m.-6:00 p.m.
53-OR  Deletion of YTHDF2 in Beta Cells Results in Glucose Intolerance
DECHENG REN, JUAN SUN, Indianapolis, IN, Chicago, IL

6:00 p.m.-6:15 p.m.
54-OR  Nitric Oxide Attenuates Viral Replication in Pancreatic β-Cells through an Inhibition of Mitochondrial Oxidative Metabolism
JOSHUA STAFFORD, JOHN A. CORBETT, Milwaukee, WI

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

Scientific Sessions
8:00 a.m.-9:40 a.m.

**Symposium**
Theme Area: Clinical Diabetes/Therapeutics
Can Taxes Alter Dietary Behaviors and Outcomes?
Chair: William H. Herman, MD, MPH
8:00 a.m.-8:20 a.m.  
*When Will a Tax Policy Change Behavior and When Will It Not?*
Lisa M. Powell, PhD

8:20 a.m.-8:40 a.m.  
*Example from California*
Dean Schillinger, MD

8:40 a.m.-9:00 a.m.  
*The UK Soft Drinks Industry Levy—Change Diet by Stimulating Reformulation*
Martin White, MD, FFPH

9:00 a.m.-9:20 a.m.  
*Example from Mexico*
Rafael Meza, PhD

9:20 a.m.-9:40 a.m.  
*Example from Philadelphia*
Christina A. Roberto, PhD

8:00 a.m.-10:00 a.m.

**Symposium**
Theme Area: Acute and Chronic Complications
Reduction of Hypoglycemia by New Therapies in Clinical Trials—Overestimated, Underestimated, or Both?
Chair: Stephanie A. Amiel, BSc, MD, FRCP
8:00 a.m.-8:40 a.m.  
*We Need to Know How Often the Glucose Is under 54 mg/dl*
Simon R. Heller, MD, FRCP

8:40 a.m.-9:20 a.m.  
*We Need to Know How Often the Glucose Is under 70 mg/dl*
Aaron J. Kowalski, PhD

9:20 a.m.-10:00 a.m.  
*The Constraints of Trial Design Determine Hypoglycemia Outcomes*
Peter A. Senior, MBBS, PhD

**Symposium**
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
ADA Education Recognition Program Symposium—Clinical Considerations for Safe, Cultural, Spiritual, and Therapeutic Fasting among People with Diabetes
Chair: Barbara Eichorst, MS, RD, CDCES
8:00 a.m.-8:30 a.m.  
*Fasting Practices and Clinical Indications for People with Diabetes*
Barbara Eichorst, MS, RD, CDCES

8:30 a.m.-9:00 a.m.  
*Religious, Cultural, and Health-Related Fasting Strategies and How They Impact Diabetes Outcomes and Care*
Lorena Drago, MS, RDN, CDN, CDCES

9:00 a.m.-9:30 a.m.  
*Effective Diabetes Self-Management Education and Support for Those Who Fast*
Joy Pape, MSN, RN, FNP-C, CDCES, FADCES

9:30 a.m.-10:00 a.m.  
*National Survey from People with Diabetes Relating to Why They Fast and What Are Their Expectations from Health Care Providers to Support Their Needs*
Anna Norton, MS

Information is subject to change. Sessions current as of 5/15/20.


SATURDAY, JUNE 13, 2020

8:00 a.m.-10:00 a.m.
(continued)

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Culinary Medicine—Its Role in the Prevention and Treatment of Obesity, Diabetes, and Metabolic Syndrome
Chair: Paula Kellogg Leibovitz, MS, RDN, CDE, CD-N
8:00 a.m.-8:40 a.m. Overview of Culinary Medicine and Teaching Kitchens as Learning Laboratories
David Eisenberg, MD
8:40 a.m.-9:20 a.m. Culinary Medicine during Medical Training and Beyond
Michelle Hauser, MD, MS, MPA, FAICM, Chef
9:20 a.m.-10:00 a.m. Culinary Medicine—Translating the Science into Solutions for Type 2 Diabetes Prevention and Management
Linda Shiue, MD, Chef

Symposium
Theme Area: Clinical Diabetes/Therapeutics
ADA Diabetes Care Symposium—Long-Term Perspectives on Study and Care of Diabetes
Chair: Matthew C. Riddle, MD
8:00 a.m.-8:05 a.m. Introductory Comments
Matthew C. Riddle, MD
8:05 a.m.-8:35 a.m. Evolution of Randomized Controlled Trials for Diabetes since the UGDP
Amanda Adler, MD, PhD
8:35 a.m.-9:05 a.m. Diabetes Is Vascular, the Heart Is Metabolic
Lars Rydén, MD, PhD
9:05 a.m.-9:30 a.m. “Profiles in Progress” Plaque Presentations
Matthew C. Riddle, MD
9:30 a.m.-10:00 a.m. How Can We Limit Development and Progression of Type 2 Diabetes in Youth and Middle Age?
Steven E. Kahn, MB, ChB

Symposium
Theme Area: Epidemiology/Genetics
The “Legacy Effect” in Diabetes—Are There Long-Term Benefits of Short-Term Tight Glycemic Management?
Chair: Elizabeth Selvin, PhD, MPH
8:00 a.m.-8:30 a.m. The Metabolic Memory in Type 1 Diabetes
John M. Lachin, ScD
8:30 a.m.-9:00 a.m. The Legacy Effect in Type 2 Diabetes
Rury R. Holman, FRCP, FMedSci
9:00 a.m.-9:30 a.m. The Legacy Effect of Lifestyle Intervention on Diabetes-Related Morbidity and Mortality
William C. Knowler, MD, DrPH
9:30 a.m.-10:00 a.m. Lack of a Legacy Effect in Modern Glucose-Lowering Trials
Neda Laiteerapong, MD, MS, FACP

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

8:00 a.m.-10:00 a.m.
(continued)

Symposium
Theme Area: Immunology/Transplantation
Engaging the Immune System to Protect Beta Cells
Chair: Todd M. Brusko, PhD
8:00 a.m.-8:30 a.m. Immune Checkpoints in Autoimmune Diabetes
Brian T. Fife, PhD
8:30 a.m.-9:00 a.m. Oxidative Stress in Type 1 Diabetes
Hubert M. Tse, PhD
9:00 a.m.-9:30 a.m. T-Cell Receptor Determinants of Tolerance in Type 1 Diabetes
Maria Bettini, PhD
9:30 a.m.-10:00 a.m. Low Dose IL-2 to Enhance Regulatory T-Cells
Alberto Pugliese, MD

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Metabolic Tracing in Nutrition, Diabetes, and Cancer
Chair: TBD
8:00 a.m.-8:30 a.m. Organ-Specific Consumption of Metabolic Fuels
Joshua D. Rabinowitz, MD, PhD
8:30 a.m.-9:00 a.m. Manipulating and Modeling Metabolism to Understand Metabolic Health and Aging
Denis Titov, PhD
9:00 a.m.-9:30 a.m. Metabolomic Approaches to Cardiovascular Disease
Mohit Jain, MD, PhD
9:30 a.m.-10:00 a.m. Folate Metabolism in Cancer
Naama Kanarek, PhD

Symposium
Theme Area: Integrated Physiology/Obesity
The Impact of Environmental Temperature on Metabolic Regulation
Chair: Brian N. Finck, PhD
8:00 a.m.-8:30 a.m. Optimal Temperatures to Mimic Human Metabolism—Not So Hot
John Speakman, PhD, DSc
8:30 a.m.-9:00 a.m. Optimal Temperatures to Mimic Human Metabolism—Get It Hot
Barbara Cannon, PhD
9:00 a.m.-9:30 a.m. Burn It Up—Temperature and Obesity Treatment
Marc L. Reitman, MD, PhD
9:30 a.m.-10:00 a.m. It Was Flamed—Skeletal Muscle Thermogenic Regulation
Muthu Periasamy, PhD

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

8:00 a.m.-10:00 a.m.

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Pediatric Type 2 Diabetes and Obesity

8:00 a.m.-8:15 AM

55-OR Cerebral Blood Flow Is Lower in Youth with Type 2 Diabetes Compared with Obese Controls
JACOB M. REDEL, MARK W. DIFRANCESCO, GREGORY R. LEE, LAWRENCE M. DOLAN, AMY S. SHAH, Cincinnati, OH

8:15 a.m.-8:30 a.m.

56-OR Degree of β-Cell Function (ßCF) Impairment and Glycemic Alterations in Obese Youth (OY) Spanning from Normal Glucose Tolerance (NGT) to Impaired Glucose Tolerance (IGT) to Type 2 Diabetes (T2D): Does Race Matter?
JOON YOUNG KIM, HALA M. TFAYLI, FIDA BACHA, NOUR GEBARA, SILVA A. ARSLANIAN, Syracuse, NY, Beirut, Lebanon, Houston, TX, Pittsburgh, PA

8:30 a.m.-8:45 a.m.

57-OR A Novel School-Based Obesity Prevention Program Improves Healthy Eating/Lifestyle among 5- to 7-Year-Olds
SUMUDU N. SENEVIRATNE, SANATHANEE SACHCHITHANANTHAN, PAVITHRA S. ANGULUGAHA GAMAGE, SAHANA RAMAMOORTHY, RENUKA PEIRIS, VITHANAGE P. WICKRAMASINGHE, NOEL SOMASUNDARAM, Colombo, Sri Lanka, Battaramulla, Sri Lanka

8:45 a.m.-9:00 a.m.

58-OR Diastolic Dysfunction, a Precursor for Heart Failure in Young Adults with Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study
AMY S. SHAH, DANA DABELEA, LAWRENCE M. DOLAN, SCOTT ISOM, RALPH DAGOSTINO, JR., LYNNE E. WAGENKNECHT, GIUSEPPINA IMPERATORE, SHARON SAYDAH, ANGELA D. LIESE, JEAN M. LAWRENCE, CATHERINE PIHOKER, ELAINE M. URBINA, Cincinnati, OH, Aurora, CO, Winston-Salem, NC, Atlanta, GA, Hyattsville, MD, Columbia, SC, Pasadena, CA, Seattle, WA

9:00 a.m.-9:15 a.m.

59-OR Lipoprotein Particle Distribution by NMR in Youth with Type 2 Diabetes (T2D) in the TODAY Study
LORRAINE E. KATZ, JAMES D. OTVOS, KIMBERLY DREWS, BEREKET TESFALDET, FIDA BACHA, STEVEN M. WILLI, SANTICA M. MARCOVINA, SIRIPOOM MCKAY, RUTH S. WEINSTOCK, Cary, NC, Rockville, MD, Houston, TX, Philadelphia, PA, Seattle, WA, Syracuse, NY

9:15 a.m.-9:30 a.m.

60-OR OGTT Glucose Response Curves (GRC), Insulin Sensitivity (IS), and β-Cell Function (ßCF) in RISE: Youth–Adult Contrast at Randomization and in Response to Interventions to Preserve ßCF
SILVA A. ARSLANIAN, LAURE EL GHORMLI, JOON YOUNG KIM, TAMARA S. HANNON, KIEREN J. MATHER, SONIA CAPRIO, ELENA BARENGOLTS, KRISTEN J. NADEAU, KRISTINA UTZSCHNEIDER, STEVEN E. KAHN, THE RISE CONSORTIUM, Pittsburgh, PA, Syracuse, NY, Indianapolis, IN, New Haven, CT, Chicago, IL, Denver, CO, Seattle, WA, Rockville, MD

(continued on next page)
61-OR  Genetic and Metabolic Determinants of the Incretin Effect in Obese Adolescent with Prediabetes
ALFONSO GALDERISI, STEPHANIE SAMUELS, BRIDGET PIERPONT, CHIARA DALLA MAN, NICOLA
SANTORO, SONIA CAPRIO, New Haven, CT, Padova, Italy

9:45 a.m.-10:00 a.m.

62-OR  Childhood Adipokine Profiles Predict the Incidence and Trajectory of Obesity in Young Adults:
The BCAMS Study
SHAN GAO, MING LI, STEVEN M. WILLI, BCAMS GROUP, Beijing, China, Philadelphia, PA
SATURDAY, JUNE 13, 2020

8:00 a.m.-10:00 a.m. (continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Glucose Monitoring and Sensing

8:00 a.m.-8:15 a.m.

63-OR Towards Point-of-Care Devices: First Evaluation of an Insulin Immunosensor for Type 1 Diabetes
KELILAH L. WOLKOWICZ, EVA VARGAS, HAZHIR TEYMOURIAN, FARSHAD TEHRANI, JORDAN E. PINSKER, MEI MEI CHURCH, MOLLY PIPER, FRANCIS J. DOYLE III, MARY-ELIZABETH PATTI, LORI M. LAFFEL, JOSEPH WANG, EYAL DASSAU, Cambridge, MA, San Diego, CA, Santa Barbara, CA, Boston, MA, La Jolla, CA

8:15 a.m.-8:30 a.m.

64-OR Sustained Intensive Treatment and Long-Term Effects on A1C Reduction (SILVER Study) by CGM in Persons with T1D Treated with MDI
MARCUS LIND, ARNDIS F. OLAFOSSDOTTIR, IRL B. HIRSCH, JAN BOLINDER, SOFIA DAHLQVIST, ALDINA PIVODIC, JARL HELLMAN, MAGNUS O. WIJKMAN, ERIK SCHWARCZ, HENRIK ALBREKTSSON, TIM HEISE, WILLIAM POLONSKY, Seattle, WA, Stockholm, Sweden, Uddevalla, Sweden, Gothenburg, Sweden, Upplands, Sweden, Boston, MA, Örebro, Sweden, Neuss, Germany, San Diego, CA

8:30 a.m.-8:45 a.m.

65-OR Remote Monitoring of CGM Data at Diabetes Camp Mitigates Hypoglycemia Day and Night
SARAH E. GLEICH, NATHANIEL D. GIBSON-NORTH, SARAH PUHR, JOHN WELSH, TOMAS C. WALKER, DANIEL CARUSO, Reno, NV, San Diego, CA

8:45 a.m.-9:00 a.m.

66-OR Effect of Time-in-Range over 14 Days on Glycaemic Controls and Hypoglycaemia Unawareness in Patients Using Freestyle Libre
HARSHAL DESHMUKH, EMMA G. WILMOT, ROSELEE HERRING, JANE PATMORE, THOZHUKAT SATHYAPALAN, ROBERT E. RYDER, CHRISTOPHER WALTON, Derby, United Kingdom, Guildford, United Kingdom, Birmingham, United Kingdom, Hull, United Kingdom

9:00 a.m.-9:15 a.m.

67-OR Benefit of Reduced Hypoglycemia with Continuous Glucose Monitoring (CGM) Is Sustained through 12 Months among Young Children with Type 1 Diabetes (T1D)
MICHELLE A. VAN NAME, KELLEE MILLER, LAUREN KANAPKA, WILLIAM V. TAMBRLANE, LINDA DIMEGLIO, New Haven, CT, Tampa, FL, Indianapolis, IN

9:15 a.m.-9:30 a.m.

68-OR Dramatic Drop in Ketoacidosis Rate after FreeStyle Libre System Initiation in Type 1 and Type 2 Diabetes in France, Especially in People with Low Self-Monitoring of Blood Glucose (SMBG): A Nationwide Study
RONAN ROUSSE, BRUNO GUERCI, ERIC VICAUT, GERARD DEPOUVOURVILLE, BRUNO DETOURNAY, CORINNE EMERY, FLEUR LEVRAT-GUILLEN, JEAN-PIERRE RIVELINE, Paris, France, Vandoeuvre lès Nancy, France, Cergy Pontoise, France, Bourg-la-Reine, France, Maidenhead, United Kingdom

(continued on next page)

Information is subject to change. Sessions current as of 5/15/20.
69-OR Freestyle Libre System Use is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes
RICHARD M. BERGENSTAL, MATTHEW S.D. KERR, GREGORY J. ROBERTS, DIANA SOUTO, YELENA NABUTOVSKY, IRL B. HIRSCH, Minneapolis, MN, Sylmar, CA, Alameda, CA, Santa Clara, CA, Seattle, WA

70-OR Change in A1C with and without Intermittent Use of CGM in Adults with Type 2 Diabetes Participating in the Onduo Virtual Diabetes Clinic
JENNIFER E. LAYNE, HOWARD ZISSER, RICHARD M. BERGENSTAL, ROBERT A. GABBAY, NATHAN A. BARLEEN, DAVID P. MILLER, RONALD F. DIXON, Newton, MA, South San Francisco, CA, Minneapolis, MN, Boston, MA
SATURDAY, JUNE 13, 2020

8:00 a.m.-10:00 a.m.
(continued)

Oral Presentations
Theme Area: Integrated Physiology/Obesity
The Guts of Obesity

8:00 a.m.-8:15 a.m.
71-OR Oligofructose Improves Small Intestinal Nutrient-Sensing Mechanisms via the Small Intestinal Microbiota
SAVANNA N. WENINGER, EVE BEAUCHEMIN, ADELINA I.L. LANE, RACHEL MEYER, FRANK DUCA, Tucson, AZ

8:15 a.m.-8:30 a.m.
72-OR Proinflammatory Intestinal Macrophages Are Increased in Obesity Potentially by Enhanced Recruitment of Blood Monocytes
THERESA V. ROHM, REGULA FUCHS, ZORA BAUMANN, LENA KELLER, ROMANO SCHNEIDER, DANNY LABES, CLAUDIA CAVELTI-WEDER, Basel, Switzerland, Lausanne, Switzerland

8:30 a.m.-8:45 a.m.
73-OR Gut–Brain Signals That Regulate Hunger
ZACHARY KNIGHT, San Francisco, CA

8:45 a.m.-9:00 a.m.
74-OR The Effect of SERCA2 Activation on Liver Metabolism and Diet-Induced Steatohepatitis in Mice
TOMASZ BEDNARSKI, MOHSIN RAHIM, JAMEY YOUNG, Nashville, TN

9:00 a.m.-9:15 a.m.
75-OR Dietary Nitrate and Fecal Transplantation Prevent Cardiac Dysfunction and Attenuate Left Ventricular Mitochondrial Reactive Oxygen Species Emission in High-Fat Diet-Fed Mice
HEATHER L. PETRICK, HENVER BRUNETTA, ALEAH KIRSH, PIERRE-ANDRE BARBEAU, LESLIE M. OGILVIE, JEREMY SIMPSON, JONATHAN D. SCHERTZER, GRAHAM HOLLOWAY, Florianópolis, Brazil, Guelph, ON, Canada, Hamilton, ON, Canada

9:15 a.m.-9:30 a.m.
76-OR UK 1st National Health Service (NHS) EndoBarrier (EB) Service for Uncontrolled Diabesity: 2-Year Outcomes for All 62 Treated Patients
ROBERT E.J. RYDER, MAHENDER YADAGIRI, SUSAN P. IRWIN, WYN BURBRIDGE, MELANIE C. WYRES, TAHIRA BASHIR, HARDEEP GANDHI, RACHAEL ALLDEN, JOHN BLEASDALE, EDWARD FOGDEN, MARK ANDERSON, PIYA SEN GUPTA, Sandwell, United Kingdom, Birmingham, United Kingdom, London, United Kingdom

9:30 a.m.-9:45 a.m.
77-OR The Gut Peptide Neurotensin Does Not Reduce Appetite and Food Intake in Healthy Young Men
SIMON VEEDFALD, CHRISTOFFER MARTINUSSEN, MARIA S. SVANE, TUMMAS JUSTINUSSEN, MORTEN G. HINDSØ, NORA HEDBÅCK, CHARLOTTE B. CHRISTIANSEN, NICOLAI J. WEWER ALBRECHTSEN, KIRSTINE N. BOJSEN-MOLLER, BOLETTE HARTMANN, MOGENS FENERG, JENS F. REHFELD, STEN MADSBAD, SR., JENS J. HOLST, Copenhagen, Denmark, Hvidovre, Denmark

(continued on next page)
9:45 a.m.-10:00 a.m.

78-OR Glycaemia, Beta-Cell Function, and Incretin Hormones Post-OGTT One Year after Gastric Bypass and Sleeve Gastrectomy in Patients with Morbid Obesity and Type 2 Diabetes: An RCT (Oseberg Study)

FARHAT FATIMA, JØRAN HJELMESÆTH, KARE I. BIRKELAND, HANNE L. GULSETH, JENS K. HERTEL, MARIUS SVANEVIK, RUNE SANDBU, BOLETTE HARTMANN, JENS J. HOLST, DAG HOFSØ, Oslo, Norway, Tønsberg, Norway, Copenhagen, Denmark

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

8:00 a.m.-10:00 a.m.  
(continued)

Oral Presentations  
Theme Area: Islet Biology/Insulin Secretion  
Stressing Out the Beta Cell

8:00 a.m.-8:15 a.m.  
79-OR Signal-Dependent Chromatin Accessibility Dynamics in Pancreatic Islet Dysfunction  
ZONG WEI, Scottsdale, AZ

8:15 a.m.-8:30 a.m.  
80-OR \( \beta \)-Cell Hif1a-miR-21 Signaling Exacerbates \( \beta \)-Cell Dysfunction Occurring during Diabetogenic Stress  
SARA IBRAHIM, CLARISSA STEPHENS, RACHEL E. MOORE, RAGHAVENDRA MIRMIRA, EMILY K. SIMS, Indianapolis, IN

8:30 a.m.-8:45 a.m.  
81-OR The Impact of Proinflammatory Cytokines on Human Pancreatic Islet Alternative Splicing Patterns  
WENTING WU, FAROOQ SYED, EDWARD SIMPSON, CHIH-CHUN LEE, DECIO L. EIZIRIK, SR., RAGHAVENDRA MIRMIRA, YUNLONG LIU, CARMELLA EVANS-MOLINA, Indianapolis, IN, Brussels, Belgium

8:45 a.m.-9:00 a.m.  
82-OR Exosomes from Human \( \beta \)-Cells Incorporate Stress Granule Components and May Serve as Biomarkers of \( \beta \)-Cell Stress in Type 1 Diabetes  
FAROOQ SYED, BERNHARD F. MAIER, EMILY ANDERSON-BAUCUM, TERESA L. MASTRACCI, CARMELLA EVANS-MOLINA, RAGHAVENDRA MIRMIRA, Indianapolis, IN

9:00 a.m.-9:15 a.m.  
83-OR Pancreatic Exocrine to Endocrine Cell Cross Talk Mediates Endoplasmic Reticulum Stress and Beta-Cell Dysfunction in MODY8  
SEVIM KAHRAMAN, DANIELLE DIEGISSER, BENTE B. JOHANSSON, ANDERS MOLVEN, ROHIT KULKARNI, Boston, MA, Bergen, Norway

9:15 a.m.-9:30 a.m.  
84-OR Laminin-Islet Interactions Protect against Cytokine-Mediated Beta-Cell Death via Down-Regulation of Protein Kinase C Delta  
NIKKI L. FARNSWORTH, ROBERT A. PISCOPIO, RICHARD K. BENNINGER, Golden, CO, Aurora, CO

9:30 a.m.-9:45 a.m.  
85-OR Islet-Autonomous Inflammatory Signaling Propagates Autoimmunity and Promotes Diabetes in Nonobese Diabetic Mice  
ANNIE PINEROS, ABHISHEK KULKARNI, MARIMAR HERNANDEZ-PEREZ, KARA ORR, LINDSEY GLENN, CHRISTOPHER A. REISSAUS, MAUREEN GANNON, MARCIA J. MCDUFFIE, JERRY NADLER, MARGARET A. MORRIS, RAGHAVENDRA MIRMIRA, SARAH A. TERSEY, Greenwood, IN, Indianapolis, IN, Nashville, TN, Charlottesville, VA, Norfolk, VA, Rockville, MD, Chicago, IL

9:45 a.m.-10:00 a.m.  
86-OR High-Fat Diet Prevents Autoimmune Diabetes in NOD Mice  
AMY L. CLARK, ZIHAN YAN, SOPHIA X. CHEN, MATT FUESS, GABRIELLE MCGINN, MARIA S. REMEDI, St. Louis, MO

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

10:15 a.m.-11:30 a.m.

ADA Chief Executive Officer Remarks
Tracey D. Brown, MBA, BChE

and

President, Health Care & Education Address
50 Years of Behavioral Science in Diabetes—A 2020 Vision of the Future
Mary de Groot, PhD

and

Outstanding Educator in Diabetes Award Lecture
Tedious, Tiresome, and Dull—An Unrecognized Problem That We Can Solve
William H. Polonsky, PhD, CDCES

11:30 a.m.-12:30 p.m.

Professional Interest Group Discussion
Theme Area: Acute and Chronic Complications
Professional Interest Group Discussion on Foot Care—Realistic Approaches to Reduce Diabetic Foot Infections
Chair: Shelley Gath, DPM
11:30 a.m.-12:00 p.m. Behaviorial Medicine Interventions for Self-Care of the Neuropathic Foot
Jeffrey S. Gonzalez, PhD
12:00 p.m.-12:30 p.m. Strategies to Reduce Severe Diabetic Foot Infections during Epidemics
Rodica Pop-Busui, MD, PhD

Professional Interest Group Discussion
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Professional Interest Group Discussion on Exercise Physiology—The Molecular Transducers of Physical Activity (MoTrPAC)
Chair: Jane E.B. Reusch, MD
11:30 a.m.-11:50 a.m. Welcome and Introductions
Jane E.B. Reusch, MD
11:50 a.m.-12:10 p.m. MoTrPAC Human Studies
Nicolas Musi, MD
12:10 p.m.-12:30 p.m. MoTrPAC Animal Studies
Laurie J. Goodyear, PhD
SATURDAY, JUNE 13, 2020

11:30 a.m.-12:30 p.m.
(continued)

Professional Interest Group Discussion
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Professional Interest Group Discussion on Nutritional Science and Metabolism—Emerging Methodologies for Personalized Nutrition—Potential Effects on Glycemic and Other Diabetes-Related Outcomes?
Chair: Judith Wylie-Rosett, EdD, RDN
11:30 a.m.-11:35 a.m. Overview and Introductions
Judith Wylie-Rosett, EdD, RDN
11:35 a.m.-11:40 a.m. Personalized Nutrition—Recommendations and Questions from the ADA 2019 Nutrition Consensus Report
Patti Urbanski, MEd, RD, LD, CDE
11:40 a.m.-12:00 p.m. Efficacy of Personalized Nutrition Based on Gut Microbiome and Clinical Data in Prediabetes
Eran Segal, PhD
12:00 p.m.-12:10 p.m. Response and Discussion
Anthony J. Pick, MD, CDCES
12:10 p.m.-12:20 p.m. Response and Discussion
Guoxun Chen, PhD
12:20 p.m.-12:30 p.m. Response and Discussion
Patti Urbanski, MEd, RD, LD, CDE

Professional Interest Group Discussion
Theme Area: Clinical Diabetes/Therapeutics
Professional Interest Group Discussion on Clinical Centers and Programs—Frequently Encountered Glycemic Management Issues without Clear Guidelines
Chair: Edward C. Chao, DO
11:30 a.m.-11:40 a.m. Introduction
Mary T. Korytkowski, MD
11:40 a.m.-12:05 p.m. Management of Steroid Associated Hyperglycemia in Inpatient and Outpatient Settings
Cecilia C. Low Wang, MD, FACP
12:05 P.m.-12:30 p.m. Use of Continuous Glucose Monitoring Devices in the Hospital—Time for Glucose Telemetry?
Ilias (Elias) Spanakis, MD

Professional Interest Group Discussion
Theme Area: Islet Biology/Insulin Secretion
Professional Interest Group Discussion on Islet Biology, Development, and Function—Debate—Chewing the Fat on the Role of Glucolipotoxicity in Type 2 Diabetes
Chair: Marc Prentki
11:30 a.m.-11:40 p.m. Introduction
Hubert M. Tse, PhD
11:40 a.m.-12:05 p.m. Is Glucolipotoxicity Involved in Islet Dysfunction in Diabetes?
Vincent Poitout, DVM, PhD
12:05 p.m.-12:30 p.m. Islet Dysfunction is More than Glucolipotoxicity
Roy Taylor, MD

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

1:45 p.m.-2:45 p.m.

Current Issues
Theme Area: Clinical Diabetes/Therapeutics
Debate—The Use of Continuous Glucose Monitoring in Type 2 Diabetes Mellitus—Is There Value?
Chair: Anne L. Peters, MD
1:45 p.m.-2:10 p.m. Yes
Athena Philis-Tsimikas, MD
2:10 p.m.-2:35 p.m. No
Elbert Huang, MD, MPH, FACP
2:35 p.m.-2:40 p.m. Rebuttal
Athena Philis-Tsimikas, MD
2:40 p.m.-2:45 p.m. Rebuttal
Elbert Huang, MD, MPH, FACP

1:45 p.m.-3:45 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Clinical Management of Diabetic Neuropathies in 2020
Chair: Rodica Pop-Busui, MD, PhD
1:45 p.m.-2:25 p.m. Lifestyle and Dietary Modifications—Relevance in the Management of Diabetic Neuropathy?
Douglas Wright, PhD
2:25 p.m.-3:05 p.m. Perspectives in Pharmacology of Painful Neuropathy in 2020
Solomon Tesfaye, MB, ChB, MD, FRCP
3:05 p.m.-3:45 p.m. Clinical Management of Gastrointestinal Autonomic Neuropathies
Karen L. Jones, PhD, DipAppSc

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Maximizing Long-Term Weight Loss Maintenance with Lifestyle Changes
Chair: Hope Warshaw, MMSc, RD, CDE, BC-ADM
1:45 p.m.-2:15 p.m. Overcoming Physiologic Changes from Weight Loss to Achieve Long-Term Weight Loss Maintenance
Michael Rosenbaum, MD
2:15 p.m.-2:45 p.m. Critical Psychological, Psychosocial, and Environmental Modifications to Achieve Long-Term Weight Loss Maintenance
Colin Greaves, PhD, CPsychol
2:45 p.m.-3:15 p.m. Essential Role of Physical Activity to Achieve Long-Term Weight Loss Maintenance and Implementation Strategies
James O. Hill, PhD
3:15 p.m.-3:45 p.m. Evidence-Based Factors and Real-World Models for Success
J. Graham Thomas, PhD

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

1:45 p.m.-3:45 p.m.
(continued)

**Symposium**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*
**Inpatient Diabetes Care and Education—What Does the Evidence Tell Us?**
Chair: Jane Jeffrie Seley, DNP, MSN, MPH, GNP, BC-ADM, CDE, CDTC, FAADE, FAAN
1:45 p.m.-2:25 p.m. *Models for Inpatient Diabetes Education in the Real World*
Carine M. Nassar, MS, RD, CDE
2:25 p.m.-3:05 p.m. *The Ever-Expanding Role of the Pharmacist in the Inpatient Setting*
Helen A. Habib, PharmD, CDE
3:05 p.m.-3:45 p.m. *Can an Inpatient Diabetes Management Service Decrease Length of Stay and Prevent Readmission?*
Mihail Zilbermint, MD

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
**Joint ADA/ISPAD Symposium—Hemoglobin A1C vs. Time-in-Range as the Primary Metric in Pediatric Diabetes?**
Chair: Aaron J. Kowalski, PhD
1:45 p.m.-2:25 p.m. *The Case for A1C as the Primary Metric*
William E. Winter, MD
2:25 p.m.-3:05 p.m. *The Case for Time-in-Range as the Primary Metric*
Thomas Danne, MD
3:05 p.m.-3:45 p.m. *Practical Strategies to Personalize and Target Time-in-Range in Pediatric Diabetes*
Daniel DeSalvo, MD

**Symposium**
*Theme Area: Insulin Action/Molecular Metabolism*
**Lipid Signaling and Lipidomics**
Chair: Yu-Hua Tseng, PhD
1:45 p.m.-2:15 p.m. *Nutrient Sensing and Bioenergetics*
Deborah M. Muoio, PhD
2:15 p.m.-2:45 p.m. *Ceramides—The New Cholesterol?*
Scott A. Summers, PhD
2:45 p.m.-3:15 p.m. *Obesity and Metabolic Disease*
Matthew S. Rodeheffer, PhD
3:15 p.m.-3:45 p.m. *Transcriptional Networks Controlling Lipid Metabolism*
Claudio Villanueva, PhD

*Information is subject to change. Sessions current as of 5/15/20.*
SATURDAY, JUNE 13, 2020

1:45 p.m.-3:45 p.m.
(continued)

Symposium
Theme Area: Integrated Physiology/Obesity
The New Physiology—Organs in a Dish—Promises, Pitfalls, and Potential Clinical Applications
Chair: Erin E. Kershaw, MD
1:45 p.m.-2:15 p.m. State-of-the-Art Lecture—The Promise and Impact of Organoid Medicine
Linda G. Griffith, PhD
2:15 p.m.-2:45 p.m. Long-Term Expansion of Pancreatic Islet Organoids from Resident Procr Progenitors
Yi Arial Zeng, PhD
2:45 p.m.-3:15 p.m. Organoids to Study Human and Molecular Genetics of Fatty Liver Disease
Stefano Romeo, MD, PhD
3:15 p.m.-3:45 p.m. Synergistic Engineering of an Ex Vivo Type 2 Diabetes Model—Organoids and Organs on a Chip
John P. Wikswo, Jr., PhD

Symposium
Theme Area: Islet Biology/Insulin Secretion
Slicing and Dicing—Prohormone Processing in Diabetes
Chair: Peter Arvan, MD, PhD
1:45 p.m.-2:15 p.m. Impaired Prohormone Processing in Type 2 Diabetes
Steven E. Kahn, MB, ChB
2:15 p.m.-2:45 p.m. Impaired Prohormone Processing in Type 1 Diabetes
Emily K. Sims, MD
2:45 p.m.-3:15 p.m. Pro-Islet Amyloid Polypeptide Processing in Diabetes
Bruce Verchere, PhD
3:15 p.m.-3:45 p.m. Histologic Analysis of Prohormone Processing
Teresa Rodriguez-Calvo, DVM, PhD

Current Issues
Theme Area: Clinical Diabetes/Therapeutics
Debate—Should the Artificial Pancreas Be Single or Dual Hormone?
Chair: Rémi Rabasa-Lhoret, MD, PhD
2:45 p.m.-3:10 p.m. Single Hormone
Roman Hovorka, PhD, FMedSci
3:10 p.m.-3:35 p.m. Dual Hormone
Steven J. Russell, MD, PhD
3:35 p.m.-3:40 p.m. Rebuttal
Roman Hovorka, PhD, FMedSci
3:40 p.m.-3:45 p.m. Rebuttal
Steven J. Russell, MD, PhD

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

1:45 p.m.-3:45 p.m.

Oral Presentations
Theme Area: Acute and Chronic Complications
Cellular Mechanisms of Atherogenesis in Diabetes—New Insights (With Edwin Bierman Award Lecture)

1:45 p.m.-2:15 p.m.
Edwin Bierman Award Lecture

Role of Epigenetics in Diabetic Vascular Complications and Metabolic Memory
Rama Natarajan, PhD, FAHA, FASN

2:15 p.m.-2:30 p.m.

87-OR NF Kappa B Expression Is Related to Diabetes and Impaired Respiratory Capacity of Human Ventricular Myocardium
ELRIC ZWECK, DANIEL SCHEIBER, TOMAS JELENIK, PATRICK HORN, DOMINIK PESTA, DIRK LASSNER, HEINZ-PETER SCHULTHEISS, UDO BOEKEN, PAYAM AKHYARI, ARTUR LICHTENBERG, MALTE KELM, MICHAEL RODEN, RALF WESTENFELD, JULIA SZENDROEDI, Düsseldorf, Germany, Biberach an der Riss, Germany, Berlin, Germany

2:30 p.m.-2:45 p.m.

88-OR Glyoxalase-1 Gene Transfer Attenuated Diastolic Dysfunction in Female db/db Mice
KESHORE BIDASEE, Omaha, NE

2:45 p.m.-3:00 p.m.

89-OR FGFR1/MAPKs/AP-1 Signaling Mediates Cardiomyopathy in Streptozotocin-Induced Type 1 Diabetes
XIONG CHEN, YAFENG WANG, FEIXIA SHEN, Wenzhou, China, Wuhan, China

3:00 p.m.-3:15 p.m.

90-OR Inhibition of miRNA-200b Rescues Diabetes-Impaired Angiogenesis
CARLA CANNIZZO, EMMA SOLLY, LUISA F. OLAYA, MARYAM ABDOLLAHI, SURYA S. SUTANTO, STEPHEN M. TWIGG, CHRISTINA BURSILL, JOANNE T. TAN, SUSAN MCLENNAN, Adelaide, Australia, Duarte, CA, Sydney, Australia

3:15 p.m.-3:30 p.m.

91-OR CTRP3, a Novel Adipokine with Anti-inflammatory and Cardioprotective Properties, in Patients with Cardiovascular Diseases and Type 2 Diabetes Mellitus
HELENA KRATOCHVILOVA, BARBORA JUDITA KASPEROVA, ZDENKA LACINOVA, IVANA LANKOVA, JAROSLAVA TRNOVSKA, IVAN NETUKA, PETER IVAK, JAKUB MAHRÍK, DANIEL HLAVÁCEK, MILOS MRAZ, MARTIN HALUZIK, Prague, Czech Republic, Praha, Czech Republic

3:30 p.m.-3:45 p.m.

92-OR EMC10, a Novel Serum Predictor for Coronary Artery Disease, Exerts an Impact on the Development of Atherosclerosis via Negatively Modulating Endothelial Insulin Signaling
YU JING, XINRU WANG, YIFEI YU, KUANGYANG CHEN, SHUOSHUO JIN, YANLIANG LI, XUANCHUN WANG, Shanghai, China

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

1:45 p.m.-3:45 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
I Got You, Babe (With Norbert Freinkel Award Lecture)

1:45 p.m.-2:15 p.m.
Norbert Freinkel Award Lecture
Paradigm Shifts in the Management of Diabetes in Pregnancy
David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)

2:15 p.m.-2:30 p.m.
93-OR Low Maternal Insulin Sensitivity Associates with DNA-Related Functions in Human First-Trimester Trophoblast
JULIA BANDRES-MERIZ, DENISE HOCH, SOPHIE HONEDER, ALEJANDRO MAJALI-MARTINEZ, EMILIO HERRERA, MATTHIAS SCHITTMAYER, RUTH BIRNER-GRUENBERGER, GERNOT DESOYE, Graz, Austria, Madrid, Spain, Vienna, Austria

2:30 p.m.-2:45 p.m.
94-OR Postpartum Circulating MicroRNAs Can Predict the Development of Type 2 Diabetes in Women with Previous Gestational Diabetes
MUGDHA JOGLEKAR, WILSON K. WONG, FAHMIDA KHAN EMA, HARRY M. GEORGIOU, ANAND HARDIKAR, MARTHA LAPPAS, Camperdown, Australia, Sydney, Australia, Parkville, Australia, Melbourne, Australia

2:45 p.m.-3:00 p.m.
95-OR Plasma miRNAs Levels at First Trimester of Pregnancy Predict Insulin Sensitivity Estimated at the Second Trimester of Pregnancy
CÉCILIA LÉGARÉ, VÉRONIQUE DESGAGNÉ, FRÉDÉRIQUE WHITE, MICHELLE S. SCOTT, PATRICE PERRON, MARIE-FRANCE HIVERT, RENÉE GUÉRIN, LUIGI BOUCHARD, Chicoutimi, QC, Canada, Sherbrooke, QC, Canada, Boston, MA, Saguenay, QC, Canada

3:00 p.m.-3:15 p.m.
96-OR Integrative Omics Analysis Revealed That the Metabolic Changes in Placental Cells from Gestational Diabetes Mellitus Are Reflected in Their Secreted Exosomes
SOUMYALEKSHMI NAIR, NANTHINI JAYABALAN, KATHERIN SCHOLZ-ROMERO, DOMINIC GUANZON, ANDREW LAI, DAVID MCINTYRE, MARTHA LAPPAS, CARLOS SALOMON, Brisbane, Australia, Herston, Australia, South Brisbane, Australia, Melbourne, Australia

3:15 p.m.-3:30 p.m.
97-OR Randomization to a Higher–Complex Carbohydrate vs. Conventional Diet in GDM Improves Glucose Tolerance and Results in Similar Cord Blood Insulin and Newborn Adiposity
TERI L. HERNANDEZ, SARAH S. FARABI, JARON ARBET, NICOLE HIRSCH, EMILY Z. DUNN, KRISTY P. HEISS, JAYNE MARTIN CARLI, NANCY F. KREBS, THERESA L. POWELL, REGINA REYNOLDS, RACHAEL E. VAN PELT, JACOB E. FRIEDMAN, LINDA (LYNN) A. BARBOUR, St. Louis, MO, Aurora, CO, Westminster, CO, Oklahoma City, OK

(continued on next page)
3:30 p.m.-3:45 p.m.

98-OR Placental DNA Methylation Changes Associated with Birthweight and Overlaps with Adult Type 2 Diabetes
FASIL TEKOLA-AYELE, TSEGASELASSIE WORKALEMAHU, XUEHUO ZENG, Salt Lake City, UT, Bethesda, MD
Oral Presentations

Theme Area: Epidemiology/Genetics

Diabetes Prediction, Prevention, and Control—Are We Making Progress?

1:45 p.m.-2:00 p.m.

99-OR An Inflection Point (IP) of C-Peptide (C-P) Decline during Progression to Type 1 Diabetes (T1D)
HEBA M. ISMAIL, JAY S. SKYLER, JAY SOSENKO, JERRY P. PALMER, CARMELLA EVANS-MOLINA, LINDA DIMEGLIO, MARIA J. REDONDO, ANDREA STECK, MARK A. ATKINSON, KEVAN C. HEROLD, BRANDON M. NATHAN, Indianapolis, IN, Miami, FL, Seattle, WA, Houston, TX, Aurora, CO, Gainesville, FL, New Haven, CT, Minneapolis, MN

2:00 p.m.-2:15 p.m.

100-OR High-Affinity Islet Autoantibodies Predict Progression to Diabetes in Those Who Seroconvert after Age 10
BRIGITTE I. FROHNERT, FRAN DONG, KATHLEEN WAUGH, ANDREA STECK, JILL M. NORRIS, LIping YU, MARIAN REWERS, Aurora, CO, Denver, CO

2:15 p.m.-2:30 p.m.

101-OR ADA Screening Guidelines and Racial Differences in Detection of Prediabetes and Diabetes in the U.S.: NHANES, 2011-2016
ALEXANDRA K. LEE, UNJALI GUJRAL, MOHAMMED K. ALI, NAMRATHA R. KANDULA, ALKA M. KANAYA, San Francisco, CA, Atlanta, GA, Chicago, IL

2:30 p.m.-2:45 p.m.

102-OR Detection of Diabetes from Whole-Body Magnetic Resonance Imaging Using Deep Learning
ROBERT WAGNER, BENEDIKT DIETZ, JÜRGEN MACHANN, PATRICK SCHWAB, JULIA K. DIENES, STEFFEN REICHTER, ANDREAS L. BIRKENFELD, HANS-ULRICH HAERING, FRITZ SCHICK, NORBERT STEFAN, MARTIN HENI, HUBERT PREISSL, BERNHARD SCHÖLKOPF, STEFAN BAUER, ANDREAS FRITSCH, Zurich, Switzerland, Dresden, Germany, Tübingen, Germany

2:45 p.m.-3:00 p.m.

103-OR Change in Lifetime Risk for Diabetes in the United States, 1997-2015
YILING J. CHENG, EDWARD W. GREGG,RALPH BRINKS, SHARON H. SAYDAH, ANN L. ALBRIGHT, GIUSEPPINA IMPERATORE, Atlanta, GA, London, United Kingdom, Düsseldorf, Germany, Hyattsville, MD

3:00 p.m.-3:15 p.m.

104-OR Lifestyle Interventions in Persons with IGT Prolong the Time Free of Major Diabetes-Related Complications: 30-Year Results of the Da Qing Diabetes Prevention Outcome Study (DQDPS)
QIUCHONG GONG, PING ZHANG, JINPING WANG, YANYAN CHEN, YALI AN, XINXING FENG, YILING J. CHENG, JIXIANG MA, PETER H. BENNETT, GUANGWEI LI, Daqing, China, Atlanta, GA, Beijing, China, Phoenix, AZ

3:15 p.m.-3:30 p.m.

105-OR Trends in Complications in Type 1 and Type 2 Diabetes in Denmark, 1996-2016
BENDIX CARSTENSEN, HANAN AMADID, MARIT E. JØRGENSEN, Gentofte, Denmark

(continued on next page)
3:30 p.m.-3:45 p.m.

**106-OR** National Trends in Lower Extremity Amputation among U.S. Medicare Beneficiaries with Diabetes, 2000-2017

JESSICA HARDING, LINDA J. ANDES, DEBORAH B. ROLKA, GIUSEPPINA IMPERATORE, YANFENG LI, ED GREGG, ANN L. ALBRIGHT, Atlanta, GA, London, United Kingdom
Oral Presentations

Theme Area: Epidemiology/Genetics

Genetics and Functional Impact of Variants in Type 1 Diabetes

1:45 p.m.-2:00 p.m.

107-OR Novel Genetic Risk Factors Influence Islet Autoimmunity Progression
SUNA ONENGUT-GUMUSCU, UMA DEVI PAILA, WEI-MIN CHEN, AAKROSH RATAN, ZHENNAN ZHU, ANDREA STECK, BRIGITTE I. FROHNERT, KATHLEEN WAUGH, BOBBIE-JO WEBB-ROBERTSON, JILL M. NORRIS, LESLIE LANGE, MARIAN REWERS, STEPHEN S. RICH, Charlottesville, VA, Aurora, CO, Richland, WA, Denver, CO

2:00 p.m.-2:15 p.m.

108-OR Application of a European Genetic Risk Score for Type 1 Diabetes in a Han-Chinese Population
RAYMOND WAN, SETH A. SHARP, CLAUDIA H.T. TAM, MICHAEL N. WEEDON, JULIANA C. CHAN, WILLIAM HAGOPIAN, RICHARD A. ORAM, RONALD C. MA, Hong Kong, China, Seattle, WA, Exeter, United Kingdom

2:15 p.m.-2:30 p.m.

109-OR Genetic Discrepancy of HLA Class I Alleles in Chinese Patients with Type 1 Diabetes at Different Onset Ages
ZIYU JIANG, WENQIAN REN, YINGXIN XIAN, JINHUA YAN, DAIZHI YANG, SIHUI LUO, XUEYING ZHENG, WEN XU, JIN-XIN BEI, LEIF GROOP, JIANPING WENG, Guangzhou, China, Hefei, China, Helsinki, Finland

2:30 p.m.-2:45 p.m.

110-OR Type 2 Diabetes (T2D)–Associated TCF7L2 Genetic Variants and Indices of Insulin Secretion and Sensitivity in Individuals at Risk for Type 1 Diabetes (T1D)
MARIA J. REDONDO, MEGAN V. WARNOCK, LAURA E. BOCCHINO, SUSAN GEYER, ALBERTO PUGLIESE, ANDREA STECK, INGRID LIBMAN, CARMELLA EVANS-MOLINA, DOROTHY J. BECKER, JAY SOSENKO, FIDA BACHA, TYPE 1 DIABETES TRIALNET STUDY GROUP, Houston, TX, Tampa, FL, Miami, FL, Aurora, CO, Pittsburgh, PA, Indianapolis, IN

2:45 p.m.-3:00 p.m.

111-OR MODY3 Diagnosis from Deidentified Pancreatic Tissue Leads to Variant Identification in Living Relatives
DAVID SPARLING, RACHANA HALIYUR, JILL LINDNER, LINDA WEBER, ANDREA RAMIREZ, MARCELA BRISSOVA, ALVIN C. POWERS, Nashville, TN, Oklahoma City, OK

3:00 p.m.-3:15 p.m.

112-OR Integrative Analysis of Chromatin Accessibility and Genetic Risk in T1D Patients and Controls
CATHERINE C. ROBERTSON, WEI-MIN CHEN, SUNA ONENGUT-GUMUSCU, PATRICK J. CONCANNON, STEPHEN S. RICH, Charlottesville, VA, Gainesville, FL

3:15 p.m.-3:30 p.m.

113-OR Circular RNAs: Promising Biomarkers for Type 1 Diabetes
CONGCONG YIN, QING-SHENG MI, Detroit, MI

(continued on next page)
3:30 p.m.-3:45 p.m.

114-OR  T1DM in the Chronically Undernourished: Rural Ethiopia

ELISABETH R. TRIMBLE, SHITAYE A. BALCHA, ABAYNEH G. DEMISSE, DIANA L. COUSMINER, RAJASHREE MISHRA, BENJAMIN F. VOIGHT, KIMBERLY LORENZ, TANWI VARTAK, SAMUEL T. JERRAM, KENYAITA M. HODGE, STANLEY SCHWARTZ, ALICE HOLMES, ARLA GAMPER, HANNAH F. WILSON, ALISTAIR J. WILLIAMS, RICHARD D. LESLIE, STRUAN F. GRANT, DAVID I.W. PHILLIPS, Belfast, United Kingdom, Gondar, Ethiopia, Philadelphia, PA, Bristol, United Kingdom, London, United Kingdom, Southampton, United Kingdom
SATURDAY, JUNE 13, 2020

1:45 p.m.-3:45 p.m.
(continued)

Oral Presentations

Theme Area: Immunology/Transplantation

Improving Transplant Outcomes

1:45 p.m.-2:00 p.m.

115-OR Early Insulin Pump Use in Pediatric Post–Total Pancreatectomy Islet Auto Transplantation Management
SIOBHAN E. TELLEZ, LINDSEY HORNUNG, JOSHUA D. COURTER, MAISAM ABU-EL-HAIJA, JAIMIE D. NATHAN, SARAH LAWSON, DEBORAH A. ELDER, Cincinnati, OH

2:00 p.m.-2:15 p.m.

116-OR Comparison of Pancreas vs. Islet Transplantation Outcomes from a Large Single Center
BRAULIO A. MARFIL-GARZA, ANNA LAM, DAVID BIGAM, PETER SENIOR, A.M. JAMES SHAPIRO, Edmonton, AB, Canada, Alberta, AB, Canada

2:15 p.m.-2:30 p.m.

117-OR Islet Cell Transplantation for Type 1 Diabetes: The UIC Experience, 2004-2020
KIRSTIE K. DANIELSON, REBECCA S. MONSON, YI LI, JOSE OBERHOLZER, Chicago, IL, Charlottesville, VA

2:30 p.m.-2:45 p.m.

118-OR HLA Matching and Clinical Outcomes in Islet Transplantation
VIRGINIA FUENMAYOR, CARMEN CHAVEZ, DAVID BAIDAL, ANA M. ALVAREZ, NATHALIA PADILLA, CAMILLO RICORDI, RODOLFO ALEJANDRO, Miami, FL

2:45 p.m.-3:00 p.m.

119-OR Total Pancreatectomy with Islet Autotransplantation in Diabetic and Prediabetic Patients with Intractable Chronic Pancreatitis
PIOTR J. BACHUL, PETER BOREK, ROI ANTEBY, LINDSAY BASTO, LAURENCIA Perea, KAROLINA GOLAB, LING-JIA WANG, MARTIN L. TIBUDAN, ANGELICA PEREZ-GUTIERREZ, MICHAL KOMORNICZAK, SAJAN NAGPAL, AARON C. LUCANDER, MICHAEL DIMITROV, JOHN FUNG, JEFFREY B. MATTHEWS, PIOTR WITKOWSKI, Tel Aviv, Israel, Chicago, IL, Gdansk, Poland

3:00 p.m.-3:15 p.m.

120-OR Diabetes-Related Quality of Life Assessment in Children following Total Pancreatectomy with Islet Autotransplantation
JACOB M. REDEL, LINDSEY HORNUNG, DEBORAH A. ELDER, JAIMIE D. NATHAN, MAISAM ABU-EL-HAIJA, Cincinnati, OH, Mason, OH

3:15 p.m.-3:30 p.m.

121-OR Immunosuppressant-Related Quality of Life and Lifestyle of Insulin Independent T1D Pancreas Transplant Recipients
RAVINDER JEET KAUR, COREY REID, SHAFAQ RAZA RIZVI, SREEDHAR BATTHULA, SHELBY K. MCCRAY-SPIZTER, BYRON H. SMITH, WALTER K. KREMMERS, PATRICK DEAN, ALEKSANDRA KUKLA, MARK D. STEGALL, YOGISH C. KUDVA, Rochester, MN

3:30 p.m.-3:45 p.m.

122-OR Profile of Type 2 Diabetes (T2D) Donors in the Integrated Islet Distribution Program (IIDP)
BARBARA J. OLACK, JULIE KILBURN, JIA-NING J. CHUANG, JAMES CRAVENS, JOYCE C. NILAND, Duarte, CA

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

4:00 p.m.-5:15 p.m.

**Symposium**
*Theme Area: Acute and Chronic Complications*

**DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?!**
Chair: Subodh Verma, MD, PhD, FRCSC

4:00 p.m.-4:25 p.m.  **Background and Main Cardiovascular Outcomes**
  John J.V. McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, FRCP, FESC

4:25 p.m.-4:40 p.m.  **Patient-Centered Outcomes**
  Mikhail N. Kosiborod, MD

4:40 p.m.-4:55 p.m.  **Metabolic Outcomes, Diabetes Prevention, and Safety**
  Silvio E. Inzucchi, MD

4:55 p.m.-5:15 p.m.  **Independent Commentary—Implications for Clinical Care and Future Directions**
  Jeffrey M. Testani, MD, MTR

4:00 p.m.-5:40 p.m.

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*

**Diabetes in Sub-Saharan Africa—Challenges and Opportunities**
Chair: Ayesha A. Motala, MB, ChB, MD, FRCP, FCP

4:00 p.m.-4:20 p.m.  **Overview of Diabetes Epidemiology and Complications in Sub-Saharan Africa**
  Jean Claude Mbanya, MD, PhD, MRCP (UK), FRCP (London), FTWAS

4:20 p.m.-4:40 p.m.  **The Diabetic Foot in Africa—Evidence-Based Strategies to Reduce the Amputation Rate**
  Zulfiqarali G. Abbas, MBBS, MMed, DTM&H (UK), FRCP (Glasgow), FRCP (London)

4:40 p.m.-5:00 p.m.  **Prevention of Type 2 Diabetes in Africa**
  Samuel Dagogo-Jack, MD, DSc

5:00 p.m.-5:20 p.m.  **Big Data from Africa—The Human Health and Heredity in Africa (H3Africa) Diabetes Study**
  Ayesha Motala, MB, ChB, MD, FRCP, FCP

5:20 p.m.-5:40 p.m.  **Transplanting Molecular Diabetology to Africa—The Nigerian Experience**
  Wasiu Gbolahan Balogun, PhD

*Information is subject to change. Sessions current as of 5/15/20.*
SATURDAY, JUNE 13, 2020

4:00 p.m.-5:50 p.m.

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Diabetes Devices and Digital Technologies—Who Does It Help the Most (and Least)? (With Richard R. Rubin Award Lecture)
Chair: Michael Harris, PhD
4:00 p.m.-4:30 p.m.
Richard R. Rubin Award Lecture—Call the Coach—Opportunities and Challenges for Parent Coaching in Pediatric Type 1 Diabetes
Randi Streisand, PhD

4:30 p.m.-4:50 p.m.
Is One-Size-Fits-All Actually a Bad Approach?
Korey K. Hood, PhD

4:50 p.m.-5:10 p.m.
Benefits of Device and Tech Use in Tech-Naive and Tech-Underutilizing Populations
Jill Weissberg-Benchell, PhD, CDE

5:10 p.m.-5:30 p.m.
How Tech May Unintentionally Widen the Health Disparities Gap
Lyndsay A. Nelson, PhD

5:30 p.m.-5:50 p.m.
Continuous Glucose Monitoring for Those Most Challenged by Diabetes—Why Not?
Kimberly B. Spiro, PhD

4:00 p.m.-6:00 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Dilemmas in Diabetic Foot Infection Management
Chair: Crystal Holmes, DPM, CWSP
4:00 p.m.-4:30 p.m.
Diabetic Osteomyelitis When Bone Biopsy Is Not an Option
Katherine M. Rasovic, DPM

4:30 p.m.-5:00 p.m.
Effects of Withholding Antibiotics Prior to Bone Biopsy
Peter Crisologo, DPM

5:00 p.m.-5:30 p.m.
Fungal Diabetic Osteomyelitis—Is It Real?
Qeena C. Woodard, DPM, CWS

5:30 p.m.-6:00 p.m.
Complications of Long-Term IV Antibiotics—Are We Considering the Risk to Our Patients?
Tejal Gandhi, MD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Myosteatosis—What Happens When Skeletal Muscle Is Marbled Like Steak?
Chair: Osama Hamdy, MD, PhD
4:00 p.m.-4:30 p.m.
Muscle Quality Matters—Associations between Intermuscular Fat and Muscle Insulin Sensitivity and Mortality Risk
Susanna M. Hofmann, MD

4:30 p.m.-5:00 p.m.
Impact of Diet, Exercise, Obesity, Aging, and Diabetes on Intermuscular and Subfascial Fat Depots
Barbara Gower, PhD

5:00 p.m.-5:30 p.m.
Interventions to Favorably Alter Muscle Fat—Where Do We Go From Here?
Lisa S. Chow, MD, MS

5:30 p.m.-6:00 p.m.
The Athlete’s Paradox—Benign vs. Pathological Skeletal Muscle Lipids
Bryan C. Bergman, PhD

Information is subject to change. Sessions current as of 5/15/20.
Symposium
Theme Area: Epidemiology/Genetics
Returning Genetic Results to the Patient with Diabetes
Chair: Stephen S. Rich, PhD, FAHA
4:00 p.m.-4:40 p.m. Returning Incidental Findings in Genomic Research in Diverse Populations
Adolfo Correa, MD, PhD
4:40 p.m.-5:20 p.m. Returning Genetic Evidence in Monogenic Diabetes
Siri Atma W. Greeley, MD, PhD
5:20 p.m.-6:00 p.m. Implementing the Return of Genetic Results in Diabetes Practice
Toni I. Pollin, MS, PhD, CGC

Symposium
Theme Area: Immunology/Transplantation
The Microbiome in Type 1 Diabetes—Where Are We Now?
Chair: Mark A. Atkinson, PhD
4:00 p.m.-4:30 p.m. Development of the Gut Microbiome in Early Childhood
Christopher Stewart, PhD
4:30 p.m.-5:00 p.m. What Does the Gut Microbiome Look Like in Type 1 Diabetes?
Eric Triplett, PhD, MS, BS
5:00 p.m.-5:30 p.m. Manipulating the Gut Microbiome to Treat Diabetes
Emma Hamilton-Williams, PhD
5:30 p.m.-6:00 p.m. Fecal Transplantation for Type 1 Diabetes
Max Nieuwdorp, MD, PhD

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Immunity, Metabolism, and Diabetes
Chair: Alan Saltiel, PhD
4:00 p.m.-4:30 p.m. Adipose Macrophage and Metabolic Homeostasis
Carey N. Lumeng, MD, PhD
4:30 p.m.-5:00 p.m. Regulation of Adipose Inflammation by Metabolic Endoplasmic Reticulum Stress
Yong Liu, PhD
5:00 p.m.-5:30 p.m. Sympathetic-Associated Macrophages in Energy Homeostasis
Ana Domingos, PhD
5:30 p.m.-6:00 p.m. Th17-Mediated Inflammation and Type 2 Diabetes
Barbara Nikolajczyk, PhD

Symposium
Theme Area: Islet Biology/Insulin Secretion
Orchestrating the Islet—Structural and Functional Interactions
Chair: Mark Huising, PhD
4:00 p.m.-4:40 p.m. Building an Islet—Location, Location, Location!
Barak Blum, PhD
4:40 p.m.-5:20 p.m. The Elusive Delta Cell—Mechanisms Underlying Somatostatin Release
Quan Zhang, PhD
5:20 p.m.-6:00 p.m. Pericytes and the Microvasculature in Islet Function
Joana Almaca, PhD

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

5:00 p.m.-6:00 p.m.

Current Issues
Theme Area: Clinical Diabetes/Therapeutics
Debate—Is There a Current Place for Sulfonylureas in the Treatment of Type 2 Diabetes?
Chair: Naveed Sattar, MD, PhD

5:00 p.m.-5:25 p.m. Yes
Sophia Zoungas, MBBS (Hons), PhD, FRACP

5:25 p.m.-5:50 p.m. No
Carol H. Wysham, MD

5:50 p.m.-5:55 p.m. Rebuttal
Sophia Zoungas, MBBS (Hons), PhD, FRACP

5:55 p.m.-6:00 p.m. Rebuttal
Carol H. Wysham, MD
SATURDAY, JUNE 13, 2020

4:00 p.m.-6:00 p.m.

Oral Presentations
Theme Area: Acute and Chronic Complications
Complications of Neuropathy

4:00 p.m.-4:15 p.m.
123-OR Short-Term Hyperglycemia Causes a Paradoxical Reduction in Sensory Neuron Excitability
VERONICA A. CAMPANUCCI, MARICRIS BAUTISTA, JOSEPH T. NEAPETUNG, Saskatoon, SK, Canada

4:15 p.m.-4:30 p.m.
124-OR Progressive Loss of Corneal Nerve Fibers and Sensitivity with Duration of Obesity Type 2 Diabetes in Sprague-Dawley Rats: Valid Marker for Peripheral Neuropathy and Treatment
MARK A. YOREK, Iowa City, IA

4:30 p.m.-4:45 p.m.
125-OR Polyunsaturated Omega-6 Fatty Acids Reduce Axonal Mitochondrial Trafficking in Dorsal Root Ganglion Sensory Neurons
AMY RUMORA, GIOVANNI LOGRASSO, JACKSON D. MCGRATH, STEPHEN I. LENTZ, EVA L. FELDMAN, Ann Arbor, MI

4:45 p.m.-5:00 p.m.
126-OR Baseline Omega-3 Status Is Associated with Nerve Regeneration following 1 Year of Omega-3 Nutrition Therapy in Patients with Diabetic Neuropathy
EVAN J.H. LEWIS, BRUCE A. PERKINS, LEIF ERIK LOVBLOM, ADAM METHEREL, THOMAS WOLEVER, VERA BRIL, Toronto, ON, Canada

5:00 p.m.-5:15 p.m.
127-OR Pharmacologic Management of Diabetic Peripheral Neuropathy
JUNGWEI FAN, MOLLY M. JEFFERY, W. MICHAEL HOOTEN, NILAY SHAH, ROZALINA G. MCCOY, Rochester, MN

5:15 p.m.-5:30 p.m.
128-OR The Ipswich Neurodiab Study: A 5-Year Longitudinal Study Examining Natural History of Diabetes Polyneuropathy (DPN)
SANJEEV SHARMA, JEN CROSS, PRASH R. VS, GERRY RAYMAN, Ipswich, United Kingdom, London, United Kingdom, Suffolk, United Kingdom

5:30 p.m.-5:45 p.m.
129-OR Abnormal Mitochondrial Activity in Pain Processing Regions of the Brain in Painful Diabetic Peripheral Neuropathy
GORDON P. SLOAN, ADRIANA ANTON, DINESH SELVARAJAH, SOLOMON TESFAYE, IAIN D. WILKINSON, Sheffield, United Kingdom

5:45 p.m.-6:00 p.m.
130-OR Effects of Intensive Risk Factor Management on Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: Findings from the ACCORD Trial
YALING TANG, HETAL SHAH, CARLOS BUENO JUNIOR, XIUQIN SUN, JOANNA MITRI, MARIA SAMBATARO, LUISA SAMBADO, HERTZEL C. GERSTEIN, VIVIAN FONSECA, ALESSANDRO DORIA, RODICA POP-BUSUI, Boston, MA, Beijing, China, Treviso, Italy, Hamilton, ON, Canada, New Orleans, LA, Ann Arbor, MI

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

4:00 p.m.-6:00 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Diabetic Dyslipidemia

4:00 p.m.-4:15 p.m.
131-OR GLP-1R in the Nodose Ganglion Modulate Intestinal Lipoprotein Production via a Neuroendocrine Mechanism
SIMON S. HOFFMAN, KHOSROW ADELI, Toronto, ON, Canada

4:15 p.m.-4:30 p.m.
132-OR Peripheral Serotonin Regulates Dietary Fat Absorption and Intestinal Chylomicron Production
FITORE RAKA, KHOSROW ADELI, Toronto, ON, Canada

4:30 p.m.-4:45 p.m.
133-OR Dyrk1b Is a Nutrient-Sensing Protein That Triggers De Novo Lipogenesis by Activating mTORC2 Complex: Implication for the Treatment of Type 2 Diabetes
NEHA BHAT, New Haven, CT

4:45 p.m.-5:00 p.m.
134-OR Effects of PCSK9 Inhibitors on Glucose Metabolism and β-Cell Function in Humans
SIMONA MOFFA, TERESA MEZZA, CHIARA MARIA ASSUNTA CEFALO, JR., FRANCESCA CINTI, GIAN PIO SORICE, FLAVIA IMPRONTA, UMBERTO CAPECE, ANDREA MARI, ANDREA GIACCARI, Rome, Italy, Padova, Italy

5:00 p.m.-5:15 p.m.
135-OR The Effect of Fixed-Dose Combination of Insulin Degludec and Liraglutide on Serum Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus
ELENI PAPPA, CHRISTINA KOSTARA, CONSTANTINOS TELLIS, ALEXANDROS D. TSELEPIS, ELENI BAIRAKTARI, VASILIS TSIMIHODIMOS, Ioannina, Greece

5:15 p.m.-5:30 p.m.
136-OR Lipid Profile in Men with Hypogonadism and Type 2 Diabetes Improves during Long-Term Treatment with Testosterone Undecanoate Injections (TU) in Comparison to an Untreated Control Group: Update of Real-World Registry Data
FARID SAAD, KARIM S. HAIDER, AHMAD HAIDER, Berlin, Germany, Bremerhaven, Germany

5:30 p.m.-5:45 p.m.
137-OR Trends in Lipid Levels Relative to Lipid-Lowering Drug Use among Danish Type 2 Diabetes Subjects
HANAN AMADID, MARIA BEKKER-NIELSEN DUNBAR, PERNILLE F. RØNN, JAKOB S. KNUDSEN, BENDIX CARSTENSEN, FREDERIK PERSSON, MARIT E. JØRGENSEN, Gentofte, Denmark, Aarhus, Denmark

5:45 p.m.-6:00 p.m.
138-OR Elevated Triglycerides as a Risk Factor for Postpartum Abnormal Glucose Metabolism in Chinese Women with Previous Gestational Diabetes
MENGYU LAI, FANG FANG, YUFAN WANG, Shanghai, China

Information is subject to change. Sessions current as of 5/15/20.
SATURDAY, JUNE 13, 2020

4:00 p.m.-6:00 p.m.
(continued)

Oral Presentations
Theme Area: Integrated Physiology/Obesity
Obesity Treatment and Weight Loss—The Causes and Consequences

4:00 p.m.-4:15 p.m.
139-OR Superior Effect of 1-Year Treatment with GLP-1 Receptor Agonist and Exercise on Weight Loss Maintenance and Body Composition after a Very Low-Calorie Diet: The S-LITE Randomized Trial
CHARLOTTE JANUS, JULIE R. LUNDGREN, SIMON JENSEN, LISA M. OLSEN, CHRISTIAN RIMER JUHL, MARTIN B. BLOND, RASMUS M. CHRISTENSEN, KIRSTINE N. BOJSEN-MOLLER, MARIA S. SVANE, THOMAS BANDHOLM, JENS-ERIK B. JENSEN, BENTE STALLKNECHT, JENS J. HOLST, STEN MADSBAD, SIGNE S. TOREKOV, Copenhagen, Denmark, Hvidovre, Denmark

4:15 p.m.-4:30 p.m.
140-OR Inhibition of Serotonin 2c Receptor Internalization Potentiates Lorcaserin Effect on Body Weight Loss
YANG HE, HAILAN LIU, YONG XU, Houston, TX

4:30 p.m.-4:45 p.m.
141-OR Efficacy and Safety of Naltrexone/Bupropion as Add-On to Incretin Agents in Patients with Obesity and T2DM
SEAN WHARTON, PETER YIN, FERNANDO CAMACHO, MELONIE BURROWS, JESSICA BLAVIGNAC, MAXIME BARAKAT, Laval, QC, Canada, Toronto, ON, Canada

4:45 p.m.-5:00 p.m.
142-OR Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding
RICHARD COSGROVE, MEGHAN P. ANTONELLI, BRIAN DROZ, WILLIAM C. ROELL, KYLE SLOOP, JULIE MOYERS, MATTHEW P. COGLIAN, PAUL EMMERSON, TAMER COSKUN, RICARDO J. SAMMS, Indianapolis, IN

5:00 p.m.-5:15 p.m.
143-OR All-Cause Mortality over 16 Years in Look AHEAD

5:15 p.m.-5:30 p.m.
144-OR The Antirheumatic Drug Auranofin Improves the Metabolic Phenotype of Obesity
AARON COX, PETER M. MASSCHELIN, NATASHA CHERNIS, PRADIP SAHA, ZEQIN LIAN, JESSICA B. FELIX, KANGHO KIM, HUAIZHU WU, SEAN M. HARTIG, Houston, TX

5:30 p.m.-5:45 p.m.
145-OR GLP-1 Analogue Effects on Neural Responses to High-Fructose Corn Syrup and Eating Behavior in Obesity
KELLY JOSEPH, JESSICA LEVENTHAL, SEUNGJU HWANG, MARI-LYNET KNIGHT, DONGJU SEO, CHERYL LACADIE, MICHELLE A. VAN NAME, SONIA CAPRIO, JENNIFER SHERR, WILLIAM V. TAMBORLANE, RAJITA SINHA, ANIA M. JASTREBOFF, New Haven, CT

(continued on next page)
5:45 p.m.-6:00 p.m.
146-OR Specific Metabolomic Signatures Associate with Diabetes Remission after Weight Loss
LYDIA C. KWEE, OLGA ILKAYEVA, MICHAEL MUEHLBAUER, BRUCE M. WOLFE, JONATHAN Q. PURNELL,
XAVIER PI-SUNYER, HAIYING CHEN, CHRISTOPHER B. NEWGARD, SVATI H. SHAH, BLANDINE LAFERRERE,
Durham, NC, Portland, OR, Winston-Salem, NC, New York, NY
SATURDAY, JUNE 13, 2020

4:00 p.m.-6:00 p.m.
(continued)

Oral Presentations
Theme Area: Integrated Physiology/Obesity
Integrative Physiology of the Brain, Gut, and Pancreas

4:00 p.m.-4:15 p.m.
147-OR Long-Term Effect of GLP-1 on Pancreas Endocrine Function after Gastric Bypass in Individuals with and without Diabetes Remission
MALINI A. PRASAD, ANKIT SHAH, VICTORIA M. MARK, NANDINI NAIR, JENS J. HOLST, BLANDINE LAFERRERE, New York, NY, Copenhagen, Denmark

4:15 p.m.-4:30 p.m.
148-OR Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans with Prediabetes
MARTIN HENI, STEPHANIE KULLMANN, ROBERT WAGNER, JULIA HUMMEL, CORINNA DANNECKER, ANDREAS VOSSELER, LOUISE FRITSCH, KONSTANTINOS KANTARTZIS, JÜRGEN MACHANN, HANS-ULRICH HAERING, ANDREAS FRITSCH, HUBERT PREISL, Tübingen, Germany

4:30 p.m.-4:45 p.m.
149-OR In Utero Exposure to Gestational Diabetes Mellitus Is Associated with Increased Food Intake and Orbital Frontal Cortex Responses to Food Cues
SHAN H. LUO, BRENDAN C. ANGELO, TING CHOW, JASMIN ALVES, THOMAS A. BUCHANAN, ANNY XIANG, KATHLEEN A. PAGE, Los Angeles, CA, Pasadena, CA

4:45 p.m.-5:00 p.m.
150-OR Brain Insulin Sensitivity Is Modulated by Menstrual Cycle
CHARLOTTE F.C. BENKENDORFF, JULIA HUMMEL, ANDREAS VOSSELER, STEPHANIE KULLMANN, LOUISE FRITSCH, ANDREAS L. BIRKENFELD, HUBERT PREISL, HANS-ULRICH HAERING, ANDREAS FRITSCH, ANDREAS PETER, ROBERT WAGNER, MARTIN HENI, Tübingen, Germany

5:00 p.m.-5:15 p.m.
151-OR Radiologic Evidence that Hypothalamic Tissue Is Abnormal in Adults with Obesity and Type 2 Diabetes or Impaired Glucose Homeostasis
JENNIFER L. ROSENBAUM, LETICIA E. SEWAYBRICKER, SUCHITRA CHANDRASEKARAN, MARY ROSALYNN DE LEON, MARY WEBB, SUSAN J. MELHORN, ELLEN SCHUR, Seattle, WA

5:15 p.m.-5:30 p.m.
152-OR Postabsorptive Splanchnic and Leg Glucagon Metabolism in Healthy Subjects: Use of 13C 15N Glucagon FNU RUCHI, YOGESH R. YADAV, DAVIDE ROMERES, SAFIA SAWEH, LINDA M. BENSON, KENNETH L. JOHNSON, CHIARA DALLA MAN, CLAUDIO COBELLI, DANIEL J. MCCORMICK, LUKE R. WILKINS, RITA BASU, ANANDA BASU, Charlottesville, VA, Padova, Italy, Rochester, MN

5:30 p.m.-5:45 p.m.
153-OR Glucose-Dependency of Insulinotropic and Glucagonostatic Effects of Glucagon-Like Peptide-1 after Gastric Bypass and Sleeve Gastrectomy
HENRI HONKA, ANAS M. AL ZUBAIDI, AMALIA GASTALDELLI, RALPH A. DEFRONZO, MARZIEH SALEHI, San Antonio, TX, Pisa, Italy

(continued on next page)
5:45 p.m.-6:00 p.m.

**154-OR** Nepriplysin Inhibition Increases Glucagon Levels with Possible Implications for Hepatic Amino Acid Metabolism

SASHA KJELDSEN, SAKENH ZRAIKA, STEVE M. MONGOVIN, LASSE H. HANSEN, DIJANA TERZIC, PETER D. MARK, JR., PETER PLOMGAARD, JENS P. GÔTZE, MARIE WINETHER-SOERENSEN, JENNA HUNT, KATRINE D. GALSgaARD, METTE M. ROENKILDE, GIJS H. GOOSENS, ELLEN E. BIAAK, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN, Seattle, WA, Copenhagen, Denmark, Virum, Denmark, Maastricht, Netherlands
SUNDAY, JUNE 14, 2020

Scientific Sessions
8:00 a.m.-9:30 a.m.

Symposium
Theme Area: Acute and Chronic Complications
Cardiorenal–Metabolic Axis in Diabetes
Chair: David Cherney, MD, PhD
8:00 a.m.-8:25 a.m. Pathophysiology of Cardiorenal Syndrome
Peter A. McCullough, MD, MPH
8:25 a.m.-8:40 a.m. Review of a Landmark Trial Focusing on Cardiovascular Outcomes (DAPA-HF)
Biykem Bozkurt, MD, PhD, FHFAA, FACC, FAHA
8:40 a.m.-8:55 a.m. Review of a Landmark Trial Focusing on Renal Outcomes (CREDEN
Katherine R. Tuttle, MD, FACP, FASN, FNKF
8:55 a.m.-9:10 a.m. Review Evidence Base Evaluating Impact of Blood Pressure, Lipid, and Glycemic Control on Cardiovascular Outcomes
Melissa L. Magwire, RN, MSN, CDE
9:10 a.m.-9:30 a.m. Translating Evidence to Practice
Jennifer B. Green, MD

8:00 a.m.-10:00 a.m.

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Lifestyle Interventions for Type 2 Diabetes Remission
Chair: Amy E. Rothberg, MD, PhD
8:00 a.m.-8:30 a.m. The DiRECT Trial and Very-Low-Calorie Eating Plans
Alison C. Barnes, RD
8:30 a.m.-9:00 a.m. Low-Carbohydrate Eating Plans
William S. Yancy, Jr., MD, MHS
9:00 a.m.-9:30 a.m. High-Fiber Diets and Plant-Based Eating Plans for Treating Type 2 Diabetes
Hana Kahleova, MD, PhD, MBA
9:30 a.m.-10:00 a.m. Exercise Alone, or Is it a Combination of Diet and Exercise?
Kristian Karstoft, MD, PhD, DMSc

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Adjunctive Glucose-Lowering Therapies for Adults with Type 1 Diabetes—Evidence
Chair: Jeremy Pettus, MD
8:00 a.m.-8:40 a.m. Metformin
Irene Hramiak, MD, FRCPC, FACP
8:40 a.m.-9:20 a.m. GLP-1 Receptor Agonists
Tina Vilsbøll, MD, DMSc
9:20 a.m.-10:00 a.m. SGLT2’s
Chantal Mathieu, MD, PhD

Information is subject to change. Sessions current as of 5/15/20.
Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

8:00 a.m.-10:00 a.m.
(continued)

**Symposium**
*Theme Area: Insulin Action/Molecular Metabolism*

**Effect of Metabolic Stress on Insulin Action**
Chair: Matthew Hirschey, PhD

8:00 a.m.-8:40 a.m.  *Role of Hypoxia in Mediating Metabolic Improvements*  
Isha Jain, PhD

8:40 a.m.-9:20 a.m.  *Molecular Benefits of Exercise in Countering Metabolic Stress*  
Juleen R. Zierath, PhD

9:20 a.m.-10:00 a.m.  *Metabolic Regulation of Cell Fate Decisions*  
Lydia Finley, PhD

**Symposium**
*Theme Area: Integrated Physiology/Obesity*

**Mind the Clock—Timing of Feeding in the Control of Metabolic Health**
Chair: Darleen A. Sandoval, PhD

8:00 a.m.-8:40 a.m.  *Meal Timing in Health and Disease*  
Satchidananda Panda, PhD

8:40 a.m.-9:20 a.m.  *Insulin Sensitization—Alternate Day Fasting vs. Caloric Restriction*  
Krista Varady, PhD

9:20 a.m.-10:00 a.m.  *Synching Tissue Clocks with Feeding to Improve Metabolic Health*  
Paolo Sassone-Corsi, PhD

**Symposium**
*Theme Area: Islet Biology/Insulin Secretion*

**The Islet under Duress in Type 1 Diabetes**
Chair: Susanne M. Cabrera, MD

8:00 a.m.-8:30 a.m.  *State of the Field—The Islets in Dialogue with the Immune System in Type 1 Diabetes*  
Decio L. Eizirik, MD, PhD

8:30 a.m.-9:00 a.m.  *Monogenic Forms of Autoimmune Diabetes*  
Sarah E. Flanagan, PhD

9:00 a.m.-9:30 a.m.  *Beta-Cell Endoplasmic Reticulum Stress in Type 1 Diabetes*  
Feyza Engin, PhD

9:30 a.m.-10:00 a.m.  *Novel Imaging Techniques to Detect Islet Inflammation*  
Richard KP Benninger, PhD

*Information is subject to change. Sessions current as of 5/15/20.*
SUNDAY, JUNE 14, 2020

8:00 a.m.-10:00 a.m.

Oral Presentations
Theme Area: Acute and Chronic Complications
Hypoglycemia—Heart and Mind (With ADA Presidents' Select Abstract Presentation)

8:00 a.m.-8:15 a.m.
155-OR ADA Presidents' Select Abstract Presentation: Symptom Responses to Hypoglycemia Are Related to Connectivity Change between the Thalamus and Frontal Lobes
PETER JACOB, MUNACHISO NWOKOLO, OWEN ODALY, FERNANDO O. ZELAYA, STEPHANIE A. AMIEL, PRATIK CHOUDHARY, London, United Kingdom

8:15 a.m.-8:30 a.m.
156-OR Fear of Hypoglycemia in People with Type 1 Diabetes and Problematic Hypoglycaemia: A Mismatch between Worry and Behaviour?
RORY H. MACLEAN, PETER JACOB, SEAN HAYWOOD, PRATIK CHOUDHARY, SIMON R. HELLER, ELENA TOSCHI, DULMINI KARIYAWASAM, THERESE C. ANDERBRO, STEPHANIE A. AMIEL, Sheffield, United Kingdom, Boston, MA, London, United Kingdom, Stockholm, Sweden

8:30 a.m.-8:45 a.m.
157-OR People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia Have a Delayed Reaction to Perform a Glucose Scan during Hypoglycemia: A Prospective Observational Study
OTHMAR MOSER, HARIS ZIKO, HESHAM ELSAYED, DANIEL A. HOCHFELLNER, TINA POETTLER, ALEXANDER MUELLER, MAX L. ECKSTEIN, LISA KNOLL, HARALD SOURIJ, JULIA K. MADER, Graz, Austria

8:45 a.m.-9:00 a.m.
158-OR Calcium Channel Blockade Protects against Severe Hypoglycemia–Induced Fatal Cardiac Arrhythmias in Rats
CANDACE M. RENO, YIQING HUANG, CAMILLE G. CHRISTENSEN, MILAN B. OXSPRING, JUSTIN BAYLES, SIMON J. FISHER, Salt Lake City, UT

9:00 a.m.-9:15 a.m.
159-OR Vitamin E Treatment Reduces Severe Hypoglycemia-Induced Fatal Cardiac Arrhythmias in Type 1 Diabetic Rats
CANDACE M. RENO, MILAN B. OXSPRING, JUSTIN BAYLES, IVANA HOLIDAY, YIQING HUANG, SIMON J. FISHER, Salt Lake City, UT

9:15 a.m.-9:30 a.m.
160-OR Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes
ANDREAS ANDERSEN, PETER G. JØRGENSEN, JONATAN I. BAGGER, SR., MARIA POMPEA ANTONIA BALDASSARRE, MIKKEL B. CHRISTENSEN, KIRSTEN U. ABELIN, ULRIK PEDERSEN-BJERGAARD, JENS J. HOLST, TOMMI B. LINDHARDT, FILIP K. KNOP, TINA VILSBØLL, Chieti, Italy, Gentofte, Denmark, Hillerød, Denmark, Hellerup, Denmark, Copenhagen, Denmark

9:30 a.m.-9:45 a.m.
161-OR Association of Frequency of Hypoglycemic Episodes with Incident Cardiovascular Events in Adults with Type 2 Diabetes Mellitus: A National Database Study
OMAR A. ALABER, APOORVA K. CHANDAR, BASMA A. DAHASH, ALEONA C. ZUZEK, AMAN RAJPAL, Cleveland, OH

(continued on next page)
9:45 a.m.-10:00 a.m.

162-OR  Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial
JULIO ROSENSTOCK, NIKOLAUS MARX, DARREN K. MCGUIRE, BERNARD ZINMAN, MARK ESPELAND, JYOTHI S. GEORGE, MICHAELA MATTHEUS, ODD ERIK JOHANSEN, Dallas, TX, Aachen, Germany, Toronto, ON, Canada, Winston-Salem, NC, Ingelheim, Germany, Asker, Norway
SUNDAY, JUNE 14, 2020

8:00 a.m.-10:00 a.m.
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Metabolic and Cardiovascular Health Impact of Exercise and Fitness in Obesity and Diabetes

8:00 a.m.-8:15 a.m.
163-OR Metabolically Unhealthy Obese Is Transient and Improves with Aerobic Exercise
KRISTIN K. HODDY, CHRISTOPHER L. AXELROD, JACOB T. MEY, ADITHYA HARI, ROBBIE A. BEYL, JOHN P. KIRWAN, Baton Rouge, LA, Athens, GA

8:15 a.m.-8:30 a.m.
164-OR Role of Small Extracellular Vesicles for the Metabolic Response to Exercising in Insulin Resistant Humans
LUCIA MASTROTOTARO, MARIA APOSTOLOPOULOU, SONJA HARTWIG, DOMINIK PESTA, KLAUS STRASSBURGER, ELISABETTA DE Filippo, YANISAVA KARUSHEVA, SOFIYA GANCHEVA, DANIEL F. MARKGRAF, STEFAN LEHR, KARSTEN MUSSIG, HADI AL-HASANI, JULIA SZENDROEDI, MICHAEL RODEN, Düsseldorf, Germany

8:30 a.m.-8:45 a.m.
165-OR High- and Moderate-Intensity Exercise Training Increased Skeletal Muscle Acylcarnitine and Phospholipid Abundance in Obese Adults
MICHAEL W. SCHLEH, BENJAMIN J. RYAN, ALISON LUDZKI, JENNA B. GILLEN, JEFFREY F. HOROWITZ, Ann Arbor, MI, Toronto, ON, Canada

8:45 a.m.-9:00 a.m.
166-OR Lower Response of Connective Tissue Growth Factor (CTGF) to Exercise Characterizes Insulin Resistant Muscle
ROCIO ZAPATA BUSTOS, PAUL R. LANGLAIS, DAWN K. COLETTA, ELENA A. DE FILIPPIS, DANIELLE GRANDJEAN, LAWRENCE MANDARINO, Tucson, AZ, Phoenix, AZ, Scottsdale, AZ

9:00 a.m.-9:15 a.m.
167-OR Exercise Training Alters Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha (PGC-1 Alpha) DNA Methylation in Human Skeletal Muscle
SUNG LEE, LUIS GARCIA, ALMA D. LEON, ROCIO ZAPATA BUSTOS, BALTAZAR CAMPOS, JUDY A. KRENTZEL, LAWRENCE MANDARINO, DAWN K. COLETTA, Tucson, AZ

9:15 a.m.-9:30 a.m.
168-OR The Inverse Association between Cardiorespiratory Fitness and Inflammation Is Modified by Plasma Levels of Omega-3 Polyunsaturated Fatty Acids
GABRIELLE FARLEY, DANIEL W. RIGGS, ARUNI BHATNAGAR, JASON HELLMANN, Louisville, KY

9:30 a.m.-9:45 a.m.
169-OR Differential Effects of Amount, Intensity, and Mode of Exercise Training on the Diabetes Risk Index
LEANNA M. ROSS, CRIS A. SLENTZ, IRINA Y. SHALAUROVA, JAMES D. OTVOS, MARGERY A. CONNELLY, CONNIE W. BALES, JOSEPH A. HOUMARD, WILLIAM E. KRAUS, Durham, NC, Cary, NC, Morrisville, NC, Greenville, NC

(continued on next page)
9:45 a.m.-10:00 a.m.

170-OR  Association of Timing of Physical Activity Bouts with Cardiorespiratory Fitness in Adults with Type 2 Diabetes in the Look AHEAD Study
JINGYI QIAN, MICHAEL P. WALKUP, SHYH-HUEI CHEN, PETER H. BRUBAKER, DALE BOND, PHYLLIS A. RICHEY, JOHN M. JAKICIC, KUN HU, FRANK A. SCHEER, ROELAND MIDDELBEEK, Winston-Salem, NC, Providence, RI, Memphis, TN, Pittsburgh, PA, Boston, MA
SUNDAY, JUNE 14, 2020

8:00 a.m.-10:00 a.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Effective Diabetes Care—At What Cost?

8:00 a.m.-8:15 a.m.
171-OR Preventing Diabetes: Resource Allocation between Risk-Based and Whole Population-Based Approaches
SIMON NEUWAHL, THOMAS J. HOERGER, MICHAEL LAXY, HUI SHAO, ANN L. ALBRIGHT, PING ZHANG, Research Triangle Park, NC, Munich, Germany, Gainesville, FL, Atlanta, GA

8:15 a.m.-8:30 a.m.
172-OR Diabetes Care Management (DCM) Under Total Cost of Care (TCOC) Budgeting: Insights from a Medicaid Cohort
ALEX R. MONTERO, CHARLES BETLEY, JASON R. BROWN, DEREK M. DELIA, NNENIA FRANCIS, LAURA SPICER, MICHELLE F. MAGEE, Washington, DC, Baltimore, MD, Hyattsville, MD

8:30 a.m.-8:45 a.m.
173-OR High Out-of-Pocket Health Care Burden for Medicare Beneficiaries with Diabetes, 1999-2015
JOOHYUN PARK, YU WANG, KEVIN A. LOOK, ELIZABETH LUMAN, PING ZHANG, Atlanta, GA, Chamblee, GA, Madison, WI

8:45 a.m.-9:00 a.m.
174-OR Budget Impact Analysis (BIA) Comparing Real-Time Continuous Glucose Monitoring (RT-CGM) with Self-Monitoring of Blood Glucose (SMBG) for all U.S. Medicaid Enrollees with Type 1 Diabetes
MICHAEL E. MINSHALL, JOHN J. ISITT, CLAUDIA GRAHAM, PETER M. LYNCH, New York, NY, San Diego, CA, Long Beach, CA, Edina, MN

9:00 a.m.-9:15 a.m.
175-OR Impact of High-Deductible Health Plan Enrollment on the Timing of Diabetic Retinopathy Care and Vision Loss Diagnosis
J. FRANK WHARAM, FANG ZHANG, CHRISTINE LU, TOMASZ STRYJEWSKI, KATHERINE CALLAWAY, JAMIE WALLACE, JOSEPH P. NEWHOUSE, DENNIS ROSS-DEGNAN, Boston, MA, Waban, MA

9:15 a.m.-9:30 a.m.
176-OR The Impact of Chronic Kidney Disease on Commercial Payers in the U.S.
TERESA KAUF, WEIYING WANG, ALLISON DILLON, INDERJIT SINGH, JOHN T. ODEGARD, CHRISTIAN RINGEMANN, STEFFEN HALDRUP, Zug, Switzerland, Hoboken, NJ, Indianapolis, IN, Mannheim, Germany, Basel, Switzerland

9:30 a.m.-9:45 a.m.
177-OR Estimating the Costs of Diabetes Complications in People <65 Years in the U.S. Using Panel Data
WENYA YANG, INNA CINTINA, THOMAS J. HOERGER, SIMON NEUWAHL, HUI SHAO, MICHAEL LAXY, PING ZHANG, Falls Church, VA, Research Triangle Park, NC, Gainesville, FL, Munich, Germany, Atlanta, GA

9:45 a.m.-10:00 a.m.
178-OR The Causal Effect of BMI on Health-Related Quality of Life: A Mendelian Randomization Study
MICHAEL LAXY, Munich, Germany

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

8:00 a.m.-10:00 a.m.  
(continued)

**Oral Presentations**  
*Theme Area: Clinical Diabetes/Therapeutics*

**Other Therapeutic Agents**

8:00 a.m.-8:15 a.m.

179-OR Mitochondrially Targeted Tamoxifen Improves Diet-Induced Obesity and Diabetes and Reduces Adipose Tissue Senescence in Experimental Mice  
JAROSLAVA TRNOVSKA, ELISKA DAVIDOVA, PETR SVOBODA, HELENA KRATOCHVILOVA, MILOS MRAZ, SONA HUBACKOVA, JIRI NEUZIL, MARTIN HALUZIK, Prague, Czech Republic, Vestec, Czech Republic, Southport, Australia, Praha, Czech Republic

8:15 a.m.-8:30 a.m.

180-OR Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia in Children with Diabetes  
TADEJ BATTELINO, RAMIN TEHRANCHI, ANITA E. MELGAARD, DORTE SKYDSGAARD, TIMOTHY S. BAILEY, LINDA DIMEGLIO, THOMAS DANNE, Ljubljana, Slovenia, Copenhagen, Denmark, Søborg, Denmark, Escondido, CA, Indianapolis, IN, Hannover, Germany

8:30 a.m.-8:45 a.m.

181-OR Effect of Sevelamer and a Synbiotic on Insulin Sensitivity in Obese Individuals  
ERIC BAEUERLE, HANYU LIANG, VINUTHA GANAPATHY, ROMAN FERNANDEZ, NATTAPOL SATHAVARodom, CHEN-PIN WANG, SARA E. ESPINOZA, NICOLAS MUSI, San Antonio, TX, Bangkok, Thailand

8:45 a.m.-9:00 a.m.

182-OR A Novel Dual-Acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients after 24 Weeks of Treatment in a Phase III Monotherapy Trial  
DALONG ZHU, YI ZHANG, LI CHEN, Nanjing, China, Shanghai, China

9:00 a.m.-9:15 a.m.

183-OR Allogenic Adipose-Derived Mesenchymal Stem Cells (ASCs) and Vitamin D Supplementation in Patients with Recent-Onset Type 1 Diabetes Mellitus: A 6-Month Follow-Up Pilot Study  
JOANA R. DANTAS, DEBORA B. ARAUJO, LEANDRA S. BAPTISTA, DEBORA L. SOUTO, KARINA PEREIRA, MARIA F. PEREIRA, CESAR S. CLAUDIO-DA-SILVA, MATHEUS S. MANTUANO, DEBORA R. DAGA, ALEXANDRA C. SENEGAGLIA, CARMEN K. REBELATTO, CARLOS EDUARDO B. COURI, JOSE E. OLIVEIRA, LENITA ZAJDENVERG, MELANIE RODACKI, Rio de Janeiro, Brazil, Curitiba, Brazil, Paraná, Brazil, Ribeirão Preto, Brazil

9:15 a.m.-9:30 a.m.

184-OR Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM  
OLGA LAVRYNENKO, MARIAM ALATRACH, MUHAMMAD ABDUL-GHANI, EUGENIO CERSOSIMO, NAIM ALKHOURI, CURTISS L. PUCKETT, JR., RALPH A. DEFRONZO, JOHN M. ADAMS, II, JUAN A. VASQUEZ, JR., GEOFFREY D. CLARKE, San Antonio, TX

(continued on next page)
9:30 a.m.-9:45 a.m.

185-OR  Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials
LAWRENCE A. LEITER, MACIEJ BANACH, ALBERICO L. CATAPANO, P. BARTON DUELL, ANTONIO GOTTO, ULRICH LAUFS, G.B. JOHN MANCINI, KAUSIK K. RAY, JEFFREY C. HANSELMAN, AMY FENG, HAROLD BAYS, Toronto, ON, Canada, Lodz, Poland, Milan, Italy, Portland, OR, New York, NY, Leipzig, Germany, Vancouver, BC, Canada, London, United Kingdom, Ann Arbor, MI, Louisville, KY

9:45 a.m.-10:00 a.m.

186-OR  Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)
RICCARDO PERFETTI, FRANCESCA C. LAWSON, JULIO ROSENSTOCK, JAMES JANUZZI, JR., SHOSHANA SHENDELMAN, STELLA WANG, AMEEN F. GHANNAM, New York, NY, Dallas, TX, Wellesley Hills, MA
SUNDAY, JUNE 14, 2020

10:15 a.m.-11:45 a.m.
President, Medicine & Science Address
Title TBD
Robert H. Eckel, MD
and
Banting Medal for Scientific Achievement
A Journey in Diabetes
Ele Ferrannini, MD

12:00 p.m.-1:00 p.m.

Professional Interest Group Discussion
Theme Area: Acute and Chronic Complications
Professional Interest Group Discussion on Diabetes and Cardiovascular Disease—Hot Topics in Diabetes
Cardiovascular Disease Management
Chair: Rodica Pop-Busui, MD, PhD
12:00 p.m.-1:00 p.m.   Excess Heart Failure and Cardiovascular Risk in Women with Diabetes—A Not-So-Sweet Truth
William B. Horton, MD, FACP

Professional Interest Group Discussion
Theme Area: Acute and Chronic Complications
Professional Interest Group Discussion on Eye Health—Common Questions Encountered by Diabetes Care Providers Related to Eye Issues Experienced by People with Diabetes
Chair: George L. King, MD
12:00 p.m.-12:30 p.m.   Common Ocular Symptoms and Questions Encountered by Primary Care Providers, Diabetes Education Specialists, and Diabetologists
Richard M. Calderon, OD, FAAO
12:30 p.m.-1:00 p.m.   AIDS That Can Help Patients with Low Vision
Richard J. Shuldiner, OD, FAAO, FIALVS

Professional Interest Group Discussion
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Professional Interest Group Discussion on Behavioral Medicine and Psychology—The Value Proposition for Behavioral Health—Examples of Effectively Making the Case
Chair: Korey K. Hood, PhD
12:00 p.m.-12:20 p.m.   What an Administrator Can Do to Advocate for Behavioral Health
Andrew Ahmann, MD
12:20 p.m.-12:40 p.m.   Implementing Screening with an Eye toward Financial Sustainability
Arwen Marker, MA
12:40 p.m.-1:00 p.m.   Putting Behavioral Evidence into Practice—Advice and Solutions
Felicia Hill-Briggs, PhD, ABPP

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

12:00 p.m.-1:00 p.m. (continued)

**Professional Interest Group Discussion**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Professional Interest Group Discussion on Diabetes Self-Management Education and Support (DSMES)—Focus on 2020 DSMES Consensus Report**
Chair: Clipper F. Young, PharmD, MPH, CDE, BC-ADM, BCGP

12:00 p.m.-12:20 p.m. *Advancing Access to DSMES*
Clipper F. Young, PharmD, MPH, CDE, BC-ADM, BCGP

12:20 p.m.-12:40 p.m. *2020 DSMES Consensus Report—Role of DSMES in Today’s Health Care Environment*
Margaret A. Powers, PhD, RD, CDE

12:40 p.m.-1:00 p.m. *Call to Action—Recommendations and the Four Critical Times*
Joan K. Bardsley, MBA, BSN, RN, CDE, FAADE

**Mini-Symposium**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Women’s Interprofessional Network of the ADA (WIN ADA)—Finding Equilibrium—Rethinking “Work-Life Balance” to Maintain Personal Wellness**
Chair: Kanakadurga Singer, MD

12:00 p.m.-12:30 p.m. *Strategies to Optimize Work-Life Integration*
Linda DiMeglio, MD, MPH

12:30 p.m.-1:00 p.m. *Recognizing and Recovering from Professional Burnout*
Mary de Groot, PhD

**Professional Interest Group Discussion**
*Theme Area: Clinical Diabetes/Therapeutics*

**Professional Interest Group Discussion on Diabetes in Youth—“Do-It-Yourself”/“Do-It-Together” (DIY/DIT)**

**Closed-Loop Systems in Youth**
Chair: Henry Rodriguez, MD

12:00 p.m.-12:20 p.m. *Do-It-Yourself/Do-It-Together*
Rayhan Lal, MD

12:20 p.m.-12:40 p.m. *Psychosocial/Behavioral Impact of DIY/DIT in Youth*
Diana Naranjo, PhD

12:40 p.m.-1:00 p.m. *DIY/DIT in the Childcare, School, and Camp Setting*
Anastasia Albanese-O’Neill, PhD, APRN, CDE

**Symposium**
*Theme Area: Integrated Physiology/Obesity*

**New Insights from the Restoring Insulin Secretion (RISE) Study—Differences between Adults and Youth with Prediabetes and Type 2 Diabetes**
Chair: Sharon Edelstein, ScM

12:00 p.m.-12:05 p.m. *Looking Back—What Have We Already Learned?*
Sharon Edelstein, ScM

12:05 p.m.-12:25 p.m. *Alpha-Cell Function*
Thomas A. Buchanan, MD

12:25 p.m.-12:45 p.m. *Proinsulin and the Beta Cell*
Kristina Utzschneider, MD

12:45 p.m.-1:00 p.m. *Looking Forward—What More Do We Need to Know?*
Kristen J. Nadeau, MD, MS

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

2:15 p.m.-3:00 p.m.
Kelly West Award for Outstanding Achievement in Epidemiology Lecture

The Epidemiology of Hemoglobin A1C—Informing Medical Practice
Elizabeth Selvin, PhD, MPH

2:15 p.m.-4:15 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Update on Lipid-Lowering Drugs
Chair: Alan Chait, MD
2:15 p.m.-2:45 p.m. How to Diagnose, Avoid, and Treat the Side Effects of Statin Therapy
Connie B. Newman, MD, FACP, FAHA, FAMWA
2:45 p.m.-3:15 p.m. Omega-3 Fatty Acids—Should More of Our Patients Be Treated with Fish Oil?
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
3:15 p.m.-3:45 p.m. PCSK9 Inhibitors—When Should You Use These Agents?
Jennifer G. Robinson, MD, MPH
3:45 p.m.-4:15 p.m. Bempedoic Acid and Lipid Drugs in Development
John R. Guyton, MD

Symposium
Theme Area: Acute and Chronic Complications
New Perspectives on Diabetic Retinopathy Diagnosis and Treatment
Room: S-106 (South, Level 1)
Chair: Rithwick Rajagopal, MD, PhD
2:15 p.m.-2:45 p.m. Retinal Neurodegeneration in Diabetes
Rafael Simó, MD, PhD
2:45 p.m.-3:15 p.m. Autonomous Artificial Intelligence for Diagnosis of Diabetic Retinopathy
Michael D. Abràmoff, MD, PhD
3:15 p.m.-3:45 p.m. Lessons from Recent Trials and Practice
Donald S. Fong, MD
3:45 p.m.-4:15 p.m. Genetic Aspects of Diabetic Retinopathy
Lucia Sobrin, MD, MPH

Case Studies
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Reaching the Hard to Reach—Real-World Stories
Chair: Dessa Garnett-Awadjie, MSN, FNP-BC, BC-ADM, CDCES
2:15 p.m.-2:55 p.m. A Day in the Life of Emerging Adults with Type 1 Diabetes Mellitus
Neesha Ramchandani, PhD, PNP, CDCES, CDTC
2:55 p.m.-3:35 p.m. Juggling Diabetes Self-Care Post-Kidney Transplant
Della Connor, PhD, RN, FNP-BC, FNKF
3:35 p.m.-4:15 p.m. Living with Diabetes after Amputation
Gary M. Rothenberg, DPM, CDE, CWS

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

2:15 p.m.-4:15 p.m.
(continued)

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Strength-Based Approaches in Diabetes Care—Challenging the Deficit Model
Chair: Jennifer Raymond, MD, MCR
2:15 p.m.-2:45 p.m.  What Teens with Type 1 Do RIGHT—Equipping Parents and Providers to Build Youths’ Diabetes Strengths
Marisa E. Hilliard, PhD
2:45 p.m.-3:15 p.m.  Promoting Resilience Resources in Distressed Teens
Joyce Yi-Frazier, PhD
3:15 p.m.-3:45 p.m.  Promoting Empowerment in Diverse Populations with Diabetes—The Resilient, Empowered, Active Living (REAL) Diabetes Studies
Elizabeth Pyatak, PhD, CDCES
3:45 p.m.-4:15 p.m.  Resilience-Based Diabetes Self-Management Education in African American Adults with Type 2 Diabetes
Mary Steinhardt, EdD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Low-Carb Diets in Pediatric Type 1 Diabetes—Pros and Cons
Chair: Michael J. Haller, MD
2:15 p.m.-2:40 p.m.  Low-Carb Diets in Pediatric Type 1 Diabetes—Pros
Belinda S. Lennerz, MD, PhD
2:40 p.m.-3:05 p.m.  Low-Carb Diets in Pediatric Type 1 Diabetes—Cons
Carmel E. Smart, RD, PhD
3:05 p.m.-3:10 p.m.  Rebuttal
Belinda S. Lennerz, MD, PhD
3:10 p.m.-3:15 p.m.  Rebuttal
Carmel E. Smart, RD, PhD
3:15 p.m.-3:45 p.m.  Behavioral and Psychosocial Aspects of Low-Carb Diets in Pediatric Diabetes
Katherine A. Gallagher, PhD
3:45 p.m.-4:15 p.m.  Psychosocial Implications of Low-Carb Diets and Disordered Eating in Pediatric Diabetes
Claire Aarnio-Peterson, PhD

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

2:15 p.m.-4:15 p.m.
(continued)

Symposium
Theme Area: Immunology/Transplantation
Joint ADA/Diabetes UK Symposium—Islet Transplantation—Quo Vadis?
Chair: Andrew M. Posselt, MD, PhD
2:15 p.m.-2:45 p.m. Current Outcomes in Islet-Cell Transplantation
Franca B. Barton, MS
2:45 p.m.-3:15 p.m. What Do Patients Expect from a Cell-Based Therapy of Diabetes?
Rebecca S. Monson, MD, MPH
3:15 p.m.-3:45 p.m. Health Economics of Islet-Cell Transplantation and Diabetes Therapy
Andrew M. Posselt, MD, PhD
3:45 p.m.-4:15 p.m. FDA Center for Biologics Evaluation and Research Perspective on Cell Therapies for Diabetes
Ilan Irony, MD

Symposium
Theme Area: Islet Biology/Insulin Secretion
Not Your Grandmother’s Transcription Factors—New Insights into Genomic Regulation of Beta-Cell Function
Chair: Lori Sussel, PhD
2:15 p.m.-2:45 p.m. RNA Methylation in the Pancreatic Beta Cell
Rohit Kulkarni, MD, PhD
2:45 p.m.-3:15 p.m. Non-coding RNAs in the Control of Pancreatic β-Cell Function and Development
Romano Regazzi, PhD
3:15 p.m.-3:45 p.m. Chromatin Remodeling Complexes and Transcriptional Regulation of Beta-Cell Development and Function
Jason Spaeth, PhD
3:45 p.m.-4:15 p.m. Lost in Translation—Illuminating Pathways of mRNA Translation in the Beta Cell
Doris A. Stoffers, MD, PhD

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

2:15 p.m.-4:15 p.m.

Oral Presentations

Theme Area: Clinical Diabetes/Therapeutics

Always Be My Baby—Diagnosing and Treating Diabetes during and after Pregnancy

2:15 p.m.-2:30 p.m.

187-OR Randomized Clinical Trial of the IADPSG vs. Carpenter Coustan Criteria for Diagnosis of Gestational Diabetes Mellitus

CHRISTINA M. SCIFRES, KALEAB ABEBE, HYAGRIV SIMHAN, PATRICK CATALANO, TINA COSTACOU, DIANE M. COMER, STEVEN R. ORRIS, KATHLEEN LY, ALISON DECKER, DARA MENDEZ, ESA DAVIS, Indianapolis, IN, Pittsburgh, PA, Boston, MA

2:30 p.m.-2:45 p.m.

188-OR Assessing the Validity of Diagnosis Codes for Gestational Diabetes Ascertainment

SARAH HSU, KENYA MATHIEU, ANJALI KAIMAL, RAVI THADHANI, KAITLYN JAMES, CAMILLE E. POWE, Boston, MA

2:45 p.m.-3:00 p.m.

189-OR Prepregnancy Plant-Based Diet and the Risk of Gestational Diabetes Mellitus: A Prospective Cohort Study of 15,999 Women

ZHANGLING CHEN, FRANK QIAN, GANG LIU, MENGYING LI, TRUDY VOORTMAN, SYLVIA H. LEY, JORGE E. CHAVARRO, SHILPA BHUPATHIRAJU, QI SUN, FRANK HU, CUILIN ZHANG, Rotterdam, Netherlands, New Orleans, LA, Boston, MA, Bethesda, MD

3:00 p.m.-3:15 p.m.

190-OR Impact of Prenatal Exposure to Maternal Obesity and Child Physical Activity Levels on Neurocognition

JASMIN ALVES, BRENDA C. ANGELO, SHAN H. LUO, TING CHOW, ALEXANDRA G. YUNKER, ANNY XIANG, KATHLEEN A. PAGE, JENNIFER ZINK, BRITNI R. BELCHER, KRISTI CLARK, Los Angeles, CA, Pasadena, CA

3:15 p.m.-3:30 p.m.

191-OR A Web-Based Lifestyle Intervention to Reduce Postpartum Weight Retention in Women with Recent Gestational Diabetes: The Balance after Baby Intervention Trial

JACINDA M. NICKLAS, GERALDINE SKURNIK, ANDREA T. ROCHE, CLAIRE SCHULTZ, KRITHIKA SURESH, ELLEN W. SEELEY, Boston, MA, Denver, CO, Aurora, CO

3:30 p.m.-3:45 p.m.

192-OR Association between Gestational Diabetes and the Risk of Short Intergestation Intervals

RONALD ANGUZU, LEONARD E. EGEDE, ABDUL R. SHOUR, ANNA PALATNIK, Milwaukee, WI

3:45 p.m.-4:00 p.m.

193-OR Physiology-Informed Type 2 Diabetes Genetic Clusters and Gestational Diabetes

CAMILLE E. POWE, MIRIAM UDLER, SARAH HSU, ALAN KUANG, CATHERINE ALLARD, ALISA MANNING, LUIGI BOUCHARD, PATRICE PERRON, JOSE C. FLOREZ, WILLIAM LOWE, JR., DENISE SCHOLTENS, MARIE-FRANCE HIVERT, Chicago, IL, Sherbrooke, QC, Canada, Cambridge, MA, Winnetka, IL, Boston, MA

4:00 p.m.-4:15 p.m.

194-OR Impaired Awareness of Hypoglycemia and Maternal/Neonatal Outcomes in the CONCEPTT Trial

JASMINE BAHRAMI, GEORGE TOMLINSON, HELEN R. MURPHY, DENICE FEIG, Hamilton, ON, Canada, Norwich, United Kingdom, Toronto, ON, Canada

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

2:15 p.m.-4:15 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Insulin Delivery Systems

2:15 p.m.-2:30 p.m.
195-OR Safety and Performance of the Tandem T:slim X2 with Control-IQ Automated Insulin Delivery System in Preschoolers, Age 2-6 Years Old
LAYA EKHLASPOUR, GREGORY P. FORLENZA, MELISSA SCHOELWER, MARK D. DEBOER, LIANA HSU, RYAN S. KINGMAN, EMILY BORANIAN, EMMA EMINO, R. PAUL WADWA, BRUCE A. BUCKINGHAM, MARC D. BRETON, Stanford, CA, Charlottesville, VA, Mountain View, CA, Aurora, CO, Palo Alto, CA

2:30 p.m.-2:45 p.m.
196-OR A Meal Detection Algorithm for the Artificial Pancreas: A Randomized Controlled Clinical Trial in Adolescents with Type 1 Diabetes
EMILIE PALISAITIS, ANAS EL FATHI, AHMAD HAIDAR, JULIA E. VON OETTINGEN, LAURENT LEGAULT, Montreal, QC, Canada

2:45 p.m.-3:00 p.m.
197-OR Six Months Experience on Hybrid Closed-Loop System in Children and Adolescents Previously Treated with Multiple Daily Injections
GORAN PETROVSKI, JUDITH CAMPBELL, FAWZIYA ALKHALAF, FARREDA UMER, KHALID HUSSAIN, Doha, Qatar

3:00 p.m.-3:15 p.m.
198-OR Individual Response of Automated Glycemic Control with the iLet Bionic Pancreas in the Insulin-Only vs. Bihormonal Configuration with the Stable Glucagon Analog Dasiglucagon
JORDAN SHERWOOD, COURTNEY A. BALLIRO, RABAB Z. JAFRI, LUZ E. CASTELLANOS, MALLORY HILLARD, RAJENDRANATH SELAGAMSETTY, EVELYN GREAX, HUI ZHENG, FIRAS EL-KHATIB, EDWARD DAMIANO, STEVEN J. RUSSELL, Boston, MA

3:15 p.m.-3:30 p.m.
199-OR Improved Glycemic Outcomes with Medtronic Minimed Advanced Hybrid Closed-Loop Delivery: Results from a Randomized Crossover Trial Comparing Automated Insulin Delivery with Predictive Low Glucose Suspend in People with Type 1 Diabetes
OLIVIA COLLYNS, RENEE MEIER, ZARA BETTS, DENNIS CHAN, CHRIS FRAMPTON, CARLA M. FREWEN, BENYAMIN GROSAM, NIRANJALA HEWAPATHIRANA, SHIRLEY JONES, NATALIE KURTZ, ANIRBAN ROY, JOHN SHIN, ROBERT VIGERSKY, BENJAMIN J. WHEELER, MARTIN DE BOCK, Christchurch, New Zealand, Dunedin, New Zealand, Northridge, CA, Agoura Hills, CA

3:30 p.m.-3:45 p.m.
200-OR Effects of Glucose Target on the Performance of a Bihormonal Bionic Pancreas
MARWA TUFFAHA, COURTNEY A. BALLIRO, MALLORY HILLARD, FIRAS EL-KHATIB, RAJENDRANATH SELAGAMSETTY, EDWARD DAMIANO, STEVEN J. RUSSELL, Boston, MA

(continued on next page)

Information is subject to change. Sessions current as of 5/15/20.
3:45 p.m.-4:00 p.m.

**201-OR** Automated Insulin Delivery (AID) System Performance with and without Meal Announcement: Effect of Meal Macronutrient Content

AMY BARTEE, RONALD L. BRAZG, MICHELLE KATZ, AMY LALONDE, HOWARD WOLPERT, RICHARD JONES,
Indianapolis, IN, Renton, WA, Cambridge, MA, Indianapolis, NY

4:00 p.m.-4:15 p.m.

**202-OR** Basal Insulin Digital Titration App vs. Enhanced Paper Titration Tool: A Randomized Control Study

ATHENA PHILIS-TSIMIKAS, ADDIE L. FORTMANN, ALESSANDRA BASTIAN, ARATI KANCHI, RICARDO ABAD, TONG SHENG, LINDA PARKS, MICHAEL GREENFIELD, MARK A. CLEMENTS, San Diego, CA, Mountain View, CA, Kansas City, MO

*Information is subject to change. Sessions current as of 5/15/20.*
SUNDAY, JUNE 14, 2020

2:15 p.m.-4:15 p.m.  
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism  
Liver Metabolism and Disease (With ADA Presidents' Select Abstract Presentation)

2:15 p.m.-2:30 p.m.

203-OR ADA Presidents' Select Abstract Presentation: Landscape of Liver Cell Heterogeneity and Reprogramming during NASH Pathogenesis Revealed by Single Cell RNA Sequencing  
XUELIAN XIONG, Ann Arbor, MI

2:30 p.m.-2:45 p.m.

204-OR Inhibition of Hepatic ACC on a High-Fat Diet Results in Hyperglycemia and Hepatomegaly Due to Excess Energy Generation  
STANISLAW DEJA, JUSTIN A. FLETCHER, BLANKA KUCEJOVA, XIAORONG FU, CHAI-WAN KIM, JEFFREY BROWNING, JAY D. HORTON, SHAWN C. BURGESS, Dallas, TX

2:45 p.m.-3:00 p.m.

205-OR Hepatic Protein Kinase C-e Is Necessary and Sufficient in Mediating Lipid-Induced Hepatic Insulin Resistance  
KUN LYU, DONGYAN ZHANG, MARIO KAHN, MARCOS R.S. RODRIGUES, SANDRO HIRABARA, PANU LUUKKONEN, SEOHYUK LEE, SANJAY BHANOT, JESSE RINEHART, NIELS BLUME, MORTEN RASCH, MIREILLE J. SERLIE, JONATHAN BOGAN, GARY CLINE, VARMAN SAMUEL, GERALD I. SHULMAN, New Haven, CT, Ponta Grossa, Brazil, São Paulo, Brazil, Carlsbad, CA, West Haven, CT, Måløv, Denmark, Bagsvaerd, Denmark, Amsterdam, Netherlands

3:00 p.m.-3:15 p.m.

206-OR Generation of Induced Pluripotent Stem Cells Derived from a Patient with PIK3R1 Mutation and Analysis of Defects in Insulin Action in Hepatocytes Differentiated from These Cells  
TETSUSHI HAMAGUCHI, YUSHI HIROTA, TAKEHITO TAKEUCHI, MICHIO KOYANAGI-AOI, TAKASHI AOI, WATARU OGAWA, Kobe, Japan

3:15 p.m.-3:30 p.m.

207-OR Liver-Preadipocyte Cross Talk Reverses Lipodystrophy-Induced Insulin Resistance  
BRUNA BRANDAO, MASAJI SAKAGUCHI, THIAGO M. BATISTA, WEIJUN QIAN, C. RONALD KAHN, Boston, MA, Kumamoto, Japan, Richland, WA

3:30 p.m.-3:45 p.m.

208-OR Emc10emc10, a Novel Circulating Factor for Systemic Energy and Metabolic Homeostasis  
YANLIANG LI, XUANCHUN WANG, GUIFEN QIANG, MAXIMILIAN A. MCCANN, VICTORIA GIL, MATTHIAS BLÜHER, CHONG WEE LIEW, Shanghai, China, Beijing, China, Chicago, IL, Leipzig, Germany

Information is subject to change. Sessions current as of 5/15/20.
Oral Presentations

Theme Area: Integrated Physiology/Obesity
Central Control of Feeding and Metabolic Homeostasis

2:15 p.m.-2:30 p.m.

209-OR Evidence that Agrp Neuron Activation Drives Cold-Induced Hyperphagia
JENNIFER D. DEEM, CHELSEA L. FABER, CHRISTIAN PEDERSEN, BAO ANH N. PHAN, KAYOKO OGIMOTO, SARAH A. LARSEN, MEGAN A. TRAN, VINCENT DAMIAN, KARL KAIYALA, JARRAD SCARLETT, MICHAEL R. BRUCHAS, MICHAEL W. SCHWARTZ, GREGORY J. MORTON, Seattle, WA

2:30 p.m.-2:45 p.m.

210-OR Activation of GFRAL Neurons Decreases Food Intake via Aversive Pathways
PAUL V. SABATINI, RANDY J. SEELEY, Ann Arbor, MI

2:45 p.m.-3:00 p.m.

211-OR Hypothalamic Slug Couples Overnutrition States to Epigenetic Reprogramming of Leptin Neural Circuits, Obesity, and Type 2 Diabetes
MIN-HYUN KIM, LIN JIANG, MARTIN G. MYERS, JR., LIANGYOU RUI, Ann Arbor, MI

3:00 p.m.-3:15 p.m.

212-OR Testosterone Deficiency Increases Hypothalamic Gliosis and Metabolic Risk
MAURICIO D. DORFMAN, JEREMY FREY, KELLY M. NESS, ANZELA NIRAULA, JENNY E. KANTER, KARIN BORNFEIT, KATYA RUBINOW, ELLEN SCHUR, JOSHUA THALER, Seattle, WA

3:15 p.m.-3:30 p.m.

213-OR Obesity-Induced Astroglisis Is Regulated by the Diabesity Factor HMG20A
JOSE M. MELLADO-GIL, ESTHER FUENTE-MARTIN, PETRA I. LORENZO, NADIA COBO-VUILLEUMIER, JOSE A. GUERRERO-MARTINEZ, SILVANA Y. ROMERO-ZERBO, JAIME M. FRANCO, JESUS ANGEL PEREZ-CABELLO, MANUEL ALVAREZ-DOLADO, DAVID POZO, FRANCISCO J. BERMUDEZ-SILVA, JOSE C. REYES, BENOIT R. GAUTHIER, Seville, Spain, Sevilla, Spain, Malaga, Spain

3:30 p.m.-3:45 p.m.

214-OR Role of Hypothalamic MAPK/ERK Signaling in Diabetes Remission Induced by the Central Action of Fibroblast Growth Factor 1 (FGF1)
JENNY M. BROWN, BAO ANH N. PHAN, HUZAIFA WASANWALA, MILES E. MATSEN, ANNA SECHER, GREGORY J. MORTON, MICHAEL W. SCHWARTZ, JARRAD SCARLETT, Seattle, WA, Orlando, FL, Måløv, Denmark

3:45 p.m.-4:00 p.m.

215-OR Silencing CCKBR Containing Neurons in the VMN Restains Hepatic Glucose Production to Ameliorate Diabetes in Mice
ALISON AFFINATI, JONATHAN FLAK, NADEJDA BOZAJIEVA, NANDAN KODUR, CORENTIN M. CRAS-MÉNEUR, DARLEEN A. SANDOVAL, MARTIN G. MYERS, JR., Ann Arbor, MI, Indianapolis, IN, Okemos, MI

(continued on next page)
4:00 p.m.-4:15 p.m.

**216-OR**  O-GlcNAc Transferase in the Ventromedial Hypothalamus Regulates Lipid Metabolism through Fat Depot–Specific Sympathetic Innervation

QI WANG, BICHEN ZHANG, YUNFAN YANG, JIA MI, GENG TIAN, QUNXIANG ONG, XIAOYONG YANG, New Haven, CT
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:00 p.m.

Symposium
Theme Area: Integrated Physiology/Obesity
Physiological Mechanisms of Remission of Type 2 Diabetes
Chair: Rita Basu, MD
4:30 p.m.-4:50 p.m.  Defining Remission of Type 2 Diabetes—What Does This Mean to the Patient and Provider?
    William T. Cefalu, MD
4:50 p.m.-5:15 p.m.  The How and Why of Nonsurgical Weight-Loss-Induced Remission of Type 2 Diabetes
    Roy Taylor, MD
5:15 p.m.-5:40 p.m.  Long-Term Remission of Type 2 Diabetes following Bariatric Surgery
    Francesco Rubino, MD
5:40 p.m.-6:00 p.m.  Panel Discussion—Remission of Type 2 Diabetes—Fact or Fiction?

4:30 p.m.-6:10 p.m.

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Menopause and Diabetes
Chair: Monique M. Hedderson, PhD
4:30 p.m.-4:50 p.m.  Effects of Diabetes on Ovarian Aging
    Melissa F. Wellons, MD
4:50 p.m.-5:10 p.m.  Vasomotor Symptoms and Diabetes Risk
    Kristen E. Gray, PhD
5:10 p.m.-5:30 p.m.  Effects of Diabetes on Menopause Onset and Symptoms and Osteoporosis
    Sarit Polsky, MD, MPH
5:30 p.m.-5:50 p.m.  Novel Treatments to Improve β-Cell Function in Obese Menopausal Women
    Dragana Lovre, MD
5:50 p.m.-6:10 p.m.  Associations of Steroid Sex Hormones Type 2 Diabetes Risk in Women
    Taulant Muka, MD, MPH, PhD

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:30 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Joint ADA/ASN Symposium—Targeting Diabetic Kidney Disease (DKD)—Are We Ready for Precision Medicine Trials?
Chair: Robert G. Nelson, MD, PhD
4:30 p.m.-5:00 p.m. Molecular Mechanism of DKD—More Than One Disease? Tobias B. Huber, MD
5:00 p.m.-5:30 p.m. Identifying Noninvasive Treatment Response Biomarkers for Patient Stratification Wenjun Ju, PhD
5:30 p.m.-6:00 p.m. Developing a Path Forward for Innovative Trial Design in DKD—A Regulator’s Perspective Peter Mol, PhD, PharmD
6:00 p.m.-6:30 p.m. Implementation of Precision Medicine Trials in DKD Hiddo L. Heerspink, PhD

Current Issues
Theme Area: Acute and Chronic Complications
Debate—Reconciling Guideline Recommendations for Cardiovascular Risk and Disease Management in Type 2 Diabetes
Chair: Sanjay Kaul, MD, FACC, FAHA
Should Blood Pressure Target for all Individuals with Type 2 Diabetes and Hypertension Be <130/80 mmHg?
4:30 p.m.-5:00 p.m. Yes, as Recommended by the 2017 ACC/AHA Guidelines Paul K. Whelton, MB, MD, MSc
5:00 p.m.-5:30 p.m. No, It Depends on Underlying Risk and whether It Can Be Safely Attained as Recommended by the 2019 ADA Standards of Care Raymond Townsend, MD

Debate—Should Metformin Be Considered First-Line Therapy for Individuals with Type 2 Diabetes with Established Arteriosclerotic Cardiovascular Disease (ASCVD) or at High Risk for ASCVD?
5:30 p.m.-6:00 p.m. No Longer Justified, per the 2019 ESC/EASD Recommendations Francesco Cosentino, MD, PhD, FESC
6:00 p.m.-6:30 p.m. Yes, It Is Time Tested and Proven, as Recommended by the 2019 ADA Standards of Care Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP

Symposium
Theme Area: Clinical Diabetes/Therapeutics
What Will Be the Impact of Proposed Health Policy Changes on Diabetes Care?
Chair: Robert E. Ratner, MD
4:30 p.m.-5:10 p.m. Coverage for Preexisting Conditions and Essential Medications Kasia J. Lipska, MD, MHS, BS
5:10 p.m.-5:50 p.m. The Future of Medicaid Rebecca Myerson, MPH, PhD
5:50 p.m.-6:30 p.m. Commercial Health Insurance and the Expansion of High-Deductible Health Plans J. Frank Wharam, MD, MPH

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:30 p.m.  (continued)

Symposium
Theme Area: Epidemiology/Genetics
Population Health Efforts in the Prevention and Treatment of Diabetes
Chair: Lynne E. Wagenknecht, DrPH
4:30 p.m.-5:00 p.m.  Looking to the Future of the National Diabetes Prevention Program—Building on Successes and Overcoming Challenges
Natalie D. Ritchie, PhD
5:00 p.m.-5:30 p.m.  Clinical Decision Support Tools and Their Role in the Prevention of Diabetes
Matthew O’Brien, MD, MS
5:30 p.m.-6:00 p.m.  Clinical Decision Support Tools and Their Role in the Treatment of Diabetes
Brian J. Wells, MD, PhD
6:00 p.m.-6:30 p.m.  Balancing Individual and Societal Approaches to Diabetes Prevention
Simon Griffin, FRCGP, FMedSci

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Nonalcoholic Steatohepatitis (NASH)—Emerging Concepts and Opportunities
Chair: Jiandie Lin, PhD
4:30 p.m.-5:00 p.m.  New Insights into Liver Macrophages in NASH Pathogenesis
Frank Tacke, MD, PhD
5:00 p.m.-5:30 p.m.  Inflammation and Cell Death in NASH
Laura Nagy, PhD
5:30 p.m.-6:00 p.m.  Gating NASH Progression by Brown Adipose Thermogenesis
Liangyou Rui, PhD
6:00 p.m.-6:30 p.m.  Novel Mechanisms and Therapeutic Opportunities in Liver Fibrosis in NASH
Ira Tabas, MD, PhD

Information is subject to change. Sessions current as of 5/15/20.
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:30 p.m.

Oral Presentations
Theme Area: Acute and Chronic Complications
Limb Salvage—Cell Therapy to Care-Delivery Systems (With Roger Pecoraro Award Lecture and ADA Presidents’ Select Abstract Presentation)

4:30 p.m.-5:00 p.m.

Roger Pecoraro Award Lecture

Collaboration for the Advancement of Diabetic Foot Research and Education

Lee J. Sanders, DPM

5:00 p.m.-5:15 p.m.

217-OR ADA Presidents’ Select Abstract Presentation: The Affordable Care Act Medicaid Expansion Correlated with Reduction in Lower Extremity Amputation among Minorities with Diabetic Foot Ulcers
TZEO-WOEI TAN, ELIZABETH CALHOUN, SHANNON M. KNAPP, DAVID G. MARRERO, WEI ZHOU, DAVID G. ARMSTRONG, Tucson, AZ, Los Angeles, CA

5:15 p.m.-5:30 p.m.

218-OR Does Antibiotic Treatment before Bone Biopsy Affect the Identification of Bacterial Pathogens from Bone Culture?
LAWRENCE A. LAVERY, EASTON C. RYAN, DAVID H. TRUONG, MATTHEW J. JOHNSON, JAVIER LA FONTAINE, PETER A. CRISOLOGO, Dallas, TX, Cincinnati, OH

5:30 p.m.-5:45 p.m.

219-OR Comparison of the Impact of Autologous Cell Therapy and Conservative Treatment on Chronic Limb-Threatening Ischemia in Patients with Diabetic Foot: A Randomized Controlled Trial
MICHAL DUBSKY, ROBERT BEM, ANDREA NEMCOVA, JITKA HUSÁKOVA, VLADIMIRA FEJFAROVA, ALEXANDRA JIRKOVSKA, KAROL SUTORIS, Prague, Czech Republic

5:45 p.m.-6:00 p.m.

220-OR Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Risk for Lower Extremity Amputation in People with Type 2 Diabetes
LOUIS POTIER, RONAN ROUSSEL, PIERRE-JEAN SAULNIER, FRÉDÉRIC FUMERON, KAMEL MOHAMMEDI, GILBERTO VELHO, Paris, France, Poitiers, France, Bordeaux, France

6:00 p.m.-6:15 p.m.

221-OR Does Cell Therapy Improve the Quality of Life of Patients with Chronic Limb-Threatening Ischemia? A Randomized Controlled Trial
JITKA HUSÁKOVA, ROBERT BEM, ANDREA NEMCOVA, VLADIMIRA FEJFAROVA, ALEXANDRA JIRKOVSKA, MICHAL DUBSKY, Prague, Czech Republic

6:15 p.m.-6:30 p.m.

222-OR A Call for a New Limb Salvage Paradigm for Patients with Diabetes
ELIZABETH G. ZOLPER, KENNETH L. FAN, DEAN MESHKIN, JENNA C. BEKENY, CHRISTINE HILL, MARK D. MISHU, PATRICK CONNOLLY, KAREN EVANS, CHRISTOPHER ATTINGER, Washington, DC
Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
The Far-Reaching Field of Clinical Nutrition—Food Insecurity, Famine, Fasting, and Fat Intake

4:30 p.m.-4:45 p.m.
223-OR Preliminary Evidence that "Structured Eating" (SE) May Be Acceptable and Promote Glycemic Control in Type 1 Diabetes (T1D)
ANGELICA CRISTELLO, ANNA R. KAHKOSKA, CARMEL E. SMART, SARAH C. COUCH, DARIA IGUDESMAN, LAUREN KAGER, ELIZABETH J. MAYER-DAVIS, Newcastle, Australia, Cincinnati, OH, Chapel Hill, NC

4:45 p.m.-5:00 p.m.
224-OR Effect of Macronutrient Intake on Glycemic Outcomes over 1 Year in Youth with T1D
REBECCA O. LA BANCA, LISA K. VOLKENING, EYAL DASSAU, SANJEEV N. MEHTA, LORI M. LAFFEL, Boston, MA, Cambridge, MA

5:00 p.m.-5:15 p.m.
225-OR The Impact of Visualizing Macronutrient Content via Food-Log App "Calomeal" on Glycemic Control and QoL in People with Type 2 Diabetes
ASAKO TSUNEMI, JUNKO SATO, MARI ENOMOTO, YUKO IWAGAKI, SAKAE SUGIMOTO, YUKI SOWYESA, MAI KIYA, EIKO MATSUHASHI, YUKI WAKABAYASHI, TAKASHI FUNAYAMA, TOYOSHI UCHIDA, TAKESHI MIYATSUKA, KOSUKE AZUMA, TOMOAKI SHIMIZU, HIROAKI SATOH, AKIO KANAZAWA, HIROTAKA WATADA, Tokyo, Japan

5:15 p.m.-5:30 p.m.
226-OR The Mediterranean Diet Increases GLP-1 and Oxyntomodulin Compared with Vegetarian Diet in Type 2 Diabetes Subjects
ANTONIO DI MAURO, DARIO TUCINARDI, ROSELLA DEL TORO, LAVINIA MONTE, RICCARDO GIORGINO, LORENZO RAMPA, GIOVANNI ROSSINI, SHADI KYANVASH, ANDREEA SOARE, MILENA M. ROSATI, YEGANEH MANON KHAZRAI, ALESSANDRA PICCOLI, NICOLA NAPOLI, PAOLO POZZILLI, SILVIA MANFRINI, Rome, Italy

5:30 p.m.-5:45 p.m.
227-OR The Effect of Dietary Fiber in Combination with Metformin Therapy in Type 2 Diabetes
FLAVIA TRAMONTANA, ERNESTO MADDALONI, SARA GRECI, GIUSEPPE DEFEUDIS, ROCKY STROLLO, PAOLO POZZILLI, NICOLA NAPOLI, Rome, Italy

5:45 p.m.-6:00 p.m.
228-OR Decoding Human Postprandial Responses to Food and Their Potential for Precision Nutrition: The PREDICT 1 Study
PAUL W. FRANKS, SARAH BERRY, ANA M. VALDES, DAVID A. DREW, RICHARD J. DAVIES, JORDI MERINO, ANDREW T. CHAN, NICOLA SEGATA, TIM D. SPECTOR, Malmö, Sweden, Nottingham, United Kingdom, Boston, MA, Trento, Italy, London, United Kingdom

Information is subject to change. Sessions current as of 5/15/20.
6:00 p.m.-6:15 p.m.

229-OR  The Gut Microbiome in Adults with Prediabetes and Effect of Dietary Glycemic Index
KIRSTINA UTZSCHNEIDER, MARIAN L. NEUHouser, KATHERINE M. NEWTON, KARA BREYMEYER,
MEREDITH A. HULLAR, Seattle, WA

6:15 p.m.-6:30 p.m.

230-OR  Personalized Nutrition for Prediabetes by Prediction of Glycemic Responses
ORLY BEN-YACOV, ANASTASIA GODNEVA, ERAN SEGAL, Rehovot, Israel
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Insulin Therapies*

4:30 p.m.-4:45 p.m.  
231-OR  Phase I Study Investigating the PD, PK, and Safety of AT247 in Comparison with Novorapid and Fiasp  
THOMAS R. PIEBER, THOMAS AUGUSTIN, CHRISTOPH MAGNES, DAVID J. GERRING, JAN JEZEK, SARAH J. HOWELL, LEON ZAKRZEWSKI, FIONA J. LAWRENCE, EVA SVEHLIKOVA, Graz, Austria, Grau, Austria, Cambridge, United Kingdom, Great Chesterford, United Kingdom, Little Chesterford, United Kingdom, Saffron Walden, United Kingdom

4:45 p.m.-5:00 p.m.  
232-OR  Long-Term Safety and Efficacy of Ultra-Rapid Lispro (URLi) in PRONTO-T1D  
LESLIE J. KLAFF, JANG IK CHO, MARY A. DELLVA, NANETTE C. SCHLOOT, JANET TOBIAN, JUNNOSUKE MIURA, DOMINIK DAHL, JULIANA M. BUE-VALLESKEY, Renton, WA, Indianapolis, IN, Bad Homburg, Germany, Tokyo, Japan, Hamburg, Germany

5:00 p.m.-5:15 p.m.  
233-OR  Ultra-Rapid Lispro (URLi) Demonstrates Similar Time-in-Target Range to Humalog with the Medtronic MiniMed 670G Hybrid Closed-Loop System  
BRUCE W. BODE, ANDERS L. CARLSON, RONG LIU, THOMAS HARDY, JENNIFER BOYD, RICHARD M. BERGENSTAL, SCOTT MORRETT, DEBRA A. IGNAUT, Atlanta, GA, Minneapolis, MN, Indianapolis, IN

5:15 p.m.-5:30 p.m.  
234-OR  Postprandial Glucose Control Using the Medtronic Advanced Hybrid Closed-Loop System: Faster-Acting Insulin Aspart vs. Insulin Aspart  
MELISSA H. LEE, SARA VOGRIN, BARBORA PALDUS, DALE MORRISON, DESSI ZAHARIEVA, JEAN LU, HANNAH JONES, SUE A. WYATT, EMMA NETZER, CATRIONA M. SIMS, RICHARD MACISAAC, BENYAMIN GROSMAN, ANIRBAN ROY, NATALIE KURTZ, ALICIA JENKINS, DAVID N. ONEAL, Stanford, CA, Melbourne, Australia, Northridge, CA, Agoura Hills, CA, Sydney, Australia, Fitzroy, Australia

5:30 p.m.-5:45 p.m.  
235-OR  Incidence of Significant Changes in Pulmonary Function during a 2-Year Study with Inhaled Technosphere Insulin  
MARISA C. JONES, TIFFANY S. TRAN, JOHN A. KRUEGER, PATRICK M. MOREY, BYRON J. HOOGWERF, DAVID M. KENDALL, Westlake Village, CA, Sarasota, FL

5:45 p.m.-6:00 p.m.  
236-OR  Molecular and Biological Properties of Insulin Icodec, a New Insulin Analog Designed to Give a Long Half-Life Suitable for Once-Weekly Dosing  
ERICA NISHIMURA, THOMAS KJELDSEN, FRANTISEK HUBALEK, TINE GLENDORF, CARSTEN E. STIDSEN, BO F. HANSEN, THOMAS A. PEDERSEN, ANNE LUETZEN, LONE PRIDAL, PETER MADSEN, Copenhagen, Denmark, Måløv, Denmark, Greve, Denmark

(continued on next page)

Information is subject to change. Sessions current as of 5/15/20.
6:00 p.m.-6:15 p.m.

**237-OR** Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes
ULRIKE HÖVELMANN, LISE BRØNDSTED, NIELS R. KRISTENSEN, RASMUS RIBEL-MADSEN, J. HANS DEVRIES, TIM HEISE, HANNE HAAHR, Neuss, Germany, Søborg, Denmark

6:15 p.m.-6:30 p.m.

**238-OR** Once-Weekly Basal Insulin Icodec Offers Comparable Efficacy and Safety vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve Patients with T2D Inadequately Controlled on OADS
JULIO ROSENSTOCK, MAIKEN I.S. KJAERSGAARD, DANIEL MOLLER, MELISSA VOIGT HANSEN, RONALD GOLDENBERG, Dallas, TX, Bagsvær, Denmark, Tubney, United Kingdom, Thornhill, ON, Canada
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:30 p.m.
(continued)

Oral Presentations

Theme Area: Epidemiology/Genetics

Genetics of Type 2 Diabetes and Identifying Targets

4:30 p.m.-4:45 p.m.

239-OR Genome-Wide Association Study (GWAS) of Hypoglycemia in the Million Veteran Program (MVP)
Sridharan Raghavan, Zeyuan Wang, Adriana M. Hung, Brian R. Charest, Lauren Costa, Elizabeth M. Litkowski, Aaron Leong, James B. Meigs, Peter W. Wilson, Peter Reaven, Mary K. Rhee, Yan V. Sun, Lawrence S. Phillips, Million Veteran Program, Aurora, CO, Nashville, TN, Jamaica Plain, MA, Boston, MA, Atlanta, GA, Phoenix, AZ, Decatur, GA

4:45 p.m.-5:00 p.m.

240-OR Combining Type 2 Diabetes Polygenic Scores Improves Prediction in 36,000 European and Non-European Participants in the Partners Healthcare Biobank
Josep M. Mercader, Jose C. Florez, Aaron Leong, Varinderpal Kaum, Miriam Udler, James B. Meigs, Bianca Porneala, Cambridge, MA, Boston, MA

5:00 p.m.-5:15 p.m.

241-OR Causal Gene Candidates for Type 2 Diabetes Based on Protein-Coding Variants in 127,676 Individuals
Peter Dornbos, Laura Raffield, Xianyong Yin, Jason Flannick, Chapel Hill, NC, Ann Arbor, MI, Cambridge, MA

5:15 p.m.-5:30 p.m.

242-OR Rare Genetic Variants in the Islet Regulome Contribute to the Heritability of Type 2 Diabetes Risk
Alisa Manning, TOPMED Diabetes Working Group, Cambridge, MA

5:30 p.m.-5:45 p.m.

243-OR Integrative Multiomics Analysis of Glucometabolic Traits, Adipose Tissue DNA Methylation, and Gene Expression Identifies Epigenetic Regulatory Mechanisms of Insulin Resistance and Obesity in African Americans
Neeraj K. Sharma, Mary Comeau, Dennis J. Montoya, Matteo Pellegrini, Timothy Howard, Carl D. Langefeld IV, Swapan K. Das, Winston-Salem, NC, Los Angeles, CA

5:45 p.m.-6:00 p.m.

244-OR Single Nuclei Chromatin and Transcriptome Profiling across Human and Rat Skeletal Muscle Identifies Regulatory Elements, Genes, and Cell Types Associated with Diabetes GWAS Signals
Stephen Parker, Fusion Tissue Sampling Group, Ann Arbor, MI

6:00 p.m.-6:15 p.m.

245-OR CIS-Regulatory Architecture of Human ESC-Derived Hypothalamic Neuron Differentiation Aids in Variant-to-Gene Mapping of Type 2 Diabetes Related Traits

(continued on next page)

Information is subject to change. Sessions current as of 5/15/20.
6:15 p.m.-6:30 p.m.

**246-OR** A Loss-of-Function Mutation in the Sucrase-Isomaltase Gene Is Linked to a Markedly Healthier Metabolic Profile in Greenlanders

MARIT E. JØRGENSEN, METTE K. ANDERSEN, LINE SKOTTE, EMIL JØRSETSBOE, NIELS GRARUP, PETER BJERREGAARD, BOLETTE SOBOG, OLUF PEDERSEN, SR., BJARKE FEENSTRA, NILS J.K. FÆRGEHAM, ANDERS KOCH, IDA MOLTKE, TORBEN HANSEN, ANDERS ALBRECHTSEN, Gentofte, Denmark, Copenhagen, Denmark, Odense, Denmark
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Immunology/Transplantation
Novel Insights into the Autoimmunity of Diabetes (With ADA Presidents' Select Abstract Presentation)

4:30 p.m.-4:45 p.m.
247-OR ADA Presidents' Select Abstract Presentation: Detection of T-Cells Reactive to Hybrid Insulin Peptides in Subjects at Risk for Type 1 Diabetes
ROCKY L. BAKER, THOMAS DELONG, MARIAN REWERS, PETER GOTTLIEB, KATHRYN M. HASKINS, Denver, CO, Aurora, CO

4:45 p.m.-5:00 p.m.
248-OR Visualizing Heterogeneous Islet Autoantibody Trajectories of Children Who Develop T1D from Multisite Birth Cohort Studies
BUM CHUL KWON, PETER ACHENBACH, VIBHA ANAND, JESSICA L. DUNNE, WILLIAM HAGOPIAN, MARKUS LUNDGREN, RIITTA VEIJOLA, BRIGITTE I. FROHNERT, THE T1DI STUDY GROUP, Munich, Germany, Cambridge, MA, New York, NY, Seattle, WA, Lund, Sweden, Oulu, Finland, Aurora, CO

5:00 p.m.-5:15 p.m.
249-OR A Randomized, Double-Blind Phase 2 Trial of the CXCR1/2 Inhibitor Ladarixin in Adult Patients with New-Onset Type 1 Diabetes
EMANUELE BOSI, PAOLO POZZILLI, FRANCESCO GIORGINO, EFISIO COSSU, THOMAS LINN, LUDGER ROSE, BART KEYMEULEN, SR., PIETER GILLARD, LUISA DAFFONCHIO, PIER A. RUFFINI, MARCELLO ALLEGRETTI, LORENZO PIEMONTE, Rome, Italy, Bari, Italy, Monserrato, Italy, Giessen, Germany, Münster, Germany, Brussels, Belgium, Leuven, Belgium, Milan, Italy

5:15 p.m.-5:30 p.m.
250-OR Hypoproliferative CD8 Effector Memory (EM) Subsets Are Linked to Preservation of C-Peptide in Alefacept-Treated Recent-Onset Type 1 Diabetes Subjects
ELISAVET SERTI, KIRSTEN E. DIGGINS, VIRGINIA S. MUIR, TINGTING LU, ELISA BALMAS, GERALD T. NEPOM, S. ALICE LONG, PETER LINSLEY, Bethesda, MD, Seattle, WA

5:30 p.m.-5:45 p.m.
251-OR Cardiac Autoantibodies (AB) Predict Cardiovascular Disease (CVD) in T1D and Are Associated with Cytokine Signatures Linked to CVD Risk
GIOVANE R. SOUSA, SR., MONIKA NIEWCZAS, MYRA A. LIPES, Boston, MA

5:45 p.m.-6:00 p.m.
252-OR Failed Genetic Protection: Type 1 Diabetes in the Presence of HLA-DQB1*06:02
KIMBER SIMMONS, ANGELA M. MITCHELL, AIMON ALKANANI, KRISTEN MCDANIEL, ERIN BASCHAL, TAYLOR ARMSTRONG, LAURA PYLE, LIPI NG YU, AARON W. MICHELS, Aurora, CO

6:00 p.m.-6:15 p.m.
253-OR Circulating Neutrophil Numbers Increase with Age, but Are Not a Biomarker of T1D Risk
ANDREA LIN, DANIEL J. PERRY, DESMOND SCHATZ, TODD M. BRUSKO, MARK A. ATKINSON, MICHAEL J. HALLER, CLAYTON E. MATHEWS, Gainesville, FL

(continued on next page)

Information is subject to change. Sessions current as of 5/15/20.
6:15 p.m.-6:30 p.m.

**254-OR** Islet Autoimmunity Is Highly Prevalent and Associated with Diminished Beta-Cell Function in Patients with Type 2 Diabetes (T2D) in the GRADE Study

BARBARA BROOKS-WORRELL, CHRISTIANE S. HAMPE, ERICA V. GONZALEZ, BRENDA M. PALOMINO, SAHAR Z. ZANGENEH, KRISTINA UTZSCHNEIDER, STEVEN E. KAHN, MARY E. LARKIN, MARY L. JOHNSON, KIEREN J. MATHER, NAJI YOUNES, NEDA RASOULI, CYRUS DESOUZA, ROBERT M. COHEN, JEAN Y. PARK, HERMES FLOREZ, WILLY MARCOS VALENCIA, GRADE BETA CELL ANCILLARY STUDY NETWORK, ALI SHOJAIE, JERRY P. PALMER, ASHOK BALASUBRAMANYAM, GRADE RESEARCH GROUP, Seattle, WA, Boston, MA, Minneapolis, MN, Indianapolis, IN, Rockville, MD, Denver, CO, Omaha, NE, Cincinnati, OH, Baltimore, MD, Miami, FL, Houston, TX
SUNDAY, JUNE 14, 2020

4:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations
Theme Area: Islet Biology/Insulin Secretion
Identity Crisis? Maintaining and Manufacturing Beta Cells (With ADA Presidents' Select Abstract Presentation)

4:30 p.m.-4:45 p.m.
255-OR  ADA Presidents' Select Abstract: Glucagon Receptor Antagonism Stimulates Beta-Cell Proliferation in Mouse and Human Islets  
KATIE C. COATE, ERICK SPEARS, CHUNHUA DAI, SCOTT WISNIEWSKI, GREG POFFENBERGER, LEONARD D. SHULTZ, DALE L. GREINER, DANIEL J. DRUCKER, HAI YAN, KYLE SLOOP, ALVIN C. POWERS, DANIELLE DEAN, MEMPHIS, TN, NASHVILLE, TN, BAR HARBOR, ME, WORCESTER, MA, TORONTO, ON, CANADA, CAMARILLO, CA, INDIANAPOLIS, IN

4:45 p.m.-5:00 p.m.
256-OR Using Human Induced Pluripotent Stem Cell Derived Organoids to Identify New Pathologies in Patients with Pdx1 Mutations  
MANS KRISHNAMURTHY, TAYLOR R. BRODA, DANIEL O. KECHELE, XINGHAO ZHANG, JOSEPH J. PALERMO, MARGARET H. COLLINS, INAS H. THOMAS, AMER HEIDER, ANDREW DAUBER, JAMES WELLS, CINCINNATI, OH, ANN ARBOR, MI, WASHINGTON, DC

5:00 p.m.-5:15 p.m.
257-OR Profiling Transcriptional Maturation of Human Pluripotent Stem Cell–Derived Islets after Transplantation  
PUNN AUGSORNOWARAWAT, KRISTINA G. MAXWELL, JEFFREY R. MILLMAN, ST. LOUIS, MO

5:15 p.m.-5:30 p.m.
258-OR DNA Methylation Regulates the Identity of Pancreatic Beta Cells  
NAZIA PARVEEN, JEAN K. WANG, SANGEETA DHAWAN, DUAWE, CA

5:30 p.m.-5:45 p.m.
259-OR Epigenetic Coregulation of Beta-Cell Function and Survival in Postnatal Life  
SANGEETA DHAWAN, TATYANA GURLO, JEAN K. WANG, DUAWE, CA, LOS ANGELES, CA

5:45 p.m.-6:00 p.m.
260-OR Transdifferentiation of a-Cells and Redifferentiation of InsulinLo β-Cells Dominate β-Cell Regeneration in Late-Stage Diabetic NOD Mice Cured with Induction of Mixed Chimerism and Administration of Gastrin and Epidermal Growth Factor  
SHANSHAN TANG, MINGFENG ZHANG, PERE SANTAMARIA, ARTHUR D. RIGGS, LIANG JIN, DE-FU ZENG, DUAWE, CA, CALGARY, AB, CANADA, NANJING, CHINA

6:00 p.m.-6:15 p.m.
261-OR CDK4-R24C Compensates for IRS2 Deficiency by Enhancing Beta-Cell Proliferation and Restoring Signaling through the AKT-Foxo1-PDX1 Pathway  
RACHEL E. STAMATERIS, ROHIT B. SHARMA, BRIAN GABLASKI, SUSHIL G. RANE, LAURA C. ALONSO, WORCESTER, MA, BETHESDA, MD, NEW YORK, NY

(continued on next page)
6:15 p.m.-6:30 p.m.

262-OR  The Transcription Factor Yin Yang 1 (YY1) Is Critical to Beta-Cell Maintenance and Glucose Homeostasis
FLAVIA LETÍCIA M. PEÇANHA, ERNESTO BERNAL-MIZRACHI, Miami, FL
MONDAY, JUNE 15, 2020

Scientific Sessions
8:00 a.m.-10:00 a.m.

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Addressing Care Gaps—New Frontiers for Diabetes Nutrition Providers and Services
Chair: Hope Warshaw, MMSc, RD, CDE
8:00 a.m.-8:30 a.m.  REAL HEALTH Diabetes—Translating Look AHEAD into Usual Care at Community Health Centers
   Linda M. Delahanty, MS, RDN
8:30 a.m.-9:00 a.m.  Expanding Access to Nutrition and Diabetes Education through Innovative Technology
   Jodi S. Krall, PhD
9:00 a.m.-9:30 a.m.  A New Era—Leveraging RDNs in Medication Management in Reducing Therapeutic Inertia
   Gretchen Benson, RDN, CDE
9:30 a.m.-10:00 a.m.  Food Is Medicine—Prescribing Food as a Specialty Drug for Food-Insecure People with Diabetes
   Michelle Passaretti, MSN, BSN, RN, CCM

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Utilizing Diabetes Technology in the Real World—Tools of the Trade
Chair: Cari Berget, RN, MPH, CDE
8:00 a.m.-8:30 a.m.  Innovative Models that Educate Patients and Care Teams on Continuous Glucose Monitoring Use
   Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
8:30 a.m.-9:00 a.m.  Continuous Glucose Monitoring—Using Trend Arrows as a Road Map to Increase Time-in-Range
   Jeniece T. Ilkowitz, MA, BSN, RN, CDE
9:00 a.m.-9:30 a.m.  Educating Patients to Succeed with Advanced Pump Therapy
   Laurel H. Messer, RN, PhD, CDE
9:30 a.m.-10:00 a.m.  The Do-It-Yourself Movement—How Do We Manage Patients That Are Looping?
   Julia E. Blanchette, PhD, RN, CDCES

Symposium
Theme Area: Clinical Diabetes/Therapeutics
How Do GLP-1 Receptor Agonists Provide Cardioprotection?
Chair: Lawrence Blonde, MD, FACP, MACE
8:00 a.m.-8:40 a.m.  GLP-1 Receptor Agonists and Cardiovascular Outcomes—The Evidence
   Mansoor Husain, MD, FRCPC
8:40 a.m.-9:20 a.m.  GLP-1 and Atherosclerosis—Direct and Indirect Mechanisms
   Sanjay Rajagopalan, MD
9:20 a.m.-10:00 a.m.  GLP-1 and Cardioprotection—Where Are the Cellular Targets?
   Daniel J. Drucker, MD

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

8:00 a.m.-10:00 a.m.  
(continued)

**Symposium**  
Theme Area: Clinical Diabetes/Therapeutics  
**Update from the TEDDY Study**  
Chair: Jeffrey Krischer, PhD

- **8:00 a.m.-8:30 a.m.**  
  - Determinants of Islet Autoimmunity and Clinical Implications  
  - Marian Rewers, MD, PhD

- **8:30 a.m.-9:00 a.m.**  
  - Metabolome Signals in the TEDDY Study  
  - Qian Li, PhD

- **9:00 a.m.-9:30 a.m.**  
  - HbA1c—Is It a Good Diagnostic Predictor of Type 1 Onset in a Pediatric Population?  
  - Kendra Vehik, PhD, MPH

- **9:30 a.m.-10:00 a.m.**  
  - Dissecting the Type 1 Diabetes and Celiac Disease Overlap in the TEDDY Study  
  - William Hagopian, MD, PhD

**Symposium**  
Theme Area: Epidemiology/Genetics  
**From Genome-Wide Association Studies to Multiomics—Defining Diabetes Risk and Clinical Relevance**  
Chair: Marie-France Hivert, MD, MMSc

- **8:00 a.m.-8:30 a.m.**  
  - Diabetes Research Using Biobanks and Multiomics Technologies  
  - Guillaume Pare, MD

- **8:30 a.m.-9:00 a.m.**  
  - Multiomic Approaches in Explaining Diabetes Risk  
  - Praveen Sethupathy, PhD

- **9:00 a.m.-9:30 a.m.**  
  - Epigenomics and Risk of Type 2 Diabetes  
  - Kyle J. Gaulton, PhD

- **9:30 a.m.-10:00 a.m.**  
  - Epigenomics and Risk of Gestational Diabetes  
  - Marie-France Hivert, MD, MMSc

**Symposium**  
Theme Area: Integrated Physiology/Obesity  
**Joint ADA/EASD Symposium—Leveraging Metabolism to Prevent, Treat, or Cure Type 1 Diabetes**  
Chair: Ananda Basu, MD  
Alternate: Stefano Del Prato, MD

- **8:00 a.m.-8:30 a.m.**  
  - Treatment—Closed-Loop Trials in the U.S.  
  - R. Paul Wadwa, MD

- **8:30 a.m.-9:00 a.m.**  
  - Treatment—Closed-Loop Trials in Europe  
  - Charlotte K. Boughton, MRCP, PhD

- **9:00 a.m.-9:30 a.m.**  
  - Prevention—Oral Insulin in Toddlers with Genetic Risk of Type 1 Diabetes Pan European Trial  
  - Olga Kordonouri, PhD

- **9:30 a.m.-10:00 a.m.**  
  - Commentary on the Future of Type 1 Diabetes Management—Treatment or Cure?  
  - Closed-Loop Trials, Immunomodulation, or Both?  
  - Jay S. Skyler, MD, MACP

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

8:00 a.m.-10:00 a.m.
(continued)

Symposium
Theme Area: Islet Biology/Insulin Secretion
Trouble in the Neighborhood—Endocrine/Exocrine Interactions in Diabetes
Chair: Martha Campbell-Thompson, DVM, PhD
8:00 a.m.-8:30 a.m. The Link between Pancreatic Cancer and Diabetes
Suresh T. Chari, MD
8:30 a.m.-9:00 a.m. Genetic Links between Pancreatitis and Diabetes
Scott A. Oakes, MD
9:00 a.m.-9:30 a.m. Hypusine Biosynthesis Is Critical for Exocrine Pancreas Development
Teresa L. Mastracci, PhD
9:30 a.m.-10:00 a.m. Interrogating a Duct-Islet Axis—Cystic Fibrosis
Andrew Norris, MD, PhD

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

8:00 a.m.-10:00 a.m.

Oral Presentations
Theme Area: Acute and Chronic Complications
Hypoglycemia—Guts and Garters

8:00 a.m.-8:15 a.m.
263-OR Counterregulatory Responses to Hypoglycemia in Totally Pancreatectomized Patients
MILLE BÆKDAL, ASGER B. LUND, MARIA POMPEA ANTONIA BALDASSARRE, JOHAN I. EGHOLK, KATHRINE ROSE, CARSTEN HANSEN, JAN H. STORKHOLM, MIKKEL B. CHRISTENSEN, BOLETTE HARTMANN, JENS FABER, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP, Hellerup, Denmark, Chieti, Italy, Copenhagen, Denmark

8:15 a.m.-8:30 a.m.
264-OR Characterizing the Distinct Glycemic Patterns Of Postbariatric Hypoglycemia (PBH)
DANIEL LEE, JONATHAN DREYFUSS, CHRISTOPHER M. MULLA, MARY-ELIZABETH PATTI, Atlanta, GA, Boston, MA

8:30 a.m.-8:45 a.m.
265-OR Identifying Adults at Risk of Unintentional Severe Hypoglycemia in Hospital Using Artificial Intelligence (RUSHH-AI)
MICHAEL FRALICK, DAVID DAI, CHLOE POU-PROM, AMOL A. VERMA, MUHAMMAD MAMDANI, Toronto, ON, Canada

8:45 a.m.-9:00 a.m.
266-OR Rebound Hyperglycemia in Real-World Data and its Mitigation with a CGM-Based Predictive Alert
GIADA ACCIAROLI, ANDREW PARKER, JOHN WELSH, SARAH PUHR, TOMAS C. WALKER, HALIS K. AKTURK, Edinburgh, United Kingdom, San Diego, CA, Aurora, CO

9:00 a.m.-9:15 a.m.
267-OR Reduction in Self-Reported Adverse Events Related to Severe Hypoglycemia in Individuals Using a Predictive Low Glucose System: Results from a Real-World Setting
HARSIMRAN SINGH, MICHELLE L. MANNING, MOLLY MCELWEE-MALLOY, STEPHANIE HABIF, San Diego, CA

9:15 a.m.-9:30 a.m.
268-OR Conversations and Reactions around Severe Hypoglycemia (CRASH): Survey Responses of People Aged 65+ with T1DM or Insulin-Treated T2DM and Caregivers
FRANK J. SNOEK, ERIK SPAEPEN, DONALD M. BUSHNELL III, CHRISTOPHER J. CHILD, ZANETA BALANTAC, BETH MITCHELL, MARK PEYROT, Amsterdam, Netherlands, Bekkevoort, Belgium, Seattle, WA, Windlesham, United Kingdom, Bethesda, MD, Indianapolis, IN, Baltimore, MD

(continued on next page)
9:30 a.m.-9:45 a.m.

**269-OR**  Effect of Insulin Degludec on Frequency of Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia: The HypoDeg Trial

RIKKE M. AGENSEN, AMRA CIRIC ALIBEGOVIC, HENRIK U. ANDERSEN, PETER GUSTENHOFF, TROELS K. HANSEN, TONNY JENSEN, SR., CLAUS B. JUHL, ANDREAS K. JENSEN, SUSANNE LERCHE, KIRSTEN NØRGAARD, HANS-HENRIK D. PARVING, ANNE L. SØRENSEN, LISE TARNOW, BIRGER THORSTEINSSON, ULRIK PEDERSEN-BJERGAARD, Søborg, Denmark, Gentofte, Denmark, Aalborg, Denmark, Aarhus, Denmark, Copenhagen, Denmark, Esbjerg, Denmark, Kolding, Denmark, Hellerup, Denmark, Hillerød, Denmark

9:45 a.m.-10:00 a.m.

**270-OR**  Nocturnal Hypoglycemia with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycemia (HypoDeg): A CGM Substudy

JULIE M. BRØSEN, RIKKE M. AGENSEN, AMRA CIRIC ALIBEGOVIC, HENRIK U. ANDERSEN, PETER GUSTENHOFF, TROELS K. HANSEN, TONNY JENSEN, SR., CLAUS B. JUHL, SUSANNE LERCHE, KIRSTEN NØRGAARD, HANS-HENRIK D. PARVING, LISE TARNOW, BIRGER THORSTEINSSON, ULRIK PEDERSEN-BJERGAARD, Søborg, Denmark, Gentofte, Denmark, Aalborg, Denmark, Aarhus, Denmark, Copenhagen, Denmark, Esbjerg, Denmark, Kolding, Denmark, Hellerup, Denmark, Hillerød, Denmark
MONDAY, JUNE 15, 2020

8:00 a.m.-10:00 a.m.
(continued)

Oral Presentations

Theme Area: Clinical Diabetes/Therapeutics

Preventing Type 1 and Type 2 Diabetes (With ADA Presidents' Select Abstract Presentation)

8:00 a.m.-8:15 a.m.

271-OR ADA Presidents’ Select Abstract Presentation: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF
SILVIO E. INZUCCHI, KIERAN DOCHERTY, LARS KOBERT, MIKHAIL N. KOSIBOROD, FELIPE MARTINEZ, PIOTR PONIKOWSKI, MARC S. SABATINE, SCOTT SOLOMON, JAN BELOHLAVEK, MICHAEL BÖHM, CHERN-EN CHIANG, RUDOLF A. DE BOER, MIRTA DIEZ, ANDREJ DUJAT, CHARLOTTA E.A. LJUNGMAN, SUBODH VERMA, DAVID L. DEMETS, OLOF BENGSTSSON, ANNA MARIA LANGKILDE, MIKAELA SIÖSTRAND, PARDEEP JHUND, JOHN J. MCMURRAY, New Haven, CT, Copenhagen, Dominica, Kansas City, MO, Cordoba, Argentina, Wroclaw, Poland, Toronto, ON, Canada, Madison, WI, Molndal, Sweden, Gothenburg, Sweden, Glasgow, United Kingdom

8:15 a.m.-8:30 a.m.

272-OR Do Diabetes Prevention Treatments Promote Regression to Normal Glucose Regulation? A Network Meta-analysis
KARLA I. GALAVIZ, MARY BETH WEBER, UNJALI GUJRAL, JINGKAI WEI, KARA SUVADA, JEEHEA SONYA HAW, K.M. VENKAT NARAYAN, MOHAMMED K. ALI, Atlanta, GA, Washington, DC

8:30 a.m.-8:45 a.m.

273-OR Comparative Effectiveness of Lifestyle Intervention on Fasting Plasma Glucose in Normal Weight vs. Overweight/Obese Adults with Prediabetes
MANDY K. SALMON, BRENDA S. WRIGHT, TERRI L. KRIDL, GEORGE C. FAIRCLOTH, RICHARD D. SALMON, NEIL F. GORDON, Savannah, GA

8:45 a.m.-9:00 a.m.

274-OR Effect of Testosterone Treatment on Type 2 Diabetes Incidence in High-Risk Men Enrolled in a Lifestyle Program: A Two-Year Randomized Placebo-Controlled Trial
GARY A. WITTERT, KRISTY P. ROBLEDOS, MATHIS GROSSMANN, KAREN BRACKEN, BU B. YEAP, BRONWYN G.A. STUCKEY, ROBERT I. MCLACHLAN, DAVID J. HANDELSMA, CAROLYN ALLAN, WARRICK INDER, DAVID JESUDASON, ANTHONY C. KEECH, ALICIA JENKINS, MARK NG TANG FUI, MARK DANIEL, Adelaide, Australia, Heidelberg West, Australia, Perth, Australia, Nedlands, Australia, Sydney, Australia, Clayton, Australia, Brisbane, Australia, Woodville South, Australia, Bruce, Australia

9:00 a.m.-9:15 a.m.

275-OR The Association between the Biological Disease-Modifying Antirheumatic Drugs and Incidence of Diabetes
CHU LIN, HONGYU JJ, XIAOLING CAI, WENJIA YANG, LINONG JI, Zhengzhou, China, Beijing, China

(continued on next page)

Information is subject to change. Sessions current as of 5/15/20.
9:15 a.m.-9:30 a.m.

**276-OR** A 2-Dimensional (2D) Analysis of Glucose and C-Peptide Shows a Teplizumab Effect in Individuals at Risk for Type 1 Diabetes (T1D) 3 Months after Treatment
EMILY K. SIMS, MEGAN V. WARNOCK, KEVAN C. HEROLD, JAY SOSENKO, Indianapolis, IN, Tampa, FL, New Haven, CT, Miami, FL

9:30 a.m.-9:45 a.m.

**277-OR** Teplizumab Reverses the Loss of C-Peptide in Relatives at Risk for Type 1 Diabetes (T1D)
EMILY K. SIMS, BRIAN N. BUNDY, KENNETH D. STIER, ELISAVET SERTI, NOHA LIM, GERALD T. NEPOM, CARMELLA EVANS-MOLINA, KEVAN C. HEROLD, Indianapolis, IN, Tampa, FL, New Haven, CT, Bethesda, MD, Seattle, WA

9:45 a.m.-10:00 a.m.

**278-OR** Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes
MATTHIAS G. VON HERRATH, STEPHEN C. BAIN, BRUCE W. BODE, JESPER OLE CLAUSEN, KEN COPPIETERS, LELYA GAYSINA, JANUSZ GUMPRECHT, TROELS K. HANSEN, CHANTAL MATHIEU, CRISTOBAL MORALES PORTILLO, OFRI MOSENZON, STINE SEGEL, GEORGE M. TSOUKAS, THOMAS PIEBER, Seattle, WA, Swansea, United Kingdom, Atlanta, GA, Søborg, Denmark, Måløv, Denmark, Kazan, Russian Federation, Katowice, Poland, Aarhus, Denmark, Leuven, Belgium, Seville, Spain, Jerusalem, Israel, Aalborg, Denmark, Montreal, QC, Canada, Graz, Austria
MONDAY, JUNE 15, 2020

8:00 a.m.-10:00 a.m.
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics
Diabetes across the Lifespan

8:00 a.m.-8:15 a.m.
279-OR Cognition in Young Adults with Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study
ALLISON SHAPIRO, DANA DABELEA, JEANETTE M. STAFFORD, RALPH DAGOSTINO, JR., CATHERINE PIHOKER, ANGELA D. LIESE, AMY S. SHAH, ANNA BELLATORRE, JEAN M. LAWRENCE, LEORA HENKIN, GRETA WILKENING, Aurora, CO, Winston-Salem, NC, Seattle, WA, Columbia, SC, Cincinnati, OH, Pasadena, CA

8:15 a.m.-8:30 a.m.
280-OR Medical Nutrition Therapy and Glycemic Control in Youth-Onset Diabetes: SEARCH for Diabetes in Youth Study

8:30 a.m.-8:45 a.m.
281-OR Type 2 Diabetes Diagnosed between 16-30 Years in South Asian and White Individuals Is Phenotypically Similar
SHIVANI MISRA, IAN F. GODSLAND, NIKITA BHARDWAJ, NICK OLIVER, KATHARINE R. OWEN, DESMOND G. JOHNSTON, ESQ., Princeton, NJ, London, United Kingdom, Oxford, United Kingdom

8:45 a.m.-9:00 a.m.
282-OR The Association of Age of Onset of Type 2 Diabetes with Long-Term Risk of End Stage Kidney Disease: A National Registry Study
JEDIDIAH I. MORTON, DANNY LIEW, STEPHEN MCDONALD, JONATHAN E. SHAW, DIANNA J. MAGLIANO, Melbourne, Australia, Adelaide, Australia

9:00 a.m.-9:15 a.m.
283-OR Changes in HbA1c between 2011-2017 in Austria/Germany, Sweden, and the United States: A Lifespan Perspective
ANASTASIA ALBANESE-O'NEILL, JULIA HERMANN, ANN-MARIE SVENSSON, KELLEE MILLER, KLEMS RAILE, KARIN AKESSON, PETER CALHOUN, KATARINA EEG-OLOFSSON, DAVID M. MAAHS, REINHARD W. HOLL, RAGNAR HANAS, Gainesville, FL, Gothenburg, Sweden, Tampa, FL, Berlin, Germany, Jönköping, Sweden, Göteborg, Sweden, Stanford, CA, Ulm, Germany, Uddevalla, Sweden

(continued on next page)
9:15 a.m.-9:30 a.m.
284-OR  Characterization of Cognitive Changes in Type 1 Diabetes of Extreme Duration by Retinal Neural Structure and Vasculature
EMILY WOLFSON, WARD FICKWEILER, KONSTANTINA SAMPANI, HETAL SHAH, LLOYD P. AIELLO, JENNIFER SUN, GEORGE L. KING, Boston, MA

9:30 a.m.-9:45 AM
285-OR  Long-Term HbA1c Trajectories and Mortality and Major Atherosclerotic Cardiovascular Events (MACE) in Type 1 Diabetes (T1D)
RACHEL G. MILLER, TINA COSTACOU, TREVOR J. ORCHARD, Pittsburgh, PA

9:45 a.m.-10:00 a.m.
286-OR  Biomedical Predictors of Cognitive Decline in Older Participants with T1DM: Longitudinal Follow-Up of the DCCT/EDIC Cohort
MONDAY, JUNE 15, 2020

8:00 a.m.-10:00 a.m.
(continued)

Oral Presentations
Theme Area: Immunology/Transplantation
Preclinical Studies in Animal Models of Diabetes

8:00 a.m.-8:15 a.m.
287-OR  TCR/HLA Humanized Mice Reveal Reduced Tolerance and Increased Immunogenicity of Posttranslationally Modified GAD65 Epitope
YI JING, YUELIN KONG, JOHN MCGINTY, GABRIELE BLAHNIK-FAGAN, MATTHEW BETTINI, EDDIE A. JAMES, MARIA BETTINI, Houston, TX, Seattle, WA, Salt Lake City, UT

8:15 a.m.-8:30 a.m.
288-OR  Myeloid-Specific Deletion of Alox15 Decreases Pancreatic Inflammation and Protects from Spontaneous Diabetes Development in Nonobese Diabetic (NOD) Mice
ANNIE PINEROS, ABHISHEK KULKARNI, KARA ORR, LINDSEY GLENN, CHRISTOPHER A. REISSAUS, MARIMAR HERNANDEZ-PEREZ, MARCIA J. MCDUFFIE, JERRY NADLER, MARGARET A. MORRIS, RAGHAVENDRA MIRMIRA, SARAH A. TERSEY, Indianapolis, IN, Charlottesville, VA, Norfolk, VA, Rockville, MD, Chicago, IL

8:30 a.m.-8:45 a.m.
289-OR  JAK Inhibitors Block Interferon and Common Gamma Chain Cytokine Signaling to Reverse Diabetes in NOD Mice
GAURANG JHALA, TINGTING GE, BALASUBRAMANIAN KRISHNAMURTHY, THOMAS KAY, HELEN E. THOMAS, Melbourne, Australia, Fitzroy, Australia

8:45 a.m.-9:00 a.m.
290-OR  Diabetes Progression in IFG-Receptor Deficient NOD Mice Is Associated with Increased CD8+ T Lymphocyte Sensitivity to Common Gamma Chain Cytokines
THOMAS KAY, GAURANG JHALA, BALASUBRAMANIAN KRISHNAMURTHY, HELEN E. THOMAS, Melbourne, Australia, Fitzroy, Australia

9:00 a.m.-9:15 a.m.
291-OR  Deletion within the Helicase 1 Domain of MDA5 Dampens Immune Cell Activation and Delays Type 1 Diabetes
SAMUEL I. BLUM, YI-GUANG CHEN, HUBERT M. TSE, Birmingham, AL, Milwaukee, WI

9:15 a.m.-9:30 a.m.
292-OR  Treg Cells Control Systemic Lipid and Iron Metabolism via the OGT-STAT5 Axis
OSCAR C. SALGADO BARRERO, HAI-BIN RUAN, Minneapolis, MN

9:30 a.m.-9:45 a.m.
293-OR  Mitochondrial Hexokinase Dissociation Correlates with Obesity-Induced Inflammation and Regulates the Fate of Glucose
FARNAZ KEYHANI NEJAD, ADAM DEJESUS, JUSTIN A. GEIER, HOSSEIN ARDEHALI, Chicago, IL

9:45 a.m.-10:00 a.m.
294-OR  Discovery of a Novel Secretory Protein from the Gut Microbiome That Promotes Immune Tolerance and Ameliorates Autoimmunity via Dendritic Cell Induction of IL-10
ALEKSANDAR KOSTIC, Boston, MA

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

8:00 a.m.-10:00 a.m.
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Peripheral Insulin Action

8:00 a.m.-8:15 a.m.
295-OR  Estrogen Receptor a Controls Energy Homeostasis in White and Brown Adipose Tissue by Regulating Polg1 Expression and Mitochondrial Remodeling
ZHENQI ZHOU, ANDREA L. HEVENER, Los Angeles, CA

8:15 a.m.-8:30 a.m.
296-OR  Identification and Characterization of New Players in Insulin-Controlled GLUT4 Trafficking
JINGSHI SHEN, Boulder, CO

8:30 a.m.-8:45 a.m.
297-OR  β-Catenin Facilitates Skeletal Muscle Insulin-Stimulated Glucose Transport through the Regulation of Actin Remodeling
STEWART W. MASSON, TROY L. MERRY, Auckland, New Zealand

8:45 a.m.-9:00 a.m.
298-OR  Disruption of Multiple Cell-Autonomous Protein Phosphorylation Networks Underlies Muscle Insulin Resistance in Type 2 Diabetes
THIAGO M. BATISTA, NICOLAI J. WEWER ALBRECHTSEN, JULEEN R. ZIERATH, MATTHIAS MANN, C. RONALD KAHN, Boston, MA, Copenhagen, Denmark, Stockholm, Sweden, Martinsried, Germany

9:00 a.m.-9:15 a.m.
299-OR  Loss of Insulin and IGF1 Receptors in Muscle Impairs Complex-I Dependent Mitochondrial Bioenergetics and Supercomplex Formation via Foxo Transcription Factors
GOURAV BHARDWAJ, CHRISTIE M. PENNIMAN, PABLO A. SUAREZ BELTRAN, JAYASHREE JENA, COLLIN M. FOSTER, KENNEDY PORO, TAYLOR JUNCK, ANTECTOR HINTON, RHONDA SOUVENIR, JORDAN FUQUA, PABLO E. MORALES, ROBERTO BRAVO-SAGUA, VITOR A. LIRA, EVAN D. ABEL, BRIAN T. ONEILL, Iowa City, IA, Santiago, Chile

9:15 a.m.-9:30 a.m.
300-OR  The Transcriptional Coregulator CITED2 Suppresses Expression of IRS-2 in Endothelial Cells and Impairs Vascular Insulin Signaling In Vivo
BRITTA KUNKEMOELLER, KUANGYANG CHEN, XUANCHUN WANG, CHRISTIAN RASK-MADSEN, Boston, MA, Shanghai, China

9:30 a.m.-9:45 a.m.
301-OR  Lipin 1–Mediated Phosphatidic Acid Phosphatase Activity in Adipocytes Regulates Systemic Insulin Sensitivity on High-Fat Diet
ANDREW J. LUTKEWITTE, BRIAN N. FINCK, St. Louis, MO

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

10:10 a.m.-11:45 a.m.
National Scientific & Health Care Achievement Awards Presentation
and
Outstanding Scientific Achievement Award Lecture
Emerging Endocrine and Paracrine Hormones in Health and Metabolic Disease
Jiandie Lin, PhD
12:00 p.m.-1:00 p.m.

Professional Interest Group Discussion
Theme Area: Clinical Diabetes Therapeutics
Professional Interest Group Discussion on Diabetes Technology—Interpreting Time-in-Range in Different Populations and Situations
Chair: Anne L. Peters, MD
12:00 p.m.-12:15 p.m. Time-in-Range as a Research Outcome Measure
John R. Petrie, PhD, FRCP
12:15 p.m.-12:30 p.m. Interpreting Time-in-Range during Pregnancy
Viral Shah, MD
12:30 p.m.-12:45 p.m. Interpreting Time-in-Range in Children
Jenise C. Wong, MD, PhD
12:45 p.m.-1:00 p.m. Utilizing Time-in-Range for Pre-Op Clearance
Joseph A. Aloj, MD

Professional Interest Group Discussion
Theme Area: Clinical Diabetes/Therapeutics
Professional Interest Group Discussion on Health Care Delivery and Quality Improvement—Leveraging Population Health Methods to Improve Diabetes Care
Chair: Mary K. Rhee, MD
12:00 p.m.-12:40 p.m. Implementing the Lessons of the Diabetes Prevention Program
Ronald T. Ackermann, MD, MPH
Tannaz Moin, MD, MBA, MSHS
12:40 p.m.-1:00 p.m. Improving Population Health in Underserved Communities with Type 2 Diabetes
Athena Philis-Tsimikas, MD

Professional Interest Group Discussion
Theme Area: Clinical Diabetes/Therapeutics
Professional Interest Group Discussion on Pregnancy and Reproductive Health—All Pregnant Women with Preexisting Diabetes Should Take Low-Dose Aspirin to Prevent Preeclampsia
Chair: Mary R. Loeken, PhD
12:00 p.m.-12:30 p.m. Pro
Fionnuala Breathnach, MD, MRCOG, FRCPI, DCH, DipGUMed
12:30 p.m.-1:00 p.m. Con
Ellen W. Seely, MD

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

12:00 p.m.-1:00 p.m.
(continued)

Professional Interest Group Discussion
Theme Area: Epidemiology/Genetics
Professional Interest Group Discussion on Public Health and Epidemiology—Diabetes and Built Environment
Chair: Hsin-Chieh "Jessica" Yeh, PhD
12:00 p.m.-12:20 p.m. Welcome and Michaela Modan Memorial Award Presentation
Hsin-Chieh "Jessica" Yeh, PhD
12:20 p.m.-12:40 p.m. Built Environment and Diabetes Risks and Related Outcomes
Gillian Booth, MD, MSc
12:40 p.m.-1:00 p.m. Built Environment and Disadvantaged Communities
Tiffany L. Gary-Webb, PhD, MHS

Professional Interest Group Discussion
Theme Area: Immunology/Transplantation
Professional Interest Group Discussion on Immunology, Immunogenetics, and Transplantation—Next Generation in Immunotherapy in Type 1 Diabetes
Chair: Todd M. Brusko, PhD
12:00 p.m.-12:20 p.m. Immunomodulation Followed by Antigen-Specific T(reg) Infusion Controls Islet Autoimmunity
Allison L. Bayer, PhD
12:20 p.m.-12:40 p.m. Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T-Cells
Kaitlin Carroll, PhD
12:40 p.m.-1:00 p.m. Altered Function of Antigen-Presenting Cells in Type 1 Diabetes—A Challenge for Antigen-Specific Immunotherapy?
Jorge Postigo Fernandez, PhD

Current Issues
Theme Area: Clinical Diabetes/Therapeutics
Debate—Primary Cardiovascular Prevention with SGLT2 Inhibitors or GLP-1 Receptor Agonists—Are We Ready for Prime Time?
Chair: Julio Rosenstock, MD
2:15 p.m.-2:40 p.m. Yes, We Are Ready for Prime Time
Mikhail N. Kosiborod, MD
2:40 p.m.-3:05 p.m. No, We Are Not Ready for Prime Time
Darren K. McGuire, MD, MHSc
3:05 p.m.-3:10 p.m. Rebuttal
Mikhail N. Kosiborod, MD
3:10 p.m.-3:15 p.m. Rebuttal
Darren K. McGuire, MD, MHSc

Information is subject to change. Sessions current as of 5/15/20.
### Symposium
**Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise**

#### Disparities in Diabetes and Diabetes Care—What Can We Do about It?
Chair: Persis V. Commissariat, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m. - 2:35 p.m.</td>
<td>Community and Family-Based Strategies to Improve Type 1 Diabetes Management in African American and Latino School-Aged Children</td>
<td>Ashley Butler, PhD</td>
</tr>
<tr>
<td>2:35 p.m. - 2:55 p.m.</td>
<td>Disparities in Care Delivery in Diabetes—Strategies for Underrepresented and Underserved Young Adults</td>
<td>Shivani Agarwal, MD</td>
</tr>
<tr>
<td>2:55 p.m. - 3:15 p.m.</td>
<td>Innovative Approaches to Address Disparities in African Americans with Type 2 Diabetes—An Important Role for Pastors and Church Leaders</td>
<td>Elizabeth Lynch, PhD</td>
</tr>
<tr>
<td>3:15 p.m. - 3:35 p.m.</td>
<td>Patient-Centered Approaches to Addressing Latino Diabetes Disparities</td>
<td>Arshiya A. Baig, MD, MPH</td>
</tr>
<tr>
<td>3:35 p.m. - 3:55 p.m.</td>
<td>Translating Diabetes Self-Management Support to Reach Socioeconomically Disadvantaged and Ethnic Minority Adults with Type 2 Diabetes</td>
<td>Jeffrey S. Gonzalez, PhD</td>
</tr>
</tbody>
</table>

### Symposium
**Theme Area: Acute and Chronic Complications**

#### Hypoglycemia—All about the Brain
Chair: Amir Moheet, MBBS

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m. - 2:45 p.m.</td>
<td>Central Mechanisms of Hypoglycemia Awareness</td>
<td>Rory J. McCrimmon, MD</td>
</tr>
<tr>
<td>2:45 p.m. - 3:15 p.m.</td>
<td>Brain Imaging in Hypoglycemia—How Does It Relate to Clinical Practice?</td>
<td>Pratik Choudhary, MD</td>
</tr>
<tr>
<td>3:15 p.m. - 3:45 p.m.</td>
<td>Cognitions and Beliefs That Increase Hypoglycemia Risk</td>
<td>Linda Gonder-Frederick, PhD</td>
</tr>
<tr>
<td>3:45 p.m. - 4:15 p.m.</td>
<td>Personality and Hypoglycemia Risk</td>
<td>Therese C. Anderbro, PhD, Lic. Psychologist</td>
</tr>
</tbody>
</table>

### Symposium
**Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise**

#### Physical Activity and Diabetes—When, How Much, Insulin Adjustments, and More
Chair: Ronald J. Sigal, MD, MPH, FRCPA

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m. - 2:45 p.m.</td>
<td>Exercise Timing Matters, or Does It? When to Be Active</td>
<td>Jane E. Yardley, PhD</td>
</tr>
<tr>
<td>2:45 p.m. - 3:15 p.m.</td>
<td>Exercise Volume Considerations for Type 2 Diabetes</td>
<td>Normand G. Boulé, PhD</td>
</tr>
<tr>
<td>3:15 p.m. - 3:45 p.m.</td>
<td>Can Insulin Be Optimally Managed for Exercise? How to Adjust Dosing</td>
<td>Rémi Rabasa-Lhoret, MD, PhD</td>
</tr>
<tr>
<td>3:45 p.m. - 4:15 p.m.</td>
<td>Have Diabetic Feet? How to Use New Technologies to Manage Activity</td>
<td>David G. Armstrong, DPM, MD, PhD</td>
</tr>
</tbody>
</table>
MONDAY, JUNE 15, 2020

2:15 p.m.-4:15 p.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Artificial Intelligence (AI), Machine Learning, and Diabetes
Chair: William H. Herman, MD, MPH
2:15 p.m.-2:55 p.m.  AI for Risk Assessment and Blood Glucose Control
Josep Vehi, PhD
2:55 p.m.-3:35 p.m.  Use of AI to Tailor Medical Therapy for Type 2 Diabetes (Precision Medicine)
Adrian Aguilera, PhD
3:35 p.m.-4:15 p.m.  Use of AI to Screen for Complications
Arianna Dagliati, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Fetal Sex and Pregnancy Outcomes
Chair: Carrie E. McCurdy, PhD
2:15 p.m.-2:45 p.m.  Maternal Diabetes and Sex of the Offspring
Samantha F. Ehrlich, PhD, MPH
2:45 p.m.-3:15 p.m.  Fetal Sex Influences Maternal Diabetes Risk and Pregnancy Complications
Claire T. Roberts, BA, BSc (Hons), PhD
3:15 p.m.-3:45 p.m.  Sex Differences in Prenatal Programming of Metabolic Syndrome—Role of Maternal-Fetal Androgens in Pregnancy
Grace Huang, MD
3:45 p.m.-4:15 p.m.  Sex Differences in Metabolic Programming by Maternal Obesity
Susan Ozanne, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Chinese Diabetes Society Symposium—Novel Antidiabetic Approaches and Potential Targets
Chair: Weiping Jia, MD
2:15 p.m.-2:45 p.m.  Thirty-Year Update of the Daqing Diabetes Study
Guangwei Li, MD
2:45 p.m.-3:15 p.m.  The Antidiabetic Effect of Dorzagliatin in Chinese Patients with Type 2 Diabetes
Dalong Zhu, MD, PhD
3:15 p.m.-3:45 p.m.  Diabetes Originates from the Liver
Xiaoying Li, MD, PhD
3:45 p.m.-4:15 p.m.  Nutrient Sensing and Metabolic Regulation in the Liver
Yu Li, PhD

Symposium
Theme Area: Epidemiology/Genetics
Twenty Years of Pediatric Diabetes Surveillance—What Do We Know and Why It Matters—The SEARCH for Diabetes in Youth Study
Chair: Dana Dabelea, MD, PhD
2:15 p.m.-2:45 p.m.  The Changing Landscape of Pediatric Diabetes in the U.S.
Jean M. Lawrence, ScD, MPH, MSSA
2:45 p.m.-3:15 p.m.  Disparities in Morbidity and Mortality Associated with Pediatric Diabetes
Amy K. Mottl, MD, MPH, FASN
3:15 p.m.-3:45 p.m.  Psychosocial and Behavioral Correlates of Pediatric Diabetes
Katherine A. Sauder, PhD
3:45 p.m.-4:15 p.m.  Barriers to Care, Cost, and Care Transitions
Catherine Pihoker
MONDAY, JUNE 15, 2020

2:15 p.m.-4:15 p.m.
(continued)

Symposium
Theme Area: Immunology/Transplantation
The Human Pancreas in Type 1 Diabetes
Chair: Clayton E. Mathews, PhD
2:15 p.m.-2:45 p.m.  Heterogeneity in the Type 1 Diabetes Pancreas
Mark A. Atkinson, PhD
2:45 p.m.-3:15 p.m.  Loss of Endocrine and Exocrine Mass in Type 1 Diabetes
Martha Campbell-Thompson, DVM, PhD
3:15 p.m.-3:45 p.m.  Beta Cells Releasing Information
Anath Shalev, MD
3:45 p.m.-4:15 p.m.  T-Cells in the Islets—What Do They See?
Maki Nakayama, MD, PhD

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Inter-organ Cross Talk in Physiology and Metabolic Disease
Chair: C. Ronald Kahn, MD
2:15 p.m.-2:45 p.m.  Role of the Nervous System in Mediating the Physiology and Pharmacology of FGF21
Steven Kliewer, PhD
2:45 p.m.-3:15 p.m.  The Role of Exosomes in Mediating Inter-organ Cross Talk, via Adiponectin / T-cadherin / MSCs
Ichiro Shimomura, MD
3:15 p.m.-3:45 p.m.  Inter-organ Effects Mediating the Beneficial Effects of Exercise on Metabolism
Laurie J. Goodyear, PhD
3:45 p.m.-4:15 p.m.  Lipids as Mediators of Inter-organ Cross Talk in Metabolism
Judith Simcox, BA, PhD

3:15 p.m.-4:15 p.m.

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Weekly Basal Insulin—The Wave of the Future?
Chair: Julio Rosenstock, MD
3:15 p.m.-3:35 p.m.  Do We Need Even Longer-Acting Basal Insulin Analogs?
Philip Home, DM, DPhil
3:35 p.m.-3:55 p.m.  Novel Pharmacological Strategies to Develop Weekly Insulin
J. Hans DeVries, MD, PhD
3:55 p.m.-4:15 p.m.  Weekly Basal Insulin Analogs—Clinical Evidence So Far!
Stefano Del Prato, MD
MONDAY, JUNE 15, 2020

2:15 p.m.-4:15 p.m.

Oral Presentations

Theme Area: Acute and Chronic Complications

Firsthand Look at Provoking Translational and Clinical Studies in Diabetic Kidney Disease (With ADA Presidents' Select Abstract Presentation)

2:15 p.m.-2:30 p.m.

302-OR ADA Presidents' Select Abstract: The Balance of Vascular Tone in the Afferent (RA) and Efferent (RE) Arterioles Associates with Diabetic Kidney Lesions and Predicts Progression to End Stage Kidney Disease (ESKD) in Type 2 Diabetes (T2D)
PIERRE-JEAN SAULNIER, HELEN C. LOOKER, MICHAEL MAUER, ROBERT G. NELSON, PETTER BJORNSTAD, Poitiers, France, Phoenix, AZ, Minneapolis, MN, Aurora, CO

2:30 p.m.-2:45 p.m.

303-OR Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial
ITAMAR RAZ, STEPHEN D. WIVIOTT, HIDDO L. HEERSPINK, JAMIE P. DWYER, AVIVIT CAHN, ERICA L. GOODRICH, SABINA MURPHY, ALIZA ROZENBERG, ILAN YANUV, JOHN WILDING, LAWRENCE A. LEITER, DEEPAK L. BHATT, DARREN K. MCGUIRE, RONALD C. MA, TSVENTALINA TANKOVA, MARTIN FREDRIKSSON, INGRID A. GAUSE-NILSSON, ANNA MARIA LANGKILDE, MARC S. SABATINE, OFRI MOSENZON, Jerusalem, Israel, Boston, MA, Groningen, Netherlands, Nashville, TN, Liverpool, United Kingdom, Toronto, ON, Canada, Dallas, TX, Hong Kong, China, Sofia, Bulgaria, Möln达尔, Sweden, Gotthenburg, Sweden

2:45 p.m.-3:00 p.m.

304-OR 5-Hydroxymethylcytosines in Circulating Cell-Free DNA Reveal Diabetic Nephropathy
CHANG ZENG, YING YANG, ZHOU ZHANG, CHUAN HE, WEI ZHANG, SONG-MEI LIU, Chicago, IL, Wuhan, China

3:00 p.m.-3:15 p.m.

305-OR Glycemic Variability and Progression of CKD: PERL Substudy
JANET B. MCGILL, IRL B. HIRSCH, PETER CALHOUN, ANDRZEJ GALECKI, KATRINA RUEDY, CHUN-YI WU, ALESSANDRO DORIA, St. Louis, MO, Seattle, WA, Tampa, FL, Ann Arbor, MI, Boston, MA

3:15 p.m.-3:30 p.m.

306-OR A Metabolic Mismatch between Renal Oxygenation and Glomerular Filtration Rate in Type 1 Diabetes
CARISSA L. VINOVSKIS, KRISTEN J. NADEAU, KALIE L. TOMMERDAHL, POTTUMARTHI V. PRASAD, LU-PING LI, LAURA PYLE, MARIAN REWERS, MARLON PRAGNELL, FARID H. MAHMUD, DANIEL H. VAN RAALTE, DAVID CHERNEY, ROBERT NELSON, PETTER BJORNSTAD, Aurora, CO, Evanston, IL, Denver, CO, New York, NY, Toronto, ON, Canada, Amsterdam, Netherlands, Phoenix, AZ

3:30 p.m.-3:45 p.m.

307-OR Activation of Mitochondrial Activities by Pyruvate Kinase M2 (PKM2) in Podocytes Improved Glomerular Metabolism and Diabetic Nephropathy
JIALIN FU, TAKANORI SHINJO, RONALD ST-LOUIS, QIAN LI, KYOUNGMIN PARK, HISASHI YOKOMIZO, YUMI ZAITSU, MARC GREGORY YU, I-HSIEN WU, HETAL SHAH, GEORGE L. KING, Boston, MA, Fukuoka, Japan

3:45 p.m.-4:00 p.m.

308-OR Deficiency of Mitochondrial Glycerol 3-Phosphate Dehydrogenase Accelerates the Progression of Diabetic Glomerular Pathology
HUA QU, YI ZHENG, Chongqing, China

(continued on next page)
4:00 p.m.-4:15 p.m.

309-OR  IGF-1 Receptors, Not Insulin Receptors, on Mesangial Cells Are Accelerating Mesangial Expansion and Albuminuria in Streptozotocin-Induced Diabetic Mice

ATSUSHI ISHIKADO, TAKANORI SHINJO, HISASHI YOKOMIZO, YASUTAKA MAEDA, KYOUNGMIN PARK, WEIER QI, RONALD ST-LOUIS, QIAN LI, GEORGE L. KING, Fukuoka, Japan, Boston, MA
MONDAY, JUNE 15, 2020

2:15 p.m.-4:15 p.m.
(continued)

Oral Presentations
Theme Area: Integrated Physiology/Obesity

Integrative Physiology—Muscling in on Liver

2:15 p.m.-2:30 p.m.

310-OR Role of Glucose Flux to Elevate Hepatic Lipogenesis in Biopsy-Proven NASH
JUSTINE M. MUCINSKI, NEAL SHARMA, MARY P. MOORE, JAMAL A. IBDAH, R. SCOTT RECTOR, ELIZABETH J. PARKS, Columbia, MO

2:30 p.m.-2:45 p.m.

311-OR Reduced Hepatic Mitochondrial Metabolism and Markers of Mitochondrial Turnover in Humans Are Linked to NAFLD Progression
MARY P. MOORE, RORY CUNNINGHAM, GRACE M. MEERS, SARAH A. JOHNSON, ANDREW A. WHEELER, RAMA RAO GANGA, JAMES PITT, NICOLE SPENCER, ALBERTO A. DIAZ-ARIAS, AHMED SWI, JAMAL A. IBDAH, ELIZABETH J. PARKS, R S. RECTOR, Columbia, MO

2:45 p.m.-3:00 p.m.

312-OR Gender-Specific Effects on Hepatic Fat Metabolism in Type 2 Diabetes before and after Remission
AHMAD AL-MRABEH, SHADEN MELHEM, SVIATLANA V. ZHYZHNEUSKAYA, CARL PETERS, ALISON C. BARNES, KIEREN G. HOLLINGSWORTH, NAVEED SATTAR, MICHAEL E. LEAN, ROY TAYLOR, Newcastle upon Tyne, United Kingdom, Glasgow, United Kingdom

3:00 p.m.-3:15 p.m.

313-OR Diurnal Pattern of Meal Tolerance in Type 2 Diabetes
YOGESH R. YADAV, DAVIDE ROMERES, FNU RUCHI, SAFIA SAWLEH, RICKEY CARTER, ANANDA BASU, RITA BASU, Charlottesville, VA, Padova, Italy, Jacksonville, FL

3:15 p.m.-3:30 p.m.

314-OR The Effect of Inhibition of Fatty Acid Spillover from Adipose Tissues on Organ-Specific Distribution of Dietary Fatty Acids
EMILIE MONTASTIER, CHRISTOPHE NOLL, RUN ZHOU YE, MEHDI AMRANI, FRÉDÉRIQUE FRISCH, MÉLANIE FORTIN, LUCIE BOUFFARD, OTMAN SARRHINI, SERGE PHOENIX, BRIGITTE GUERIN, ERIC E. TURCOTTE, ANDRÉ C. CARPENTIER, Sherbrooke, QC, Canada

3:30 p.m.-3:45 p.m.

315-OR Hyperglycemia Increases Central Aortic Stiffness in Response to Insulin in Healthy Humans
WILLIAM B. HORTON, LINDA JAHN, LEE HARTLINE, JAMES T. PATRIE, EUGENE BARRETT, Charlottesville, VA

3:45 p.m.-4:00 p.m.

316-OR Oral vs. Intravenous Glucose Administration Produce Opposing Microvascular Actions in Skeletal Muscle of Healthy People
KATHERINE ROBERTS-THOMSON, LEWAN PARKER, ANDREW C. BETIK, MICHELLE KESKE, Melbourne, Australia

4:00 p.m.-4:15 p.m.

317-OR Assessing Sarcopenia in T2D: Results from the Large UK Biobank Imaging Study
JENNIFER LINGE, OLOF DAHLQVIST LEINHARD, Linköping, Sweden

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

2:15 p.m.-4:15 p.m.
(continued)

Oral Presentations
Theme Area: Islet Biology/Insulin Secretion
A (Dys)functional Family—Insulin and Glucagon Secretion

2:15 p.m.-2:30 p.m.
318-OR Ciliary GPCRs Regulate Glucose-Stimulated Insulin Secretion
CHIEN-TING WU, KEREN HILGENDORF, YAN HANG, ROMINA J. BEVACQUA, CARL T. JOHNSON, CHARLES A. CHANG, SANGBIN PARK, KRISSE TELLEZ, SEUNG KIM, PETER K. JACKSON, Stanford, CA, San Mateo, CA

2:30 p.m.-2:45 p.m.
319-OR First Responder Beta-Cell Subpopulation Affects Islet Response to Glucose
VIRA KRAVETS, JAEANN M. DWULET, WOLFGANG SCHLEICHER, RICHARD K. BENNINGER, Aurora, CO

2:45 p.m.-3:00 p.m.
320-OR Bariatric Surgery Improves Ca2+ Dynamics across Pancreatic Islets In Vivo
ELINA AKALESTOU, KINGA SUBA, LIVIA LOPEZ NORIEGA, PAULINE L. CHABOSSEAU, ISABELLE LECLERC, VICTORIA SALEM, GUY A. RUTTER, London, United Kingdom

3:00 p.m.-3:15 p.m.
321-OR Deletion of 14-3-3? in Pancreatic ß-Cells Increase Mitochondrial Activity and Insulin Secretion
YVES MUGABO, MARIA GALIPEAU, JU JING TAN, EVGENIA FADZEYEVA, RYSZARD GRYGORCZYK, GARETH E. LIM, Montreal, QC, Canada, Ottawa, ON, Canada

3:15 p.m.-3:30 p.m.
322-OR Impairment of Alpha-Cell Bioenergetics Contributes to Increased Basal Yet Decreased Glucose Stimulated Oxygen Consumption Rates of Isolated Human Pancreatic Islets in T1DM and T2DM
NICOLAI M. DOLIBA, ANDREA V. ROZO, WEI QIN, JEFFREY ROMAN, CHENGYANG LIU, ALI NAJI, KLAUS H. KAESTNER, DORIS A. STOFFERS, FRANZ MATHSCHINSKY, Philadelphia, PA

3:30 p.m.-3:45 p.m.
323-OR Synergism between Protein Quality Control Pathways to Maintain Alpha-Cell Mass and Function
RACHEL B. REINERT, XIANWEI CUI, NEHA SHRESTHA, LING QI, Ann Arbor, MI

3:45 p.m.-4:00 p.m.
324-OR The Incretin Action of GIP Is Mediated through Both Alpha and Beta Cells
KIMBERLEY M. EL, MEGAN CAPOZZI, SARAH M. GRAY, JENNIFER L. BROWN, FRANCIS S. WILLARD, PAUL EMMERSON, KYLE SLOOP, DAVID D’ALESSIO, JONATHAN CAMPBELL, Durham, NC, Indianapolis, IN

4:00 p.m.-4:15 p.m.
325-OR ß-Arrestin 1 Regulates Glucagon-Like Peptide-1 Receptor Mediated Insulin Secretion in a Ligand-Dependent Manner
JONATHAN D. DOUROS, II, KYLE SLOOP, JONATHAN CAMPBELL, DAVID D’ALESSIO, Durham, NC, Indianapolis, IN
MONDAY, JUNE 15, 2020

4:30 p.m.-6:10 p.m.

Symposium
Theme Area: Acute and Chronic Complications

Novel Approaches for Cell and Tissue Interrogation—Using the Kidney as a Model
Chair: Katherine R. Tuttle, MD, FACP, FASN, FNKF

4:30 p.m.-4:50 p.m.  The Value of Kidney Biopsies to Empower New Discoveries in Diabetic Kidney Disease
Matthias Kretzler, MD

4:50 p.m.-5:10 p.m.  Linking Structure to Function in Early Diabetic Kidney Disease via Single Cell Analysis in Renal Biopsy Cohorts
Rajasree Menon, PhD

5:10 p.m.-5:30 p.m.  Visualizing Diabetic Kidney Disease Damage by 3D Multifluorescence Biopsy Imaging
Tarek Ashkar (El-Achkar), MD

5:30 p.m.-5:50 p.m.  Interrogation of Kidney Disease with Spatial Transcriptomics
Jamie Marshall, PhD

5:50 p.m.-6:10 p.m.  Lessons from Single Cell Genomics and Kidney Organoids
Anna Greka, MD, PhD

4:30 p.m.-6:30 p.m.

Symposium
Theme Area: Clinical Diabetes Therapeutics

The Year in Review—Highlights of the Past Year in Basic, Translational, and Clinical Science
Chair: Julio Rosenstock, MD

4:30 p.m.-5:10 p.m.  Basic Science
Alan Saltiel, PhD

5:10 p.m.-5:50 p.m.  Translational Science
Lora K. Heisler, PhD

5:50 p.m.-6:30 p.m.  Clinical Science
David M. Nathan, MD

Symposium
Theme Area: Clinical Diabetes/Therapeutics

Interpreting Cardiovascular Outcomes Trials—Implications for Practice
Chair: Yehuda Handelsman, MD

4:30 p.m.-4:40 p.m.  Which Medication Is Best to Prevent a Cardiovascular Event in a Patient with Type 2 Diabetes and Established or at High Risk for Heart Disease?
Yehuda Handelsman, MD

4:40 p.m.-4:50 p.m.  Case Presentation
Yehuda Handelsman, MD

4:50 p.m.-5:10 p.m.  Choosing a GLP-1 Receptor Agonist
Ofri Mosenzon, MD, MSc

5:10 p.m.-5:30 p.m.  Choosing an SGLT2 Inhibitor
Sunder Mudaliar, MD

5:30 p.m.-5:50 p.m.  Choosing a PCSK9 Inhibitor
Christopher Cannon, MD

5:50 p.m.-6:10 p.m.  Choosing a Fish Oil
Sergio Fazio, MD, PhD

6:10 p.m.-6:30 p.m.  Panel Discussion—Choosing the “Winning” Medication

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

4:30 p.m.-6:30 p.m.
(continued)

Symposium
Theme Area: Epidemiology/Genetics
Perspectives on the Future of Precision Diabetes Medicine—A Joint ADA/EASD Symposium
Chair: Paul W. Franks, PhD
4:30 p.m.-4:45 p.m.  Introduction
  Paul W. Franks, PhD
4:45 p.m.-5:20 p.m.  Optimizing Precision Medicine in Diabetes Using Monogenic Testing
  Andrew T. Hattersley, FRCP, DM
5:20 p.m.-5:55 p.m.  How Can We Better Target Treatment to Lower HbA1c in Patients with Type 2 Diabetes?
  Ewan Pearson, PhD
5:55 p.m.-6:30 p.m.  Are Precision Medicine-Based Diabetes Guidelines Translatable across Populations?
  James B. Meigs, MD, MPH

Symposium
Theme Area: Integrated Physiology/Obesity
Cognitive Function in Obesity and Appetite Regulation
Chair: Shenelle Alyse Edwards-Hampton, PhD
4:30 p.m.-5:10 p.m.  The Bidirectional Relationship between Obesity and Executive Function
  Luke E. Stoeckel, PhD
5:10 p.m.-5:50 p.m.  The Role of Cognitive Function on Obesity Treatment Success—Predictor, Outcome, or Both?
  Misty A.W. Hawkins, PhD
5:50 p.m.-6:30 p.m.  This Is Your Brain on Food—Food as an Addictive Substance
  Ashley N. Gearhardt, PhD

Symposium
Theme Area: Islet Biology/Insulin Secretion
It's All in the Timing—Time and Age-Related Changes in Islet Function
Chair: Joseph T. Bass, MD, PhD
4:30 p.m.-5:00 p.m.  Type 2 Diabetes in Youth—A Different Disease?
  Tamara S. Hannon, MD, MS
5:00 p.m.-5:30 p.m.  Age-Related Metabolic Rewiring of Pancreatic β-Cell Function
  Matthew Wortham, PhD
5:30 p.m.-6:00 p.m.  Time Zones of Pancreatic Islet Metabolism
  Charna Dibner, PhD
6:00 p.m.-6:30 p.m.  Role of the Islet Circadian Clock in Beta-Cell Maturation and Function
  Aleksey Matveyenko, PhD

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

4:30 p.m.-6:30 p.m.

Oral Presentations
Theme Area: Acute and Chronic Complications
Clinical Management of and Novel Biomarkers for Diabetic Retinopathy

4:30 p.m.-4:45 p.m.
326-OR Faricimab for Diabetic Macular Edema: A Novel Anti–Angiopoietin-2/Anti–Vascular Endothelial Growth Factor Bispecific Antibody in Clinical Trials
VEERAL SHETH, JAYASHREE SAHNI, IVAYLO STOIOV, JEFFREY R. WILLIS, ROBERT WEIKERT, Lemont, IL, South San Francisco, CA, Basel, Switzerland

4:45 p.m.-5:00 p.m.
327-OR Association of Retinol Binding Protein 3 with Retinal Neural Structure and Clinical Parameters in Diabetic Retinopathy
WARD FICKWEILER, KYOUNGMIN PARK, EMILY WOLFSON, HYUNSEOK PARK, HISASHI YOKOMIZO, I-HSIEN WU, DANIEL GORDIN, VALMA HARJUTSAILO, PER-HENRIK GROOP, LLOYD P. AIELLO, JENNIFER SUN, GEORGE L. KING, Helsinki, Finland, Boston, MA

5:00 p.m.-5:15 p.m.
328-OR Retinopathy Screening in Adolescents with Type 1 Diabetes
ANDRZEJ S. JANUSZEWSKI, VALLIMAYIL VELAYUTHAM, PAUL Z. BENITEZ-AGUIRRE, MARIA E. CRAIG, GERALD LIEW, YOON HI CHO, ALICIA JENKINS, KIM C. DONAGHUE, Sydney, Australia, Campbelltown, Australia

5:15 p.m.-5:30 p.m.
329-OR REDD1 Suppresses the Retinal Antioxidant Response to Diabetes by Destabilizing Nrf2
WILLIAM P. MILLER, ALLYSON TORO, JOSEPH GIORDANO, MICHAEL D. DENNIS, Hershey, PA

330-OR WITHDRAWN

331-OR WITHDRAWN

5:30 p.m.-5:45 p.m.
332-OR Medicare Part B Fee-for-Service Claims for Diabetes-Related Eye Diseases
ELIZABETH A. LUNDEEN, DAVID B. REIN, JOHN WITTENBORN, JINAN B. SAADDINE, Chicago, IL, Atlanta, GA

5:45 p.m.-6:00 p.m.
333-OR DMHCA Reduces the Development of Diabetic Retinopathy (DR) in db/db Mice by Lowering Cholesterol Levels and Altering the Transcriptomic Profile of Hematopoietic Stem Cells
CRISTIANO P. VIEIRA, SETH D. FORTMANN, ANA LEDA LONGHINI, TODD A. LYDIC, JULIA V. BUSIK, MARIA B. GRANT, Birmingham, AL, East Lansing, MI

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

4:30 p.m.-6:30 p.m.
(continued)

Oral Presentations

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Delivering Patient and Professional Diabetes Education across Diverse Populations

4:30 p.m.-4:45 p.m. 334-OR  Project ECHO T1D Tackles Complexity of Diabetes Cases in Primary Care
Nicolás Cuttriss, Claudia Anez-Zabala, Linda G. Baer, Stephanie L. Filipp, Marina Basina, Matthew J. Gurka, Lauren Figg, Michael J. Haller, Korey K. Hood, Xanadu Roque, Rayhan Lal, Sarah C. Westen, David M. Maahs, Marissa Town, C Jason Wang, Jessie J. Wong, Katarina Yabut, ECHO T1D STUDY GROUP, Ashby F. Walker, Gainesville, Fl, Stanford, CA

4:45 p.m.-5:00 p.m. 335-OR  A Successful Diabetes Management Model of Care in Long-Term Care Facilities
Sarah L. Sy, Medha Munshi, Boston, MA

336-OR WITHDRAWN

5:00 p.m.-5:15 p.m. 337-OR  Continuous Glucose Monitoring Shared Medical Appointments Improve A1C and Diabetes Self-Efficacy
Diana Isaacs, Ana Simonyan, Julia E. Blanchette, Sanela Lekic, Dawn Noe, Nicholas R. Galloway, Cleveland, OH, Beachwood, OH, Avon Lake, OH

5:15 p.m.-5:30 p.m. 338-OR  Evaluation of the Spectrum Training Program for Real-Time Continuous Glucose Monitoring: A Multicenter Prospective Study in 120 Adults with Type 1 Diabetes
Guido Freckmann, Sandra Schlueter, Peter Wintergerst, Lutz Heinemann, Tobias Rücker, Andrea Hinz, Marita Wernsing, Florian Thielen, Torben Biester, Philipp Von Blankenburg, Winfried Keuthage, Ralph Ziegler, Ekkehard Martin, Martin Holder, Dorothée Deiss, Gebhard Buchal, Louisa Van Den Boom, Karin Lange, Ulm, Germany, Northeim, Germany, Düsseldorf, Germany, Gifhorn, Germany, Quakenbrück, Germany, Hannover, Germany, Hameln, Germany, Münster, Germany, Braunschweig, Germany, Stuttgart, Germany, Berlin, Germany, Siegen, Germany, Frankfurt, Germany

5:30 p.m.-5:45 p.m. 339-OR  Increased Diabetes Self-Efficacy and Transition Readiness in Teens with Uncontrolled Type 1 Diabetes Receiving a Group Education Curriculum
Katharine Garvey, Taylor Dean, Sinead Christensen, Kristen Rice, Virginia B. Rich, Shannon Terrio, Laura Berbert, Enju Liu, Lori M. Laffel, Boston, MA

5:45 p.m.-6:00 p.m. 340-OR  Outcomes of a Digital Diabetes Self-Management Support Program Stratified by A1C
Jonathan Patterson, Matt Allison, Kelly J. Brassil, Stephen B. Burton, Thupten T. Norbu, Mazi Rasulnia, Dhiren Patel, Birmingham, Al

6:00 p.m.-6:15 p.m. 341-OR  Expanding Diabetes Self-Management Education to Include Chronic Kidney Disease Education
Preetha Prithivathithi, Michael Spigler, Melanie Paris, Molly Alawode, Moreniike Bello, Urooj Fatima, Austin, TX, Rockville, MD

Information is subject to change. Sessions current as of 5/15/20.
MONDAY, JUNE 15, 2020

4:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Pediatric Type 1 Diabetes Potpourri

4:30 p.m.-4:45 p.m.
342-OR Optimal Ages for Screening for T1D Risk in Children
MOHAMED GHALWASH, VIBHA ANAND, WILLIAM HAGOPAIN, MARKUS LUNDGREN, MARIAN REWERS, RIITTA VEIJOLA, ANETTE-GABRIELE ZIEGLER, JESSICA L. DUNNE, T1DI STUDY, Yorktown Heights, NY, Cambridge, MA, Seattle, WA, Lund, Sweden, Denver, CO, Oulu, Finland, Munich, Germany, New York, NY

4:45 p.m.-5:00 p.m.
343-OR HOMA2β Stratifies Risk for Type 1 Diabetes (T1D) Development among TrialNet Pathway to Prevention Participants
JAMIE L. FELTON, KULDEEP LOHANO, FARAH MEAH, JAY SOSENKO, CARMELLA EVANS-MOLINA, Indianapolis, IN, Dubai, United Arab Emirates, Hines, IL, Miami, FL

5:00 p.m.-5:15 p.m.
344-OR Slowed Metabolic Decline after Oral Insulin (OI) in Relatives at High Risk for Type 1 Diabetes (T1D)
JAY SOSENKO, JERRY P. PALMER, MICHAEL J. HALLER, JAY S. SKYLER, ALBERTO PUGLIESE, DESMOND SCHATZ, Seattle, WA, Gainesville, FL, Miami, FL

5:15 p.m.-5:30 p.m.
345-OR First Home Evaluation of the Omnipod Horizon Automated Glucose Control System at Specific Glucose Targets in Children with Type 1 Diabetes
GREGORY P. FORLENZA, BRUCE A. BUCKINGHAM, AMY B. CRIEGO, SUE A. BROWN, BRUCE W. BODE, CAROL J. LEVY, TRANG T. LY, OMNIPOD HORIZON STUDY GROUP, Aurora, CO, Palo Alto, CA, Minneapolis, MN, Charlottesville, VA, Atlanta, GA, New York, NY, Acton, MA

5:30 p.m.-5:45 p.m.
346-OR In Young People with T1D, Additional Mealtime Insulin Produces a Dose-Dependent Improvement in Glycemia after a High-Fat, High-Protein Meal
TENELE A. SMITH, CARMEL E. SMART, MICHELLE E. FUERY, BRIDG KNIGHT, PETER HOWLEY, BRUCE R. KING, Newcastle, Australia, Brisbane, Australia

5:45 p.m.-6:00 p.m.
347-OR Trends in Glycemic Control among Youth with Diabetes: The Search for Diabetes in Youth Study
FAISAL MALIK, KATHERINE A. SAUDER, SCOTT ISOM, ALISSA J. ROBERTS, ELIZABETH J. MAYER-DAVIS, LAWRENCE M. DOLAN, DANA DABELEA, JEAN M. LAWRENCE, CATHERINE PIHOKER, Aurora, CO, Winston-Salem, NC, Seattle, WA, Chapel Hill, NC, Cincinnati, OH, Pasadena, CA

6:00 p.m.-6:15 p.m.
348-OR Metabolic Phenotype of Autoantibody Positive (AbPos) Long-Term Nonprogressors (LTNPs) to Type 1 Diabetes (T1D)

6:15 p.m.-6:30 p.m.
349-OR Pancreas Volume Is Smaller in Individuals with Stage 1 Type 1 Diabetes (T1D) and Correlates with Disease Progression
JOHN VIROSTKO, JONATHAN M. WILLIAMS, MELISSA A. HILMES, JORDAN J. WRIGHT, BRENNA D. HAMMEL, LI-PING DU, HAKMOOK KANG, WILLIAM E. RUSSELL, ALVIN C. POWERS, DANIEL J. MOORE, Austin, TX, Nashville, TN
MONDAY, JUNE 15, 2020

4:30 p.m.-6:30 p.m.

(continued)

Oral Presentations

Theme Area: Clinical Diabetes/Therapeutics

Incretin-Based Therapies

4:30 p.m.-4:45 p.m.

350-OR  A Novel Long-Acting GLP-1 Agonist (GL0034) Demonstrates Remarkable Efficacy on HbA1c, Weight Loss, and Triglycerides in a Model of Type 2 Diabetes, the db/db Mouse
RAJAMANNAR THENNATI, VINOD S. BURADE, TINA VILSBØLL, BERNARD THORENS, GUY A. RUTTER, Vadodara, India, Copenhagen, Denmark, Lausanne, Switzerland, London, United Kingdom

4:45 p.m.-5:00 p.m.

351-OR  Six-Day Subcutaneous GIP Infusion Increases Glycemic Time-in-Range in Patients with Type 1 Diabetes
SEBASTIAN M. NGUYEN HEIMBÜRGER, BJØRN HOE, CHRIS N. NIelsen, NATASHA C. BERGMANN, BOLETTE HARTMANN, JENS J. HOLST, JOACHIM STØRLING, TINA VILSBØLL, THOMAS F. DEJGAARD, MIKKEL B. CHRISTENSEN, FILIP K. KNOP, Hellerup, Denmark, Gentofte, Denmark, Copenhagen, Denmark

5:00 p.m.-5:15 p.m.

352-OR  Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study
MARIAM ALATRACH, CHRISTINA AGYIN IV, JOHN M. ADAMS, II, OLGA LAVRYNENKO, NITCHAKARN LAICHUTHAI, EUGENIO CERSOSIMO, CURTIS L. TRIPLITT, AMALIA GASTALDELLI, MUHAMMAD ABDUL-GHANI, RALPH A. DEFRONZO, San Antonio, TX, Bangkok, Thailand

5:15 p.m.-5:30 p.m.

353-OR  Oral Small Molecule GLP-1R Agonist PF-06882961 Robustly Reduces Plasma Glucose and Body Weight after 28 Days in Adults with T2DM
ADITI SAXENA, DONAL GORMAN, KRISTIN CHIDSEY, CLARE BUCKERIDGE, ALBERT M. KIM, ARTHUR BERGMAN, Cambridge, United Kingdom, Cambridge, MA, Groton, CT

5:30 p.m.-5:45 p.m.

354-OR  Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content
DARRENA ROBERTSON, LARS HANSEN, PHILIP AMBERY, RUSSELL L. ESTERLINE, LUTZ JERMUTUS, YI-TING CHANG, MARCELLA PETRONE, EDVIN JOHANSSON, LARS JOHANSSON, FOLKE B. SJÖBERG, VICTORIA PARKER, Cambridge, United Kingdom, Gaithersburg, MD, Malmö, Sweden, Linköping, Sweden

5:45 p.m.-6:00 p.m.

355-OR  Effects of a Six-Week Intervention with Glucagon-Like Peptide-1 Analogue on Pancreatic Volume, Edema, and DNA Synthesis in Obese Men
MARIA S. SVANE, HELLE H. JOHANNESEN, CHRISTOFFER MARTINUSSEN, KIRSTINE N. BOJSEN-MOLLER, MARTIN L. HANSEN, ADAM E. HANSEN, CAROLYN F. DEACON, BOLETTE HARTMANN, SUNE H. KELLER, THOMAS L. KLAUSEN, ANNIKA LOFT, ANDREAS KJAER, STEN MADSBAD, SR., JOHAN O. LÖFGREN, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN, Hvidovre, Denmark, Copenhagen, Denmark

6:00 p.m.-6:15 p.m.

356-OR  Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial
JONATHAN E. SHAW, FADY T. BOTROS, RALEIGH MALIK, CHARLES ATISSO, HELEN M. COLHOUN, HERTZEL C. GERSTEIN, Melbourne, Australia, Indianapolis, IN, Edinburgh, United Kingdom, Hamilton, ON, Canada

(continued on next page)
6:15 p.m.-6:30 p.m.  
**357-OR** Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11  
JUAN P. FRIAS, ENZO BONORA, LUIS A. NEVAREZ RUIZ, GRACE LI, ZHUOXIN YU, ZVONKO MILICEVIC, RALEIGH MALIK, ANGELYN BETHEL, DAVID COX, Los Angeles, CA, Verona, Italy, Chihuahua, Mexico, Branchburg, NJ, Vienna, Austria, Indianapolis, IN
MONDAY, JUNE 15, 2020

4:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Immunology/Transplantation
Refined Glycemic Phenotypes in the Transplant Setting

4:30 p.m.-4:45 p.m.
358-OR R-Cell Function and Insulin Sensitivity with Islet Alone and Islet-after-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation (CIT) Consortium
MICHAEL R. RICKELS, THOMAS EGGERMAN, LEVENT BAYMAN, JULIE QIDWAI, JOSEPH NAJI, HUONG-LAN T. NGUYEN, RODOLFO ALEJANDRO, MELENA BELLIN, PETER SENIOR, LAWRENCE G. HUNSICKER, CLINICAL ISLET TRANSPLANTATION CONSORTIUM, Philadelphia, PA, Rockville, MD, Iowa City, IA, Miami, FL, Minneapolis, MN, Alberta, AB, Canada

4:45 p.m.-5:00 p.m.
359-OR a- or β-Adrenergic Blockade Does Not Affect Transplanted Islet Responses to Hypoglycemia in Type 1 Diabetes (T1D)
MICHAEL R. RICKELS, MELENA BELLIN, DARKO STEFANOVSKI, AMY J. PELECKIS, CORNELIA V. DALTON-BAKES, EILEEN MARKMANN, HUONG-LAN T. NGUYEN, ALI NAJI, Minneapolis, MN, Philadelphia, PA

5:00 p.m.-5:15 p.m.
360-OR BETA-2 Score Is Highly Correlated with Acute Insulin Response to Intravenous Glucose: An Analysis of the Clinical Islet Transplantation Consortium Trials
PETER A. SENIOR, MICHAEL R. RICKELS, THOMAS EGGERMAN, LEVENT BAYMAN, JULIE QIDWAI, RODOLFO ALEJANDRO, JAMES F. MARKMANN, LAWRENCE G. HUNSICKER, CLINICAL ISLET TRANSPLANT CONSORTIUM, Edmonton, AB, Canada, Philadelphia, PA, Rockville, MD, Iowa City, IA, Miami, FL, Boston, MA

5:15 p.m.-5:30 p.m.
361-OR BETA-2 Score Is Highly Predictive of Graft Function after Islet Transplant: Analysis of Clinical Islet Transplant Consortium Trials
PETER A. SENIOR, MICHAEL R. RICKELS, THOMAS EGGERMAN, LEVENT BAYMAN, JULIE QIDWAI, RODOLFO ALEJANDRO, JAMES F. MARKMANN, LAWRENCE G. HUNSICKER, CLINICAL ISLET TRANSPLANT CONSORTIUM, Edmonton, AB, Canada, Philadelphia, PA, Rockville, MD, Iowa City, IA, Miami, FL, Boston, MA

5:30 p.m.-5:45 p.m.
362-OR The Biological Variability of the BETA-2 Score in Islet Transplant Recipients
ROBYN MILLOTT, RICHARD A. ORAM, SHAREEN FORBES, A.M. JAMES SHAPIRO, PETER A. SENIOR, ANNA LAM, Exeter, United Kingdom, Edinburgh, United Kingdom, Edmonton, AB, Canada

5:45 p.m.-6:00 p.m.
363-OR Comprehensive Assessment of Glycemic Control after Pancreas Transplantation
RAVIDER JEET KAUR, COREY REID, PRABIN THAPA, SHAFIQ RAZA RIZVI, SHELLY K. MCCRADY-SPITZER, SREEDHAR BATTHULA, BYRON H. SMITH, PATRICK DEAN, WALTER K. KREMERS, ALEKSANDRA KUKLA, MARK D. STEGALL, YOGISH C. KUDVA, Rochester, MN

6:00 p.m.-6:15 p.m.
364-OR Igls Classification for Islet Autotransplantation
KENDALL R. MCEACHRON, YI YANG, TIMOTHY L. PRUETT, MELENA BELLIN, Minneapolis, MN

(continued on next page)
6:15 p.m.-6:30 p.m.

365-OR  Glycemic Outcomes at One Year Post Pediatric TPIAT
SARAH SWAUGER, LINDSEY HORNUNG, DEBORAH A. ELDER, JAIMIE D. NATHAN, MAISAM ABU-EL-HAIJA,
Cincinnati, OH, Mason, OH
MONDAY, JUNE 15, 2020

4:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Integrated Physiology/Obesity
Regulation of Hepatic Metabolism and Hepatokine Action

4:30 p.m.-4:45 p.m.
366-OR Characterization of Gene Expression Networks That Are Oppositely Regulated by Human and Mouse Metabolic Disease Using a Humanized Mouse Model
HAIMING CAO, Bethesda, MD

4:45 p.m.-5:00 p.m.
367-OR High-Fat and Fructose Feeding Severely Impairs Hepatic Glucose Effectiveness
DALE S. EDGERTON, GUILLAUME KRAFT, BEN FARMER, MELANIE SCOTT, MARTA S. SMITH, ALAN D. CHERRINGTON, Nashville, TN

5:00 p.m.-5:15 p.m.
368-OR Activation of Hepatic Gluconeogenesis Is Required to Suppress DNL and Stimulate Ketogenesis during Fasting
STANISLAW DEJA, JOAO DUARTE, JUSTIN A. FLETCHER, BLANKA KUCEJOVA, XIAORONG FU, GONÇALO VALE, JAMEY YOUNG, JEFFREY BROWNING, SHAWN C. BURGESS, Dallas, TX, Cambridge, United Kingdom, Nashville, TN

5:15 p.m.-5:30 p.m.
369-OR [1,2-13C2]-L-Glutamine Mass Isotopomers Map Hepatic Mitochondrial Metabolism without Tracer Interference
STEPHAN SIEBEL, REBECCA L. CARDONE, ABUDUKADIER ABULIZI, RAAISA RAAISA, RICHARD M. WILLIAMS, RAGHAV SEHGAL, GINA MARIE BUTRICO, GARY CLINE, DOUGLAS L. ROTHMAN, GRAEME F. MASON, RICHARD KIBBEY IV, London, United Kingdom, New Haven, CT

5:30 p.m.-5:45 p.m.
370-OR Hepatic FGF21 Expression Is Under the Regulation of the Canonical Wnt Signaling Pathway
YASAMAN BADAKHSHI, WEIJUAN SHAO, LILI TIAN, TIANRU JIN, Toronto, ON, Canada

5:45 p.m.-6:00 p.m.
371-OR Reduced Hepatic Expression of the Mitochondrial Quality Control Factor PARKIN Hastens the Progression of NAFLD in Mice and Is Associated with NASH in Patients
RAMYA UNDAMATLA, LIA R. EDMUNDS, BINGXIAN XIE, AMANDA MILLS, IAN J. SIPULA, SATDARSHAN P. MONGA, MICHAEL J. JURCZAK, Pittsburgh, PA

6:00 p.m.-6:15 p.m.
372-OR Ablation of the Hepatokine TSK Protects Mice against Obesity and Metabolic Disorders Caused by MC4R Deficiency
QIUYU WANG, JIANDIE LIN, Ann Arbor, MI

6:15 p.m.-6:30 p.m.
373-OR Paternal SGLT2 Inhibition Upregulates Hepatic Expression of Oxidative Phosphorylation Genes in Both Fetal and Adult Offspring
LEI SU, SORAVIS OSATAPHAN, CHIARA MACCHI, JEREMY I. CHIMENE-WEISS, JONATHAN DREYFUSS, HUI PAN, MARY-ELIZABETH PATTI, Boston, MA, Milan, Italy

Information is subject to change. Sessions current as of 5/15/20.
TUESDAY, JUNE 16, 2020

Scientific Sessions
8:00 a.m.-9:00 a.m.

Current Issues
Theme Area: Acute and Chronic Complications
Debate—Microvascular and Macrovascular Complications of Diabetes Are Distinct Pathophysiologic Entities
Chair: Anne L. Peters, MD
Microvascular and Macrovascular Complications of Diabetes—Distinct Pathophysiologic Entities or a Part of a Continuum?
8:00 a.m.-8:15 a.m.  Definitely Yes
Deborah J. Wexler, MD, MSc
8:15 a.m.-8:30 a.m.  No, They Are Part of a Continuum
Deborah J. Wexler, MD, MSc

The Cardiologist’s Perspective
8:30 a.m.-8:45 a.m.  Definitely Yes
Jasper Tromp, MD, PhD
8:45 a.m.-9:00 a.m.  No, They Are Part of a Continuum
Sanjiv J. Shah, MD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Diabetes Meets the Sandman—Sleep, Diabetes, and Glycemic Management
Chair: Sarah C. Westen, PhD
8:00 a.m.-8:20 a.m.  Which Comes First—Poor Sleep or Poor Glycemic Control?
Susana R. Patton, PhD
8:20 a.m.-8:40 a.m.  Mechanisms Linking Sleep to Glycemic Control
Erin C. Hanlon, PhD
8:40 a.m.-9:00 a.m.  Addressing Zzz’s in Diabetes Management
Michelle Perfect, PhD
9:00 a.m.-9:20 a.m.  Technology and Overnight Diabetes Management—Is Nighttime Still the Worst Time?
Michelle A. Van Name, MD
9:20 a.m.-9:40 a.m.  To Sleep or Not to Sleep? That Is the Question for Youth with Type 1 Diabetes
Sarah S. Jaser, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
SGLT2 Inhibitors—How Do They Reduce Cardiorenal Disease?
Chair: Ele Ferrannini, MD
8:00 a.m.-8:40 a.m.  It Is a Metabolic Mediation
Ele Ferrannini, MD
8:40 a.m.-9:20 a.m.  Primary Effect Is in the Heart
Subodh Verma, MD, PhD, FRCSC
9:20 a.m.-10:00 a.m.  Primary Effect Is in the Kidney
David Cherney, MD, PhD

Information is subject to change. Sessions current as of 5/15/20.
TUESDAY, JUNE 16, 2020

8:00 a.m.-10:00 a.m.
(continued)

Symposium
Theme Area: Epidemiology/Genetics
New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)
Chair: William C. Knowler, MD, DrPH
8:00 a.m.-8:20 a.m. Overview of the DPPOS
   David M. Nathan, MD
8:20 a.m.-8:40 a.m. Microvascular Complications
   Mark Molitch, MD
8:40 a.m.-9:10 a.m. Metformin and Lifestyle Effects on Cardiovascular Events
   Ronald B. Goldberg, MD
9:10 a.m.-9:40 a.m. Metformin and Lifestyle Effects on Cancer Incidence
   Brandy M. Heckman-Stoddard, PhD, MPH
9:40 a.m.-10:00 a.m. Age-Sensitive Outcomes in the DPPOS
   Jose A. Luchsinger-Stuart, MD, MPH

Symposium
Theme Area: Immunology/Transplantation
Immune Intervention During the Stages of Type 1 Diabetes Development—Type 1 Diabetes TrialNet
Chair: Jessica L. Dunne, PhD
8:00 a.m.-8:40 a.m. Progressing through the Stages of Type 1 Diabetes
   Diane K. Wherrett, MD, FRCPC
8:40 a.m.-9:20 a.m. The Anti-CD3 Antibody Teplizumab Delays Type 1 Diabetes Onset in Stage 2 Type 1 Diabetes—Responder Characteristics
   S. Alice Long, PhD
9:20 a.m.-10:00 a.m. Response to Low-Dose Anti-thymocyte Globulin in Stage 3 Type 1 Diabetes
   Laura M. Jacobsen, MD

Symposium
Theme Area: Integrated Physiology/Obesity
Economic Drivers of Obesity Treatment—From Individuals to Systems
Chair: Sangeeta Kashyap, MD
8:00 a.m.-8:30 a.m. Financial Incentives for Weight Management
   Amy E. Rothberg, MD, PhD
8:30 a.m.-9:00 a.m. Overcoming Economic Barriers to Treating Obesity
   Kimberly Gudzune, MD, MPH, FTOS
9:00 a.m.-9:30 a.m. Cost-Effective Models of Care for Obesity Treatment
   Bartolome Burguera, MD, PhD
9:30 a.m.-10:00 a.m. Clinical Assessment of Social Determinants of Health in Patients with Obesity
   Monica E. Peek, MD, MPH, MSc
TUESDAY, JUNE 16, 2020

8:00 a.m.-10:00 a.m.
(continued)

Symposium
Theme Area: Islet Biology/Insulin Secretion
What’s New with GLP-1?
Chair: Jonathan Campbell, PhD
8:00 a.m.-8:30 a.m. Role of Incretins in Glucose Homeostasis
Filip K. Knop, MD, PhD
8:30 a.m.-9:00 a.m. Bariatric Surgery and a New Pathway in the Regulation of Alpha Cell GLP-1
Bethany Cummings, DVM, PhD
9:00 a.m.-9:30 a.m. Neprilysin—An Underappreciated Player in GLP-1 Action
Sakeneh Zraika, PhD
9:30 a.m.-10:00 a.m. The Role of Alpha-Cell GLP-1 in Physiology and Stress
Darleen A. Sandoval, PhD

9:00 a.m.-10:00 a.m.

Current Issues
Theme Area: Acute and Chronic Complications
Debate—Drawing the Line between Primary and Secondary Prevention—Necessary or Too Simplistic?
Chair: Christie M. Ballantyne, MD
Atherothrombotic Complications
9:00 a.m.-9:15 a.m. Necessary
Christie M. Ballantyne, MD
9:15 a.m.-9:30 a.m. Too Simplistic
Roger Scott Blumenthal, MD
Heart Failure Complications
9:30 a.m.-9:45 a.m. Necessary
Milton Packer, MD
9:45 a.m.-10:00 a.m. Too Simplistic
Javed Butler, MD, MPH, MBA

Information is subject to change. Sessions current as of 5/15/20.
TUESDAY, JUNE 16, 2020

10:15 a.m.-12:15 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Results of the eValuation of ERTugliflozin Efficacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
Chair: Javed Butler, MD, MPH, MBA

10:15 a.m.-10:35 a.m. Introduction, Study Rationale, and Design
    Richard E. Pratley, MD

10:35 a.m.-10:55 a.m. Baseline Characteristics and Metabolic Results
    Samuel Dagogo-Jack, MD, DSc

10:55 a.m.-11:15 a.m. Cardiovascular and Renal Outcomes
    Christopher Cannon, MD

11:15 a.m.-11:35 a.m. Safety Results and Updated Cardiovascular Meta-analysis
    Darren K. McGuire, MD, MHSc

11:35 a.m.-11:55 a.m. Overall Conclusions
    David Cherney, MD, PhD

11:55 a.m.-12:15 p.m. Independent Commentary
    Mark E. Cooper, MBBS, PhD